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Background: Maternal obesity and diabetes are known risk factors for the development of child 
autism spectrum disorder (ASD). The association of other maternal metabolic disorders with 
ASD have been much less studied. Elevated branched-chain amino acids (BCAAs) are also 
associated with metabolic disorders and lower BCAAs have been linked to ASD. This 
dissertation sought to explore the role of maternal plasma BCAAs in the pathway from maternal 
metabolic disorders to child ASD and whether the associations differed by child’s. 
Methods: This study leveraged the Boston Birth Cohort (BBC), an ongoing prospective cohort 
study in the Boston area representing a predominantly urban, low-income, minority population. 
Of over 3,000 mother-infant pairs from the BBC prospectively from birth since 2004, this 
dissertation analyzed 864 with pertinent data. Maternal lipids were measured using standard 
clinical methods, and targeted BCAA metabolites were quantitatively profiled using liquid 
chromatography-tandem mass spectrometry (LC-MS/MS), using plasma samples collected 24-72 
hours postpartum. A composite BCAA score was created using factor analysis and dichotomized 
at the median. Maternal obesity and diabetes were combined into one binary variable (ob/DM), 
and cholesterol subtypes were dichotomized using clinical cut-points. A multiple maternal 
metabolic disorders score was developed and dichotomized into (MMD<3 vs. 3). Logistic 
regression was used to explore the association between maternal BCAAs and child ASD risk and 
the potential role of BCAAs as mediators. Joint effects between BCAAs and maternal metabolic 
conditions (ob/DM (n=864), low high-density lipoprotein cholesterol (HDL-C) (n=829), and 
multiple metabolic disorders (MMD) (n=829)) as well as child’s sex were also explored for both 
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ASD and other developmental disorders. Lastly, joint associations between all three risk factors 
– BCAAs, maternal metabolic conditions, and child’s sex – were examined. 
Results: While maternal BCAAs alone were not associated with child risk of ASD and did not 
mediate the association between maternal metabolic disorders and ASD, they were jointly 
associated with maternal ob/DM on child ASD risk (adjusted BCAA score OR 2.35, 95% CI 
1.21, 4.55). While maternal HDL-C alone was not associated with child ASD risk, HDL-C and 
child’s sex had a joint effect on this risk. Among mothers with low HDL-C, elevated BCAA 
score was associated with higher risk of child ASD (OR 4.67, 95% CI 1.33, 16.36; 
pinteraction=0.006). Maternal MMD and above median BCAA score synergistically increased the 
risk of ASD (adjusted OR: 3.20, 95% CI: 1.65-6.18; pinteraction= 0.019). Finally, the risk of ASD 
was the greatest among male children with mothers with elevated BCAAs and metabolic 
disorder(s) compared to other groups.  
Conclusions: Maternal metabolic disorders had joint effects with elevated maternal plasma 
BCAAs and with male sex on child risk of ASD, and the risk was greatest among children with 
all three risk factors. These findings, raise the prospect of early risk assessment and primary 
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CHAPTER 1 INTRODUCTION 
 
Autism spectrum disorders (ASDs) are characterized by deficits in social interaction and 
communication, and restricted or repetitive behaviors and are often accompanied by co-occurring 
conditions, including attention deficit hyperactivity disorder (ADHD), intellectual disability, and 
anxiety and mood disorders, among others.1 The etiology of ASD is complex and though it is 
highly heritable, various environmental factors have also been implicated.2 There is building 
evidence that the developing brain of the fetus can be influenced by an inflammatory maternal 
environment and immune activation.3 Metabolic conditions, including obesity, diabetes, 
dyslipidemia and hypertensive disorder can be considered environmental stressors giving rise to 
oxidative stress and inflammation.3,4  
The present research was motivated by recent findings from the Boston Birth Cohort (BBC), 
which have brought to new light on the importance of maternal metabolic disorders on child’s 
risk of ASD. The BBC is an ongoing birth cohort following mother-infant pairs prospectively 
from birth up to age 21 years, representing a sample of urban, low-income, minority population 
in the United States. An earlier publication from this cohort has shown that maternal obesity and 
diabetes mellitus are independently as well as jointly associated with an increased risk of child 
development of ASD.5 This has been replicated by studies in diverse populations.6,7 Maternal 
hypertension has also been associated with child ASD.4 There is less known about the 
associations between maternal cholesterol and child risk of ASD, though another recent 
publication from the BBC reported an association between maternal cholesterol, specifically 
lower levels of high-density lipoprotein cholesterol (HDL-C) and higher levels of triglycerides, 
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and attention deficit hyperactivity disorder (ADHD), a commonly co-occurring condition with 
ASD.8  
To date, the molecular mechanisms underlying associations of maternal metabolic disorders and 
child ASD risk remain unclear. This study focuses on branched-chain amino acids (BCAAs), 
comprised of leucine, isoleucine, and valine for several reasons. First, BCAAs are specifically  
associated with obesity and diabetes, and at elevated levels they are predictive of incident type 2 
diabetes.9,10 Another line of research shows that an altered amino acid metabolite profile is a 
signature of ASD in laboratory and clinical studies, and is mainly found in lower levels in 
children with ASD than in TD children.11,12 BCAAs are essential amino acids that have 
important direct and indirect signaling roles, including activation of the mechanistic target of 
rapamycin (mTOR).13 The mTOR signaling pathway is also activated by insulin-like growth 
factor 1 (IGF-1) and promotes synaptic protein synthesis; thus its dysregulation has been 
implicated in neurocognitive abnormalities, including ASD.14 However, major gaps exist, 
especially since most studies to date are cross-sectional by design, and there are no prospective 
birth cohort studies examining the inter-relationships of maternal metabolic disorders, maternal 
BCAAs, and child risk of ASD.  
This study attempted to bring together several lines of research under a life course framework to 
better understand early life origins of ASD. It also sought to understand the underlying 
mechanisms of the male preponderance in ASD prevalence.15 The goal of this research is to 
understand the pathways underlying the associations between maternal metabolic conditions and 
subsequent diagnosis of ASD in the child and the role BCAA play in this relationship. 
Specifically, the objectives were:  
1. To explore the role of maternal plasma branched-chain amino acids (leucine, isoleucine, 
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and valine) in the pathway from maternal obesity/diabetes to child ASD.  
Hypotheses:  
- Maternal BCAAs either mediate or have joint effects with maternal ob/DM in the 
relationship between maternal ob/DM and child ASD risk. 
- The risks from the associations above are higher in males than in females. 
2. To assess the association between maternal cholesterol and child ASD and explore the 
role of maternal plasma branched-chain amino acids in the pathway from maternal 
dyslipidemia to child ASD. 
Hypotheses:  
- Low maternal high-density lipoprotein cholesterol (HDL-C), high maternal low-
density lipoprotein cholesterol (LDL-C), and high maternal non-HDL-C, are 
associated with child ASD risk 
- Maternal BCAAs either mediate or have joint effects with maternal lipids in the 
relationship between maternal lipids and child ASD risk 
- The risks from the associations above are higher in males than in females. 
3. To assess the association between maternal multiple metabolic disorders (MMD) and 
child ASD and explore the role of maternal plasma branched-chain amino acids in the 
pathway from maternal MMD to child ASD.  
Hypotheses: 
- Maternal BCAAs either mediate or have joint effects with maternal MMD in the 
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relationship between maternal MMD and child ASD risk 
- The risks from the associations above are higher in males than in females. 
This dissertation is organized into chapters. Chapter 2 presents the background and significance 
for the present topic, focusing on the burden, risk factors, maternal metabolic disorders, immune 
dysregulation and neuroinflammation, mitochondrial and oxidative stress, branched-chain amino 
acids, and sex differences. In Chapter 3, the data collection methods and study setting are 
described. This research study was nested within a larger prospective birth cohort study 
examining early life origins of pediatric and adult diseases. Chapters 4, 5, and 6 present the 
results of each of the specific aims outlined above. Chapter 4 explores the relationship of 
maternal BCAAs with ASD in conjunction with maternal obesity and diabetes and sex of the 
child. Chapter 5 investigates the association between maternal cholesterols and child ASD and 
evaluates joint effects of sex and the BCAAs with dyslipidemia. Chapter 6 then examines the 
relationship between MMD and ASD and again evaluates joint effects with BCAAs, stratifying 
by sex. Interactions between the maternal metabolic conditions and BCAAs as well as sex are 
also explored. Finally, in Chapter 7, the overall study findings are discussed along with strengths 
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CHAPTER 2 LITERATURE REVIEW 
 
BACKGROUND  
Autism spectrum disorder (ASD) is a neurodevelopmental disorder characterized by impaired 
cognitive abilities that range from mildly to severely disabling and the diagnosis is virtually 
irreversible. The current prevalence estimate from the Center for Disease Control (CDC) in the 
United States is 1 in 59.1 In 2010, there were 52 million cases of ASD worldwide, making it the 
leading cause of disability in children under five among all mental health disorders (measured by 
years lived with disability (YLD)).2 The prevalence of ASD is reportedly similar across all 
regions of the world differing only slightly by socioeconomic status, race, and ethnicity. 
However, the most recent surveillance report from the Autism and Developmental Disabilities 
Monitoring (ADDM) network reported a higher prevalence among non-Hispanic white children 
than non-Hispanic black children and both of these groups had higher prevalence than Hispanic 
children.1 This discrepancy may be reflective of poorer access to resources and diagnosis among 
minority and low-income populations. 
In 2015, a study estimated that the total economic burden of ASD, including direct and indirect 
medical costs and productivity costs, in the United States was around $268 billion for that year, 
which exceeded the economic burden of hypertension and stroke.3 Given the steady incline in the 
prevalence, they forecasted the economic burden at around $461 billion for 2025, far surpassing 
that of ADHD and diabetes in the country. Though children with ASD are eligible for Medicaid 




The etiology of ASD is quite complex and thought to include genetic, environmental, and 
epigenetic factors.5 There is also no cure or highly effective primary preventive measure for 
ASD. Decades of research have gone into understanding both facets of this enigmatic disorder. 
Early interventions have shown the most promise to increase IQ, language skills, and social 
behavior in diagnosed children.6 However, as primary prevention is always preferred over 
secondary prevention and therapeutic efforts, there is a need for investigation of early risk 
assessment, prediction, and primary prevention before or during pregnancy. 
DEFINITION AND DIAGNOSIS 
The current diagnostic criteria used in the United States are found in the fifth version of the 
Diagnostic and Statistical Manual of Mental Disorders (DSM-5), released by the American 
Psychiatric Association in May 2013.7 Diagnosis is made using a developmental screening and a 
comprehensive diagnostic evaluation by a trained clinician; there is no biological marker that has 
been determined as an indicator for the disorder. The current criteria include two domains where 
sustained deficits must be shown in people with ASD: “persistent social communication and 
social interaction” and “restricted and repetitive patterns of behavior.” Clinicians will also 
diagnose the level of severity based on “level of support” required for the individual to carry on 
with their daily lives. These tests are considered reliable for diagnoses at two years of age but 
ASD can be detected as early as 18 months and sometimes younger. Under the previous DSM 
(DSM-IV), conditions such as Asperger syndrome were categorized separately from autism; 
these are now included under a broad spectrum. ASD affects individuals in different ways. 
People with ASDs may have atypical ways of communicating and interacting than most other 
people and may have learning disabilities. They may also display advanced abilities in a specific 
area such as drawing or mathematical ability.  
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CURRENT UNDERSTANDING OF ASD ETIOLOGY  
Brain Structure and Function: Rather than having atypical brain regions, ASD individuals are 
thought to have differences in the neural connectivity, both short- and long-range, compared to 
typically developing individuals.8 This is in part due to molecular genetics of synaptic proteins, 
cell adhesion molecules, and the imbalance of excitatory and inhibitory neurotransmitters. The 
PI3K/AKT/mTOR signaling pathway plays a central role in synaptic protein synthesis,9 and its 
dysregulation results in many behavioral abnormalities, which may contribute to the etiology of 
ASD.10 PTEN negatively regulates the PI3K/AKT/mTOR pathway, and thus, deletion of the 
PTEN gene results in an overactive PI3K/AKT/mTOR pathway and autism-like behaviors in 
mice.11   
Genetics: Recent estimates suggest that genetic factors explain around 40-50% of ASD risk.12 
Some studies report even higher heritability estimates at around 95%.13 However, there are 
several hundred genes implicated as risk factors of ASD as opposed to one or a few.14 In one 
study, monozygotic twins had a higher concordance rate (80%, 95% CI 51.9-95.7%) than 
dizygotic twins (13.6%, 95% CI 2.9-34.9%).15 Male sex is also a strong predictor, associated 
with ASD in about a three to one ratio between males and females.16  
Rare genetic mutations, including de novo and inherited account for an estimated 10-30% of 
ASDs. This includes the approximate 10% of cases, ASD is the result of a genetic syndrome.17 
For example, up to 60% of males with Fragile X Syndrome cases, caused by a known mutation 
in the FMR1 gene, show signs of ASD.17,18 There are several other genes that have cumulatively 
been implicated in ASD etiology, though no common gene loci have been identified for ASD, as 
is the case for schizophrenia.19  
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Epigenetics: Epigenetics, including DNA methylation and histone methylation and acetylation, 
have been shown to play a large role in the etiology of autism.20 Autism is associated with 
several disorders that are caused by mutations in genes that regulate the expression of other 
genes.21 Furthermore, several parental imprinting regions on specific chromosomes have also 
been reported to be associated with autism.22,23 A recent report examined the joint analysis of 
genotype with DNA methylation data from cord and peripheral blood in relation to ASD 
phenotypes and found that together, they provide more insight than each factor alone.24 
Furthermore, prenatal stress from a variety of sources discussed below can also induce epigenetic 
changes owing to ASD pathology.25  
Sex differences: Autism is a sexually dimorphic disorder with an approximate four-fold higher 
prevalence in males than females.45 There is evidence of the association between gonadal 
hormones in infancy and sex-specific differentiation of brain morphology and function as well as 
neurochemical differences. This difference in sex hormones is also been shown to be associated 
with development of language and motor skills,46,47 behaviors such as aggression, as well as the 
risk of development of autism.48 The hypothalamic-pituitary-gonadal (HPG) axis of the fetus of 
both sexes is active during mid-gestation, repressed later in pregnancy by placental hormones, 
and reactivated postnatally, peaking at around three months and declining through six months of 
age. However, in girls, follicle stimulating hormone (FSH) levels stay elevated until 3-4 years of 
age.49 The main estrogen in females, estradiol, was not only found to have receptors on the 
mitochondria, but also was found to signal antioxidant pathways in the organelle.50 Additionally, 
pre-pubertal girls have approximately eight times more estrogen than pre-pubertal boys.51 
Estrogen is protective against glutamate-driven neurotoxicity, which is consistently shown in the 
literature as reviewed by Pastural et al (2009).45,52 Thus, this might be one mechanism protecting 
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females in infancy from developing oxidative stress-related disorders including ASD and 
ADHD. This is also evidenced by sex differences in aging as females have greater longevity than 
males; females have lower levels of oxidants present in their mitochondria than males due to 
upregulation of antioxidant enzymes via estrogen signaling of nuclear genes directed toward the 
energy producing organelle. The evidence is more equivocal for FSH. A study in rats found that 
FSH was protective against oxidative stress and apoptosis in pre-ovulatory follicles.53 However, 
a later study showed that though apoptosis of mouse ovarian granular cells was inhibited with 
FSH treatment, oxidative stress levels in the cells remained the same.54  
Immune Dysregulation and Neuroinflammation: A proposed underlying mechanism of ASD 
is the dysregulation of glutamatergic neurotransmission in the brain, which causes increased 
excitation of pro-inflammatory cytokines leading to neuroinflammation.55 Over the past few 
decades, there has been growing evidence linking maternal inflammation and autism, especially 
through the diet, due to both over- and under-nutrition. Inflammation caused by infection and 
environmental exposures has also been studied linking maternal stress during gestation to a host 
of neurodevelopmental disorders including autism, schizophrenia, and attention deficit 
hyperactivity disorder.56 Maternal inflammation or “maternal immune activation” (MIA) has 
been shown to be associated with neurodevelopmental disorders.57 The theory is that pro-
inflammatory markers in the maternal environment due to infection or other stressors can enter 
fetal circulation through the placenta and cross the blood-brain-barrier, causing excessive 
neuronal growth and abnormal neural plasticity.58 Chronic low-grade inflammation can be 
caused by long-term stresses to the body, including environmental stressors such as sun exposure 
and air pollution, dietary exposures including high-fat diets, and chronic health conditions like 
diabetes or obesity.  
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Mitochondria and Oxidative Stress: Beta-oxidation occurring in the mitochondria during the 
breakdown of fatty acids produces reactive oxygen species (ROS) and reactive nitrogen species 
(RNS) in small quantities.59 In normally functioning mitochondria, these reactive species are 
regulated and contained for the most part. However, an imbalance in input can cause disruption 
to this regulation, causing leakage of the free radicals, which can cause oxidative stress by 
reacting to and thus damaging cellular components including DNA. This in turn leads to an 
inflammatory response, which can remain chronic and unresolved at low levels if the source of 
this oxidative stress is not removed. An example is in the evidence that obesity (associated with 
an excess of lipids) is a risk factor for other chronic and inflammatory diseases like type 2 
diabetes and cardiovascular disease (CVD).60  
In order to compensate for the increase in ROS and RNS, mitochondria become overactive.61 
Thus, high levels of reactive species resulting in oxidative stress can further exacerbate the beta 
oxidation process leading to mitochondrial dysfunction (MD). This affects ATP synthesis, which 
in turn decreases glutathione (GSH) production. A meta-analysis by Rossignol and Frye (2012) 
found that 30% of children with ASD had biomarkers for MD62 and a follow up study by Frye 
found up to 50% of children with ASD had biomarkers of MD.63  
Though a low level of reactive species is required for normal cellular functioning, higher levels 
of exposure could lead to “oxidative stress,” causing functional impairments via damage to 
cellular membranes, proteins, and DNA.59 The ASD brain is thought to be particularly vulnerable 
to damages caused by oxidative stress. A study showed that plasma levels of glutathione (GSH), 
and the ratio of reduced to oxidized glutathione, an indicator of antioxidant capacity and redox 
homeostasis, were significantly decreased in children with ASD compared to controls (52). Of 
all antioxidants produced by the body, GSH is present at the highest concentration, and is thus 
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necessary in the defense against damage from oxidative stress. In a GSH-deficient state, a cell’s 
capacity to buffer excessive reactive species is decreased due to faster depletion of GSH leaving 
the cell vulnerable to the damage. One theory for an etiologic mechanism of ASD is exposure to 
environmental toxins that deplete the GSH pool.59 As GSH is a product of the methionine 
metabolism, disruptions in the methionine/ homocysteine/ folate pathway, including folate 
deficiency, can also affect GSH production. 
Environmental factors: Mother’s diet, nutritional status, and infection during pregnancy are all 
known risk factors. For example, maternal obesity and diabetes mellitus (DM) have been shown 
to be independently associated with a two-fold increased risk of autism.26 Obesity and DM 
combined had an even higher risk (hazard ratio 3.91, 95% CI 1.76–8.68) as did obesity and 
gestational diabetes (GDM) (hazard ratio 3.04, 95% CI 1.21–7.63). Nutritional deficiencies have 
also been implicated in the risk of ASD, which may also occur in overweight and obese 
individuals. Vitamin D and folate are important nutrients for proper brain development during 
gestation. The direct link between vitamin D deficiency and ASD is not yet confirmed but has 
grounding in several observational studies and open label trials as evidenced in a recent review.27 
The review reported higher maternal concentrations of vitamin D were associated with lower risk 
of autism-related traits in children. Along with decreasing the risk of neural tube defects, folate 
supplementation during pregnancy has been shown to be protective against the risk of ASD.28 
However, a recent study has shown that extremely high folate and vitamin B12 levels during 
pregnancy can also be a risk factor for ASD, resulting in a “U” shaped relationship.29 Insufficient 
fatty acids, including omega-3 DHA and EPA, can also lead to abnormal development of the 
brain and have also been associated with ASD.28  
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Gestational zinc deficiency is another known risk factor for ASD.30 Lipopolysaccharides (LPS), 
an endotoxin in bacteria, plays a role in autism as it leads to hypozincaemia, causing gestational 
zinc deficiency. Eating a high-fat diet has been linked to increased levels of LPS in healthy 
humans and mice.31 A study done in rats to examine the effects of zinc supplementation with 
high LPS found that impairment induced by LPS was reduced to the level of control pups when 
the mothers were also given zinc.30 This further led to reduced level of BDNF to the level of 
controls as well as prenatal LPS increases levels of BDNF, even as adults. ASD has also been 
shown to be associated with other micronutrient deficiencies apart from zinc.32 Epigenetic 
changes may occur when these micronutrients are lacking or altered during pregnancy, including 
folic acid and vitamin B12. Deficiencies in these nutrients can lead to preterm birth as well as 
behavioral disorders including autism. These findings may support methods of preventing 
micronutrient deficiency as well as sanitation and hygiene to prevent bacterial infection.  
Older maternal and paternal age are both known risk factors for ASD.33-35 Low birthweight and 
being born prematurely are also known biological risk factors.36-38 One theory behind the 
association between preterm birth and ASD is via an event or chronic condition triggering an 
inflammatory fetal environment that causes the prior to term birth and also leads to microglial 
activation in the fetal brain, leading in turn to abnormal synapse formation and brain 
development.38  
Other environmental factors, including air pollution,39,40 environmental toxins,5,41 psychological 
stress,25 and migration37,42 have all been identified as maternal risk factors, which likely act via 
epigenetic mechanisms.28 At the cellular level, there are multiple mechanisms at play that may be 
useful in studying the etiology of the disorder. Cellular dysfunction, including oxidative stress, 
mitochondrial abnormalities, neuroinflammation, and abnormal synaptic plasticity, are generally 
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seen in ASD patients and can play a role in providing several biomarkers for the study of the 
disorder.43 For example, neurotoxicants, including air pollution, induce neuroinflammation and 
oxidative stress, and disproportionally affect males over females due to several protective 
mechanisms in females, including the neuroprotective effects of estrogen and progesterone.44 
There are also several preclinical studies reporting the effects of neurotoxicants as well as 
psychological stress of dams on autism-like characteristics in the offspring.25,44 Critically, a 
better understanding of these factors, whether or not they are in a causative pathway, should lead 
to a better understanding of means and avenues with which to intervene to improve behavioral 
and cognitive outcomes. 
Obesity and Diabetes: There is building evidence that the developing brain of the fetus can be 
influenced by an inflammatory maternal environment due to diet or obesity. For example, rats 
exposed to a high-fat diet before and during pregnancy had increased dam weight as well as 
leptin, CRP, and IL-6 concentrations, which in turn activated the maternal immune system and 
led to increased expression of cytokines in the offspring brain at birth. Long-term changes in 
brain function and behavior of the offspring due to high dam weight and a high-fat diet were 
“strikingly similar to that observed following an early-life bacterial infection.”64  
Maternal obesity and diabetes mellitus (DM) have been shown to be independently as well as 
jointly associated with an increased risk of child development of ASD.26 The most recent meta-
analysis on pre-pregnancy and pregnancy body mass index (BMI) reported increased risk of 
offspring ASD among overweight mothers (OR (odds ratio): 1.16; 95% CI 1.05-1.27) and obese 
mothers (OR: 1.41; 95% CI 1.19-1.67) compared to normal weight mothers.65 A recent meta-
analysis on maternal diabetes reported a 48% increased risk of child ASD in mothers with 
diabetes compared to those without the condition (RR (risk ratio): 1.48; 95% CI: 1.26–1.75.66 
 
 16 
Furthermore, the subset of moderate and high quality studies resulted in a 62% increased risk 
(RR: 1.62; 95% CI: 1.35–1.94). 
The presently held hypothesis in scientific literature of the underlying mechanism behind the 
association between these metabolic conditions and child ASD risk is maternal chronic, low-
grade inflammation leading to oxidative stress.43,59 The neonatal brain is susceptible to cytokines 
and other pro-inflammatory markers that can cross the placenta as well as the blood brain barrier, 
affecting the developing brain of the fetus. Another hypothesis is excess brain growth during the 
critical period of catch-up growth for children born with low birthweight (LBW), with maternal 
obesity being a risk factor for LBW babies.67 An animal study also showed maternal 
inflammation contributed to brain overgrowth and autistic features in offspring.68  
Like obesity, maternal diabetes also creates an inflammatory environment in utero, which has 
been associated with ASD in offspring.66 Maternal hyperglycemia, as a result of diabetes, is 
linked to oxidative stress and can also lead to hyperinsulinemia in the fetus, causing increased 
oxygen consumption and hypoxia. Both oxidative stress and hypoxia are known risk factors for 
ASD. Further, if the mother is both obese and diabetic, there can be a potential interaction, 
presenting an even higher risk than each alone 
Cholesterol and Vitamin D: At normal levels, cholesterols are important components of 
cellular membranes, regulating permeability and synapse formation in the brain. Approximately 
25% of the cholesterol in the body is found in the brain and the myelin sheath, which protects 
neuronal axons, contains 70% of brain cholesterol.69 They also play important roles in the 
development of the fetal brain as they are involved in cellular membrane and steroid hormone 
formation. Certain cholesterols may cross the placenta affecting the concentrations in the womb, 
and aberrant concentrations have been shown to be associated with adverse outcomes in the 
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offspring. Fragile X syndrome, closely related to ASD, is marked by low levels of myelin.70 Low 
maternal high-density lipoprotein cholesterol (HDL-C) and high triglycerides were also found to 
be associated with ADHD in the BBC.71 Finally, both low and high total cholesterol were 
associated with preterm birth.72 Both ADHD and preterm birth are highly associated with ASD. 
Cholesterols are precursors of all steroid hormones except for vitamin D. However, vitamin D 
and cholesterol are both derived from the same molecule, 7-dehydrocholesterol (7DHC).70 
Steroid hormones have been associated with ASD and other mood disorders and there is building 
evidence implicating vitamin D in ASD etiology.27,73,74 The genes expressing serotonin, 
oxytocin, and vasopressin each contain a vitamin D response element (VDRE) and require 
vitamin D to activate them.74 All three hormones are reported to be dysregulated in ASD and are 
also regulated by cholesterol. A recent study showed that low concentrations of 25-
hydroxyvitamin D in the first trimester of pregnancy had significantly increased levels of total 
cholesterol, low-density lipoprotein cholesterol (LDL-C) and total cholesterol to HDL-C ratio 
compared to pregnant women with adequate levels of the vitamin.75  
Metabolic Syndrome: Metabolic syndrome is a loosely defined term for a cluster of co-
occurring metabolic risk factors of type 2 diabetes and cardiovascular disease.76 Though there is 
no obligatory component, metabolic syndrome typically comprises elevated blood pressure, 
dyslipidemia, hyperglycemia, and central obesity. We and others have shown maternal obesity 
and diabetes are associated with child risk of ASD.26,65,66 The prevalence of pre-pregnancy 
hypertension was also higher among mothers who had children with ASD, and together with 
obesity and diabetes, was associated with a higher likelihood of having a child with ASD.77 
Amino Acids: Extensive evidence points to differences in levels, metabolism, and functionality 
of amino acids in the autistic brain. Most of these studies consider glutamate, the major 
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excitatory neurotransmitter and γ-aminobutyric acid (GABA), the main inhibitory 
neurotransmitter as reviewed by Zheng et al (2017).78 This review also highlights the function 
and significance of other neuroactive amino acids, including tryptophan, serine, glycine, and the 
branched-chain amino acids (BCAAs) – leucine, isoleucine, and valine. Ten studies report higher 
glutamate concentrations in blood plasma of individuals with ASD compared to healthy controls, 
while one reported a lower concentration. However, while three neuroimaging studies also found 
higher glutamate in the brain of individuals with ASD compared to control, one study reported 
lower glutamate and another found no difference. All three studies of urine metabolites found 
lower glutamate concentrations in individuals with ASD. Two studies in plasma and one in urine 
found higher GABA levels but all five neuroimaging studies reported lower levels of GABA in 
the brain in individuals with ASD. Similarly, all other amino acids also had inconsistent findings, 
except leucine and isoleucine, which were lower in individuals with ASD compared to controls 
in all reports of plasma, urine, and cerebrospinal fluid.  
Branched-chain amino acids: The BCAAs – leucine, isoleucine, and valine – are essential 
amino acids and the most abundant in animal proteins.79 They are involved in protein synthesis, 
metabolic and glucose homeostasis, and are key nitrogen donors in the form of glutamate, 
glutamine, and alanine.80 Glutamate is the major excitatory neurotransmitter and also the 
precursor for GABA, the major inhibitory neurotransmitter. Leucine is also important in cellular 
signaling and is a potent activator of the mammalian target of rapamycin (mTOR). mTOR is a 
kinase that regulates a vast network of cellular mechanisms, including insulin release, lipid 
synthesis, and promotion of protein synthesis in the periphery as well as in the CNS. BCAAs 
have been studied as biomarkers associated with obesity,81,82 diabetes,80,81,83 inflammation and 
the immune system,80,84 and cholesterol metabolism.85,86  
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BCAAs are first metabolized via transamination by branched-chain aminotransferase (BCAT) 
into their respective branched-chain α-keto acids (BCKAs).80 The BCKAs then undergo 
oxidative decarboxylation by the branched-chain α-keto acid dehydrogenase enzyme 
complex (BCKDC) to produce their respective branched-chain acyl-CoA derivatives. Maple 
syrup urine disease (MSUD) is the most well-known BCAA-related disorder caused by 
mutations in the BCKDC protein, and can cause severe neurological damage.84 The branched-
chain acyl-CoA derivatives are then further catabolized until they finally enter the tricarboxylic 
acid (TCA) cycle or serve as precursors for lipogenesis or gluconeogenesis.80 Imbalance of TCA 
cycle inputs can disrupt beta oxidation in the mitochondria and lead to mitochondrial 
dysfunction, implicated in ASD etiology.43,59 As mentioned in the section above, BCAA 
concentrations are consistently reported to be lower in ASD individuals compared to typically 
developing individuals.78,87,88  There are no intergenerational studies, to our knowledge, 
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CHAPTER 3 METHODOLOGY 
 
DATA SOURCE  
The Boston Birth Cohort (BBC) was established in 1998 at the Boston Medical Center by 
principal investigator, Dr. Xiaobin Wang and the study is ongoing. The BBC was initially 
designed as a molecular epidemiologic study to investigate risk factors for preterm birth and low 
birthweight in a low income, minority population in the Boston area. Employing a rolling 
ongoing enrollment, the study has successfully recruited over 8,600 mother-infant pairs to date 
with over a 90% participation rate among eligible mothers approached by the study staff. 
Mothers were recruited 24-72 hours post-partum, and written informed consent was obtained 
from the participants. Exclusion criteria included multiple births, pregnancies due to in vitro 
fertilization, babies with chromosomal abnormalities or major birth defects, and children with 
other developmental disorders.  
Beginning in 2003, a subset of children receiving care at the Boston Medical Center were 
enrolled in the Children’s Health Study and followed up during well-child visits.1-3 In 2003, the 
Boston Medical Center implemented the Electronic Medical Records (EMR) system, from which 
the BBC was able to collect information on physician diagnoses on children based on the 
International Classification of Diseases, Ninth Revision or Tenth Revision (ICD-9 or ICD-10). 
This information became a rich source of clinical data for the BBC and included EMR of 
inpatient and outpatient units as well as the emergency and operating rooms and laboratory tests. 
The BBC has obtained EMR data from each postnatal visit during 2003 – 2016. The Children’s 
Health Study has over 3,000 participants, from which our study samples were selected. Only 
mothers with metabolite measurements and children receiving continued care at the BMC were 
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included in the present study. Both the initial and follow-up studies were approved by the 
Institutional Review Boards (IRB) of the Johns Hopkins Bloomberg School of Public Health and 
the Boston University Medical Center. The exclusion criteria for the present study (Aim 1) is 
shown in Figure 3-1. Sample sizes for each aim are presented in Table 3-1 and maternal and 
child characteristics for included and excluded participants (from Aim 1) are compared in Table 
3-2.  
The power calculation reflects maternal branched-chain amino acid (BCAA) score for Aims 2 
and 3 since these aims had the smallest sample size (n=829). The rate of ASD in the BBC is 
10.4%, higher than the CDC reported rate,4 this is in part due to the fact that the BBC is enriched 
by children with preterm and low birthweight, which are known risk factors of ASD.5 With our 
sample size, H. 
Figure 3-1. Flowchart of study sample included and excluded in the analyses 
 
3,163 mother-infant pairs with EMR records of well-child and specialty visits 
1,933 typically developing children; 150 children with ASD; 1080 cases of  
other developmental disabilities (DD) 
    
864 mother-infant pairs  
   775 typically developing children 
   89 children with ASD with or without other DD 
1202 excluded for missing 
metabolite measurement  
1080 excluded due to 
other DDs 




Table 3-1. Sample size 
 Sample Size N ASD 
Typically 
Developing 
Aim 1    
 Maternal obesity/diabetes and 
BCAAs 
864 89 775 
Aim 2    
 Maternal cholesterol and 
BCAAs 
829 86 743 
Aim 3    
 Maternal multiple metabolic 
disorders and BCAAs  





Table 3-2. Maternal and child characteristics between participants excluded and included in the 
analysis 
 
Characteristics Total, N (%) Excluded, N (%) Included, N (%) P-valuea 
Total 3138 (100.00) 2274 (72.47) 864 (27.53)  
Maternal age (years), mean (SD)b 28.64 (6.50) 28.64 (6.48) 28.21 (6.51) 0.094 
Nulliparous, n (%) 1337 (42.61) 958 (42.13) 379 (43.87) 0.379 
Race or ethnicity, n (%)c    <0.0001 
   Black 1998 (63.67) 1387 (60.99) 611 (70.72)  
   White 227 (7.23) 192 (8.44) 35 (4.05)  
   Hispanic 701 (22.34) 540 (23.75) 161 (18.63)  
   Other 212 (6.76) 155 (6.82) 57 (6.60)  
Maternal education, n (%)    0.973 
   Below college degree 2690 (85.72) 1949 (85.71) 741 (85.76)  
   College degree or above 426 (13.58) 309 (13.59) 117 (13.54)  
   Missing 22 (0.70) 16 (0.70) 6 (0.69)  
Maternal BMI, n (%)     
   Mean (SD) 26.58 (6.65) 26.59 (6.67) 26.56 (6.60) 0.918 
   Normal weight (<25) 1452 (46.27) 1046 (46.00) 406 (46.99) 0.842 
   Overweight (25 - <30) 813 (25.90) 595 (26.17) 218 (25.23)  
   Obese (≥30) 703 (22.40) 501 (22.03) 202 (23.38)  
   Missing 170 (5.42) 132 (5.80) 38 (4.40)  
Maternal Diabetesd    0.099 
   No diabetes 2751 (87.67) 1980 (89.68) 771 (89.24)  
   Diabetes 387 (12.33) 294 (12.93) 93 (10.76)  
Maternal smoking, n (%)e     
   Never 2542 (81.01) 1812 (79.68) 730 (84.49) 0.001 
   Quit 241 (7.68) 186 (8.18) 55 (6.37)  
   Continuous 336 (10.71) 267 (11.74) 69 (7.99)  
   Missing 19 (0.61) 9 (0.40)  10 (1.16)  
Child’s, n (%)    0.001 
   Male 1583 (50.45) 1187 (52.20) 396 (45.83)  
   Female 1555 (49.55) 1087 (47.80) 468 (54.17)  
Gestational age, n (%)    0.001 
   Term (≥37 weeks) 2448 (78.01) 1712 (75.29) 736 (85.19)  
   Late preterm (34-36 weeks) 306 (9.75) 238 (10.47) 68 (7.87)  
   Early preterm (<34 weeks) 384 (12.24) 324 (14.25) 60 (6.94)  
Birthweight    <0.0001 
   ≥2,500 grams 2275 (72.50) 1573 (69.17) 702 (81.25)  
   <2,500 grams 863 (27.50) 701 (30.83) 162 (18.75)  
SD, standard deviation 
aP-values were obtained from chi-square or t-tests; missing values for categorical variables incorporated with largest 
sized group 
bMaternal age at time of delivery 
cBlack includes self-reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; 
other includes Asian and Pacific Islander races 
dType II diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking six months prior to conception or during 
pregnancy; some smoking includes mothers who smoked at some point in the window of six months prior to 
conception to delivery but did not smoke throughout that window; continuous is defined as mothers that smoked 





Mothers were recruited into the BBC within 72 hours post-partum and informed consent was 
obtained from the participants. A standardized questionnaire interview was conducted to obtain 
maternal demographic information and smoking status. A medical abstraction form was used to 
collect clinical data from maternal and newborn medical records, including parity, pre-pregnancy 
weight and height, pre-pregnancy diabetes, hypertensive disorders, pregnancy-related 
complications, gestational age, and birthweight. A non-fasted venous blood samples was also 
collected by antecubital venipuncture at this time. Blood plasma was analyzed for a lipid panel, 
including total cholesterol, high-density lipoprotein (HDL), low-density lipoprotein (LDL), and 
triglycerides (TG). Targeted metabolites, selected for their associations with obesity and 
metabolic disorders, from the plasma were quantified using an LC-MS/MS at the Massachusetts 
Institute of Technology Broad Institute Metabolite Profiling Laboratory. ASD diagnosis was 
obtained from EMR records at every postnatal visit starting in 2003. This study was approved by 
the Institutional Review Boards of the Johns Hopkins Bloomberg School of Public Health and 
Boston University Medical Center. 
MEASURES 
Primary outcome 
The primary outcome of this investigation is the child’s clinical diagnosis of ASD. ASD cases 
were defined by clinician diagnosed ICD codes in the EMR. Prior to October 1st, 2015, ICD-9 
codes used for autism were 299.0, 299.00, 299.01, 299.8, 299.80, 299.81, 299.9, 299.90, or 
299.91 and beginning on October 1st, 2015, ICD-10 codes were used (F84.0, F84.8, or F84.9). 
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The Diagnostic and Statistical Manual of Mental Disorders (DSM) is set by the American 
Psychiatric Association, with DSM-IV being released in 1994 and DSM-5 in 2013.6 The DSM-
IV included sub-diagnoses, including Autistic Disorder, Asperger Syndrome, Pervasive 
Developmental Disorder Not Otherwise Specified, and there were three areas of diagnostic 
criteria: social reciprocity, communicative intent, restricted and repetitive behaviors. In the 
DSM-5, there is only one diagnosis of Autism Spectrum Disorders and the diagnostic criteria 
have been condensed to two areas: social communication/interaction and restricted and repetitive 
behaviors. Symptom severity for each of these areas is also defined. Across both diagnostic 
criteria, the symptoms are required to be functionally impairing and must be present in early 
childhood, though they may not fully manifest until later under increasing social demands. The 
diagnoses of all ASD cases were obtained from electronic medical records after having been 
evaluated by highly trained staff the ASD evaluation center at the Boston Medical Center, who 
are in direct contact with primary care physicians center. Table 3-3 presents the ICD9 codes for 
our case definition of ASD. 
Primary exposures/risk factors 
The primary exposures are listed in Table 3-4. Maternal plasma total cholesterol, HDL, LDL, 
TG, and metabolites were measured using nonfasting blood samples obtained between 24-72 





Table 3-3. List of ICD-9 and ICD-10 codes for the diagnosis of each developmental disorder 
Developmental disorder ICD-9 codes ICD-10 codes 
ASD 299.0, 299.00, 299.01, 299.8, 
299.80, 299.81, 299.9, 299.90, 
299.91 
F84.0, F84.8, F84.9 
ADHD 314.0, 314.00, 314.01, 314.1, 
314.2, 314.8, 314.9 
F90, F90.0, F90.1, F90.2, F90.8, 
F90.9 
Developmental delays 315.0, 315.9 F81.0, R48.0, F81.81, F81.2, 
F81.89, F80.1, F80.2, H93.25, 
F80.4, F80.81, F80.0, F80.82, 
F80.89, F82, F88, F81.9, F89 





Table 3-4. List of primary exposures 
Primary exposures Source  Definition 
Aim 1 (N=864)   
Maternal obesity Standardized interview Pre-pregnancy BMI  30 
kg/m2 
Maternal diabetes   




EMR ICD-9 codes 648.00 and 
648.03 
Maternal Plasma 
BCAAs & score 
Collected within 1-3 days of birth; 
quantified via LC-MS/MS 
Cut off at the median 
Aim 2 (N=829)   
Maternal TC Collected within 1-3 days of birth Cut off at 240 mg/dL 
Maternal HDL  Collected within 1-3 days of birth Cut off at <50 mg/dL 
Maternal LDL  Collected within 1-3 days of birth; 
calculated from Friedewald 
equation 
Cut off at 160 mg/dL 
Maternal non-HDL Subtracted HDL-C from TC Cut off at 190 mg/dL 
Maternal Plasma 
BCAAs & score 
Collected within 1-3 days of birth; 
quantified via LC-MS/MS 
Cut off at the median 
Aim 3 (N=829)   
Maternal obesity Standardized interview Pre-pregnancy BMI 30 
kg/m2 
Maternal diabetes   




EMR ICD-9 codes 648.00 and 
648.03 




EMR Any one of the following: 
eclampsia, pre-eclampsia, 
chronic hypertension, 
gestational hypertension, or 
hemolysis elevated liver 
enzymes low platelet count 
(HELLP) syndrome) 
Maternal Multiple 
Metabolic Disorders  
A score comprising the above 
components 
MMD cut-off 3; see Table 
3-5 for full definition 
Maternal Plasma 
BCAAs & score 
Collected within 1-3 days of birth; 
quantified via LC-MS/MS 





Table 3-5. Maternal Multiple Metabolic Disorders (MMD) Definition 
Component Points 
Maternal BMIa  
Normal (<25 kg/m2) 0 
Overweight (25 - <30 kg/m2) 1 
Obese (30 kg/m2) 2 
Maternal diabetesa  
None 0 
Gestational diabetes  1 
Type 2 diabetes 2 
Maternal HDL  
 50 mg/dl 0 






Note: MMD is defined as a score of  3 with a total possible score of 6 
aMutually exclusive categories  
bSee Table 3-4 for definition of hypertensive disorders 
Other covariates  
Table 3-6 provides a list of pertinent pre- and peri-natal and child factors that could potentially 
confound the relationship between maternal obesity/diabetes, cholesterol, multiple metabolic 
disorders, BCAAs and ASD risk. These factors were adjusted for in the multivariate models. 
Table 3-6. Maternal pre-pregnancy and child factors used as covariates in the models 
Variables  Definition Type 
Maternal factors   
Maternal age Maternal age at the time of enrollment Continuous 
Parity Number of previous deliveries not including index 
pregnancy - nulliparous vs. multiparous 
Binary 
Maternal education Below college degree vs. college or more Binary 
Maternal race/ethnicity Black, White, Hispanic and other Categorical 
Smoking during pregnancy Whether mother ever smoked 3 months before 
pregnancy/during pregnancy - never, quit, 
continuous 
Categorical 
Child factors     
Sex Child's sex  Binary 
Gestational age Preterm (<37 weeks) vs. term delivery Binary 




Descriptive data analysis and derived variables: Exploratory data analysis was conducted to 
examine ranges and distributions for all key variables. The BCAA metabolites were inverse 
normally transformed to produce Gaussian distributions. The primary outcome, ASD diagnosis, 
was binary. The exposure variables obesity/diabetes, and cholesterols were treated as binary and 
BCAAs were examined as binary, categorical, and continuous. The BCAA score was created 
using factor analysis of the three BCAAs, leucine, isoleucine, and valine using the Anderson-
Rubin Method.7 Each BCAA and the BCAA score were dichotomized into “below median” and 
“above median.” Chi-squared tests were conducted for binary and categorical variables and t-
tests were conducted for continuous variables across the ASD and TD groups. Missing values for 
categorical covariate variables were incorporated into the largest sized group. Any un-detectable 
metabolite values were imputed with one-half the limit of detection. Since gestational age and 
birthweight were highly correlated, they combined into one categorical variable with four groups 
(1. full term (37 completed weeks of gestation) and non-LBW (2500g); 2. full term and LBW; 
3. preterm and non-LBW; 4. preterm and LBW). All analyses were completed in Stata v14.0 
(Stata Corporation, College Station, TX, USA). 
Analysis for Aim 1 
Due to the high correlation between the exposure variables, obesity and diabetes, the two were 
combined into one variable. This variable was analyzed as a binary variable (no obesity or DM 
vs either/both obesity or DM), as well as a categorical variable (1. no obesity nor DM; 2. either 
obesity or DM; 3. both obesity and DM). The associations between BCAAs and ASD were 
evaluated using multinomial logistic regression. The logistic regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1BCAA + 𝜀 
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We further tested for mediation and joint effects, including interaction. The hierarchical 
regression method was conducted for mediation analysis of BCAAs for the association between 
ob/DM and ASD.8 Interaction was tested between BCAAs and ob/DM as well as BCAAs and 
child’s sex employing tests for additive and multiplicative interaction and the relative excess risk 
due to interaction (RERI).9 To examine joint effects of ob/DM with BCAAs, a categorical 
variable with four groups was created as follows: 
Ob/DM BCAA New variable 
0 0 0 
0 1 1 
1 0 2 
1 1 3 
 
The logistic regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1ob/DM0BCAA0i + 𝛽2ob/DM0BCAA1i + 
𝛽3ob/DM1BCAA0i + 𝛽4ob/DM1BCAA1i + 𝛽cCi + 𝜀i 
where Yi is the outcome for subject i, Ci  are the set of covariates for subject i, and 𝛽 represents 
the corresponding regression coefficient for each term. Subscripts 0 are for the condition being 
absent and subscripts 1 are for the condition being present.  
With interaction term: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1ob/DM0BCAA0i + 𝛽2ob/DM0BCAA1i + 
𝛽3ob/DM1BCAA0i + 𝛽4ob/DM1BCAA1i + 𝛽cCi + 𝛽5ob/DM*BCAA + 𝜀i 
The joint effect of BCAAs and child’s sex on child risk of ASD was also investigated. The 
logistic regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1BCAA0Sex0i + 𝛽2BCAA1Sex0i + 𝛽3BCAA0Sex1i 
+ 𝛽4BCAA1Sex1i + 𝛽cCi + 𝜀i 
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With interaction term: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1BCAA0Sex0i + 𝛽2BCAA1Sex0i + 𝛽3BCAA0Sex1i 
+ 𝛽4BCAA1Sex1i + 𝛽cCi + 𝛽5BCAA*Sexi + 𝜀i 
Further (unadjusted) joint analysis was conducted with all three risk factors: ob/DM, BCAAs, 
and child’s sex. The logistic regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1ob/DM0BCAA0Sex0i + 𝛽2ob/DM0BCAA1Sex0i + 
𝛽3ob/DM1BCAA0Sex0i + 𝛽4ob/DM1BCAA1Sex0i + 𝛽5ob/DM0BCAA0Sex1i + 
𝛽6ob/DM0BCAA1Sex1i + 𝛽7ob/DM1BCAA0Sex1i + 𝛽8ob/DM1BCAA1Sex1i + 𝜀i 
 
Analysis for Aim 2  
 
The analysis for Aim 2 is similar to that of Aim 1. Categorical variables with four groups were 
created with the BCAAs and BCAA score for each maternal cholesterol measure. Because the 
cholesterol measurements were taken during a non-fasted state, all but HDL were not considered 
reliable and thus were not the focus of this aim. The logistic regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1HDL0BCAA0i + 𝛽2HDL0BCAA1i + 
𝛽3HDL1BCAA0i + 𝛽4HDL1BCAA1i + 𝛽cCi + 𝜀i 
With interaction term: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1HDL0BCAA0i + 𝛽2HDL0BCAA1i + 
𝛽3HDL1BCAA0i + 𝛽4HDL1BCAA1i + 𝛽5HDL*BCAAi + 𝛽cCi + 𝜀i 
In this aim, the joint effect of HDL and child’s sex on child ASD was investigated. The logistic 
regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1HDL0Sex0i + 𝛽2HDL1Sex0i + 𝛽3HDL0Sex1i + 
𝛽4HDL1Sex1i + 𝛽cCi + 𝜀i 
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With interaction term: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1HDL0Sex0i + 𝛽2HDL1Sex0i + 𝛽3HDL0Sex1i + 
𝛽4HDL1Sex1i + 𝛽5HDL*Sexi + 𝛽cCi + 𝜀i 
Further joint analysis was conducted with all three risk factors: HDL, BCAAs, and child’s sex. 
The logistic regression model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1HDL0BCAA0Sex0i + 𝛽2HDL0BCAA1Sex0i + 
𝛽3HDL1BCAA0Sex0i + 𝛽4HDL1BCAA1Sex0i + 𝛽5HDL0BCAA0Sex1i + 𝛽6HDL0BCAA1Sex1i + 
𝛽7HDL1BCAA0Sex1i + 𝛽8HDL1BCAA1Sex1i + 𝜀i 
Analysis for Aim 3  
The analysis for Aim 3 also closely follows that of Aim 1. Logistic regression was first 
conducted for each MMD component on the risk of child ASD. The logistic regression model is 
represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1Ei + 𝜀i 
where Ei is each component for subject i. 
The MMD score was also evaluated as a categorical variable for its association with child ASD 
risk (0, 1, 2, or 3+) and a likelihood test for trend was conducted. The logistic regression model 
is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1MMD0i + 𝛽1MMD1i + 𝛽1MMD2i + 𝛽1MMD3+i + 
𝜀i 
Categorical variables with four groups were created for each of the BCAAs and the BCAA score 
with the MMD score (binary). The logistic regression model is represented by: 
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ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1MMD0BCAA0i + 𝛽2MMD0BCAA1i + 
𝛽3MMD1BCAA0i + 𝛽4MMD1BCAA1i + 𝛽cCi + 𝜀i 
With interaction term: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1MMD0BCAA0i + 𝛽2MMD0BCAA1i + 
𝛽3MMD1BCAA0i + 𝛽4MMD1BCAA1i + 𝛽5MMD*BCAAi + 𝛽cCi + 𝜀i 
The unadjusted version of these models were then stratified by child’s sex. Further joint analysis 
was conducted with all three risk factors: MMD, BCAAs, and child’s sex. The logistic regression 
model is represented by: 
ln (Pr(Yi = ASD)/Pr(Yi = non-ASD)) = 𝛽0 + 𝛽1MMD0BCAA0Sex0i + 𝛽2MMD0BCAA1Sex0i + 
𝛽3MMD1BCAA0Sex0i + 𝛽4MMD1BCAA1Sex0i + 𝛽5MMD0BCAA0Sex1i + 𝛽6MMD0BCAA1Sex1i 






1. Kumar R, Tsai HJ, Hong X, et al. Race, ancestry, and development of food-allergen 
sensitization in early childhood. Pediatrics. 2011;128(4):821. doi: 10.1542/peds.2011-0691. 
2. Wang G, Divall S, Radovick S, et al. Preterm birth and random plasma insulin levels at birth 
and in early childhood. JAMA. 2014;311(6):587-596. doi: 10.1001/jama.2014.1. 
3. Li M, Fallin MD, Riley A, et al. The association of maternal obesity and diabetes with autism 
and other developmental disabilities. Pediatrics. 2016;137(2):e20152206. doi: 
10.1542/peds.2015-2206. 
4. Baio J, Wiggins L, Christensen DL, et al. Prevalence of autism spectrum disorder among 
children aged 8 years - autism and developmental disabilities monitoring network, 11 sites, 
united states, 2014. MMWR Surveill Summ. 2018;67(6):1-23. doi: 10.15585/mmwr.ss6706a1. 
5. Schieve LA, Tian LH, Rankin K, et al. Population impact of preterm birth and low birth 
weight on developmental disabilities in US children. Ann Epidemiol. 2016;26(4):267-274. doi: 
10.1016/j.annepidem.2016.02.012. 
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 
(DSM-5®). American Psychiatric Pub; 2013. 
7. Anderson TW, Rubin H. Statistical inference in factor analysis. Proceedings of the Berkeley 




8. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological 
research: Conceptual, strategic, and statistical considerations. J Pers Soc Psychol. 
1986;51(6):1173-1182. 
9. Knol MJ, VanderWeele TJ, Groenwold RH, Klungel OH, Rovers MM, Grobbee DE. 
Estimating measures of interaction on an additive scale for preventive exposures. Eur J 





CHAPTER 4 MATERNAL OBESITY/DIABETES, PLASMA 
BRANCHED-CHAIN AMINO ACIDS (BCAAS), AND RISK OF 





Maternal obesity/diabetes (ob/DM) are known risk factors for child ASD. Branched-chain amino 
acids (BCAAs) are associated with ob/DM in adults and BCAAs were also associated with ASD 
in children. We examined the joint associations of maternal ob/DM and BCAAs on child ASD 
risk and whether the associations differed by child’s.  
Methods: 
We analyzed 864 mother-infant pairs, a subset of the Boston Birth Cohort with pertinent data. 
Maternal plasma BCAAs were measured by liquid chromatography-tandem mass spectrometry 
(LC-MS/MS) in samples collected 24-72 hours postpartum. A composite BCAA score was 
created using factor analysis, and pre-pregnancy obesity and diabetes (ob/DM) were combined 
into one variable. Logistic regression was used to explore the role of BCAAs as mediators or co-
factors with ob/DM and sex on child ASD risk. BCAA-ob/DM and BCAA-sex interactions were 




Maternal BCAAs alone were not associated with ASD and did not mediate the path between 
ob/DM and ASD. In the presence of maternal ob/DM (n=202), BCAA score was significantly 
associated with ASD (adjusted OR 2.35, 95% CI 1.21, 4.55). Interactions were present for 
leucine and valine with ob/DM and for leucine and isoleucine with male sex on ASD risk. The 
OR was the greatest with all three risk factors – male sex, high BCAA score, and ob/DM (OR 
8.72, 95% CI 3.62, 20.99). Similar patterns were found for other developmental disorders, 
though not as strong as for ASD. 
Conclusions: 
While male sex and maternal ob/DM are known risk factors of child ASD, we found elevated 
maternal plasma BCAAs further increased this risk. Additional studies are warranted to clarify 
the role of maternal BCAAs in ASD and to help elucidate mechanisms behind the 3:1 male to 






Autism spectrum disorder (ASD) is an array of neurodevelopmental conditions characterized by 
deficits in social interaction and communication and by restricted or repetitive interests and 
behaviors.1 The etiology of ASD is complex and poorly understood. Though highly heritable, 
various environmental factors are also implicated in its pathophysiology.2 This study focuses on 
two major research gaps. First, maternal obesity and type II diabetes mellitus (T2DM) are 
important risk factors of ASD as demonstrated by us and others; however, the underlying 
molecular mechanisms are unclear.3-5 Since 20-40% of mothers in developed countries enter 
pregnancy obese, this is a matter of great urgency.6-8 Second, though ASD is much more 
common in males, with a male to female ratio of approximately 3:1, there is a lack of 
understanding of factors responsible for this disproportionate risk.9  
Branched-chain amino acids (BCAAs) – leucine, isoleucine, and valine – are essential amino 
acids mainly found in animal-sourced foods and have important cellular signaling roles. Altered 
amino acids are known to be associated with obesity and diabetes.10,11 For example, elevated 
circulating BCAAs are predictive of incident T2DM.12,13 Studies also show links between BCAA 
and ASD with inconsistent findings.14-16 However, the role of maternal circulating BCAAs in 
children ASD remains uncertain as the few metabolomics studies that exist were conducted in 
ASD individuals rather than in an inter-generational setting. These studies were also small in 
sample size and reported mostly inconsistent results. There is a lack of prospective birth cohort 
studies to assess the temporal relationship of maternal circulating BCAAs on child risk of 
developing ASD. 
In light of persistently high rates of maternal obesity/diabetes and growing evidence of BCAA 
involvement in obesity/diabetes and ASD, we sought to investigate the joint associations of 
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maternal obesity/diabetes and maternal plasma BCAAs on offspring risk of ASD. Further, we 
aimed to clarify the role of maternal BCAAs as mediators or co-factors in the pathway from 
maternal obesity/diabetes to child ASD. Given the striking sex difference in ASD, we were also 
interested in exploring whether the aforementioned associations differ by child’s. We took 
advantage of an intergenerational prospective cohort to illuminate the role of the prenatal 
metabolic environment – as assessed by both clinical measurements of maternal obesity/diabetes 
and maternal plasma BCAA metabolites – in the development of ASD in children.  
METHODS 
Participants and Data Collection Procedure 
This study included 864 mother-infant pairs, a subset of the Boston Birth Cohort (BBC), an 
ongoing study at the Boston Medical Center (BMC). The present study includes mothers 
recruited from 2004 – 2015 and children prospectively followed from 2004 – 2017. Details of 
BBC recruitment have been previously published.3 Both the initial and follow-up studies were 
approved by the Institutional Review Boards (IRB) of the Johns Hopkins Bloomberg School of 
Public Health and the Boston University Medical Center. 
Briefly, mothers were recruited 24-72 hours post-partum, and written informed consent was 
obtained from the participants. Exclusion criteria included multiple births, pregnancies due to in 
vitro fertilization, babies with chromosomal abnormalities or major birth defects, and children 
with other developmental disorders. Only mothers with metabolite measurements and children 
receiving continued care at the BMC were included in this study (Supplemental Figure 4-1). 
Maternal and infant medical records were reviewed using standardized abstraction forms and 
mothers were interviewed face-to-face using a standardized questionnaire. Maternal blood was 
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collected at the time of enrolment and fractionated at the BMC. Liquid chromatography tandem 
mass spectrometry (LC-MS/MS) was used to quantitatively profile maternal plasma metabolites 
at the Harvard-MIT Broad Institute Metabolite Profiling Laboratory.  
Identification of Children with ASD 
ASD was defined based on the electronic medical records (EMR) which contain clinicians’ 
primary and secondary diagnoses using ICD-9 or ICD-10 codes from all child visits at the BMC, 
including primary care and subspecialty care (Supplemental Table 4-1). Based on EMR ICD 
codes, children who were ever diagnosed with autism (299.00), Asperger syndrome (299.80), 
and/or pervasive developmental disorder - not otherwise specified (299.90) constituted the ASD 
cases. Of note, while we did not conduct a systematic screen for ASD, the sensitivity and 
specificity of ASD diagnosis from the BMC is high due to its excellent autism evaluation 
program; all children with an ASD diagnosis were evaluated by them and they communicate 
regularly with the primary care pediatricians at the BMC. Children with attention deficit 
hyperactivity disorder (ADHD), developmental delays, or intellectual disabilities without ASD 
were classified as having other developmental disorders. Children without any diagnosis of ASD 
or other developmental disorders were classified as typically developing (TD).  
Exposures 
Maternal body mass index (BMI) was calculated using the pre-pregnancy weight and height 
obtained from the standardized questionnaire. Obesity was defined as BMI 30kg/m2. Diabetes 
(DM) was identified by ICD-9 codes (250.00–250.93 for pre-gestational diabetes and 648.00 and 
648.03 for gestational diabetes (GDM)). Because obesity and diabetes are highly correlated, they 
were combined into one variable and analyzed as a dichotomous variable (no obesity or DM vs 
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either/both obesity or DM), or a categorical variable (1. no obesity nor DM; 2. either obesity or 
DM; 3. both obesity and DM). Each maternal plasma BCAA was dichotomized into “below 
median” vs “median or above.” A composite BCAA score was created using factor analysis and 
it was dichotomized in the same fashion. 
Covariates 
Maternal covariates included: age at delivery; race-ethnicity (black, white, Hispanic, or other); 
smoking during pregnancy (“never smoked,” “ever smoked,” or “continuous smoking” three 
months prior to pregnancy); parity (nulliparous vs multiparous), and education (“high school or 
less” vs “some college or more”). Child covariates included: child’s sex (female vs male); and 
gestational age and birthweight (categorized into four groups: 1. full term (37 completed weeks 
of gestation) and non-low birthweight (non-LBW; 2500g); 2. full term and LBW; 3. preterm 
and non-LBW; 4. preterm and LBW). 
Statistical Analysis 
Our central hypothesis was that maternal plasma BCAA concentrations and maternal obesity 
and/or diabetes are jointly associated with child ASD risk. We also queried whether there is a sex 
difference in the association. As a first step, maternal and child characteristics for the ASD and 
TD groups were compared using t-tests for continuous variables and chi-squared tests for 
categorical variables. Missing values for categorical variables were incorporated into the largest 
sized group. The intensity levels of the metabolites were inverse-normally transformed to 
produce standardized distributions for all subsequent analyses, and any metabolite values below 
the limit of detection were imputed with one-half the limit of detection. A factor analysis score 
for BCAA (BCAA score) was calculated based on the three BCAAs using the Anderson-Rubin 
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Method.17 Multinomial logistic regression modeling was conducted to explore the association 
between ASD and maternal BCAA metabolites as well as the BCAA score. 
We further evaluated for mediation and joint effects, including interaction. Mediation analysis of 
BCAAs for ob/DM was conducted employing the hierarchical regression method.18 Joint effects 
of BCAAs with ob/DM were also analyzed. Based on previous literature, we assigned children 
with maternal BCAA below median concentrations and without ob/DM as the reference group, 
and all three other groups (BCAAs below the median and any ob/DM, BCAAs above the median 
and no ob/DM, and BCAAs above the median and any ob/DM) were compared to it. We tested 
interactions between BCAAs and ob/DM and between BCAAs and child’s sex using tests for 
additive and multiplicative interaction and the relative excess risk due to interaction (RERI).19 
All analyses were conducted in Stata v14.0 (Stata Corporation, College Station, TX, USA) and 
RStudio v1.1.423 (RStudio, Inc., Boston, MA, USA). 
RESULTS 
A total of 864 mother-infant pairs were included in the analysis: 89 with ASD children and 775 
with TD children. Children with ASD had co-occurring, non-mutually exclusive conditions, 
including ADHD (n = 36) and intellectual disabilities (n = 14). On average, mothers of children 
diagnosed with ASD were approximately two years older than mothers of TD children (p<0.01) 
(Table 4-1). Pre-pregnancy BMI was significantly higher among mothers of ASD children than 
those of TD children (28.2 kg/m2 vs 26.4 kg/m2, p=0.02) as was obesity status (34.8% vs 22.1%, 
p = 0.01). DM was also more prevalent among mothers with ASD children than those with TD 
children, though this was only marginally significant (17.1% vs 9.9%, p = 0.05). More ASD 
children were male (31.6 percentage point difference, p <0.0001), born early preterm (16.1 
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percentage point difference, p <0.0001), and LBW (9.2 percentage point difference, p = 0.04) 
compared to their TD counterparts. There were no significant differences in maternal parity, 
race-ethnicity, education, or smoking status. Maternal and child characteristics for included and 
excluded participants are compared in Supplemental Table 4-2. 
We reported maternal and child characteristics by level of maternal plasma BCAAs for the 
overall sample (Supplemental Table 4-3) and among males only (Supplemental Table 4-4). All 
three BCAAs were highly correlated with each other (Supplemental Figure 4-2), and there were 
no notable differences in the distribution of maternal BCAA score by child’s sex (Supplemental 
Figure 4-3) nor by maternal ob/DM (Supplemental Figure 4-4). 
When BCAAs were considered alone, there was no association between the BCAAs and child 
risk of ASD (Supplemental Table 4-5), nor did they mediate the effect of ob/DM on this risk 
(Supplemental Table 4-6). However, there was a synergistic effect of BCAAs and ob/DM – 
compared to mothers with no ob/DM and a low BCAA score, mothers with ob/DM and a high 
BCAA score had greater than a two-fold risk of child ASD (odds ratio (OR) 2.35, 95% CI 1.21, 
4.55) (Table 4-2). Conversely, mothers with ob/DM and below median BCAA concentrations 
had no significant risk of bearing a child with ASD (BCAA score OR 0.96, 95% CI 0.46, 2.04). 
Interactions between the BCAAs and ob/DM were significant on the additive scale for leucine 
(p=0.04) and valine (p<0.01) but not for isoleucine or the overall BCAA score. Multiplicative 
interactions between valine and ob/DM on ASD risk were also present (p<0.01). Stratified odds 
ratios are also presented, showing differences in ORs across the strata. Sensitivity analyses were 
consistent with our results (Supplemental Tables 4-7 – 4-10). 
We observed similar patterns for the joint effects between maternal BCAA score and child’s sex 
on child ASD risk (Table 4-3). For the doubly-exposed category (male fetus and high BCAA 
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score) the BCAA score OR was 4.91, 95% CI 2.48, 9.69, while the OR for a male fetus with low 
BCAA score level was also significant but not as high (OR 2.61, 95% CI 1.28, 5.34). 
Conversely, the ORs of ASD risk for mothers carrying female fetuses were not significant, 
regardless of BCAA level. Further, when stratified by BCAA level, ORs for the association 
between child’s sex and ASD outcome were notably disparate, indicating effect modification by 
maternal BCAA level. Tests for interaction between the BCAAs and child’s sex were significant 
on the additive scale, with the strongest BCAA score-ASD associations found for male children 
(p=0.03). There was also evidence of multiplicative interaction for above median maternal 
isoleucine and male sex (p=0.03).   
Effects of ob/DM on child risk of ASD also differed by child’s sex. Compared to no ob/DM 
mothers with female fetuses, mothers with any ob/DM and a male fetus had a six-fold increased 
risk for having a child with ASD when adjusting for demographic factors (Supplemental Table 4-
11). Figure 4-1 further illustrates the association of BCAA score on ASD risk, overall and by sex 
(a.-c.) and when stratified by ob/DM status, overall and by sex (d.-f.). These associations are also 
shown for individual BCAAs (Supplemental Figure 4-5). The risk of the child developing ASD 
was 8.7 times higher (95% CI 3.62, 20.99) in women with all three risk factors - high BCAA 
concentrations, ob/DM, and carrying a male fetus - combined, compared to the reference group 
of mothers with low BCAA concentrations, no ob/DM and carrying a female fetus (Figure 4-2). 
Similar to ASD, maternal BCAAs alone were not associated with other developmental disorders 
(DD) (data not shown), and ob/DM was marginally associated with other DD (p=0.057, data not 
shown). However, a trend was also observed in analysis of the association between joint risk 
factors – ob/DM and BCAAs – and other DD (BCAA score OR 1.50, 95% CI 1.05, 2.13, p for 
interaction = 0.021) (Supplemental Table 4-12). Of note, this effect was mainly driven by 
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leucine, though valine also had a significant interaction (p = 0.018). As found in ASD, there was 
a sex difference observed for other DD as well (Supplemental Tables 4-13 - 4-14), with males at 
a higher risk than females (BCAA score OR 2.51 95% CI 1.59, 3.95, p for interaction = 0.033). 
The risk for other DD was also the highest with all three risk factors combined – male sex, 
maternal ob/DM, and above median maternal BCAAs – adjusted for key covariates 
(Supplemental Figure 4-6). 
DISCUSSION 
Main findings 
Examined alone, maternal plasma BCAAs were not significantly associated with child ASD risk 
and did not mediate the risk conferred by maternal metabolic conditions. However, BCAAs did 
have significant joint effects with maternal ob/DM and child male sex on increasing the risk of 
ASD. The interactions between BCAAs and child’s sex and between BCAAs and maternal 
ob/DM were predominantly additive, consistent with our hypothesis regarding biological 
mechanisms. The combination of maternal ob/DM and below median BCAA concentrations was 
not associated with child risk of ASD, highlighting the strong influence of BCAA concentrations 
in mothers with ob/DM. While child’s sex and ob/DM are previously known risk factors of child 
ASD, our data suggest that elevated BCAA concentrations are associated with further increases 
in this risk. When examined altogether, the three risk factors conferred a nearly nine-fold higher 
risk of child ASD. These effects were also observed with other DD though they were not as 




Over the past several years, multiple studies have brought into focus the association between 
maternal ob/DM and offspring ASD.4,5,20 While the exact biological mechanisms are not clear, 
metabolic conditions, like obesity and diabetes, are associated with chronic, systemic 
inflammation as reflected by increased concentrations of circulating cytokines and 
proinflammatory markers, which can pass through the placenta and adversely affect the 
development of the fetal brain.21,22 Insulin also plays a role in neurodevelopment, and maternal 
diabetes can cause dysregulation of insulin signaling in the fetal brain.23 BCAAs are intricately 
involved in the cellular mechanisms underpinning obesity and diabetes.13,24 For example, 
HOMA-IR (homeostasis model assessment-insulin resistance index) is more strongly correlated 
with BCAAs than with fatty acids.13 Insulin resistance leads to a decrease in BCAA catabolism 
and consequently an increase in circulating BCAAs. Conversely, elevated concentrations of 
BCAAs promote accumulation of fatty acids, which can result in insulin resistance.24  
There are a few studies showing the link between BCAA and ASD.14-16 While exact mechanisms 
underlying the role of BCAAs in ASD remain to be investigated, previous literature has raised 
several possibilities. The relationship between BCAAs and insulin is mediated through the 
mammalian target of rapamycin (mTOR) pathway. mTOR is a kinase within a vast signaling 
network and regulates several key cellular functions, including cellular growth and energy 
balance.25 As the mTOR signaling pathway promotes synaptic protein synthesis, its 
dysregulation has been implicated in the etiology of ASD, in which pruning of neurons during 
development is inhibited.26 Chronic activation of mTOR can inhibit the cellular uptake of 
glucose and lead to insulin resistance, and BCAAs, especially leucine, are known inducers of 
mTOR.25,27 Though the studies on BCAAs and ASD were conducted on individuals with ASD, it 
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is possible that elevated BCAA concentrations in mothers may induce mTOR activity in both the 
mother and fetus. 
Another possibility is that elevated BCAA concentrations tip the balance to increased BCAA 
catabolism, which can overload mitochondria and lead to defective energy metabolism.28 This is 
especially true with an existing inflammatory condition such as obesity or diabetes. Disruption of 
beta oxidation is a precursor to mitochondrial dysfunction, a condition more prevalent in 
individuals with ASD and thought to be linked to its etiology.26,29 ASD is more common among 
patients with propionic acidemia, a metabolic disorder marked by a deficiency in propionyl-CoA 
carboxylase (PCC), the enzyme responsible for the catabolism of BCAAs and other amino 
acids.30 Insufficient PCC leads to disruptions in tricarboxylic acid (TCA) cycle intermediates that 
feed into the mitochondrial respiratory chain. Altered BCAA concentrations are also associated 
with other mental health disorders. For example, treatment for major depressive disorder was 
shown to be more effective in individuals with lower BCAA concentrations, allowing for 
possible prediction of response to treatment via metabolic profile analysis.31 Furthermore, 
supplementation with BCAAs in mice resulted in anxiety-like behavior, a common characteristic 
in several neurocognitive disorders.32 With both BCAAs and metabolic conditions linked to ASD 
via overlapping inflammatory pathways in utero, it is plausible that in combination they may 
contribute to a compounded risk of the disorder.  
Male preponderance in ASD prevalence is well-established in the literature.9 Our findings 
suggest that sexual dimorphism in ASD is influenced by maternal obesity and diabetes in 
conjunction with maternal plasma BCAA concentrations and thus may begin in utero. A recent 
study showed a sex-specific effect in GDM-altered maternal metabolites in second trimester 
amniotic fluid.33 The authors reported while other amino acids are reduced in the amniotic fluid 
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milieu, leucine, along with methionine and tyrosine, was elevated with maternal GDM. 
Furthermore, leucine metabolites concentrations shifted more in the amniotic fluid of female 
fetuses than in their male counterparts. Our findings on sex differences may be explained by the 
theory that the female brain is better protected from inflammation in utero by higher 
concentrations of estradiol, leaving the male brain more vulnerable to inflammatory insults.34,35 
There may also be a higher threshold for genetic mutations in female fetuses before the disorder 
manifests.36 
Strengths and Limitations 
A particular strength of this study is its prospective, longitudinal, and intergenerational design. 
Additionally, we explored targeted maternal circulating metabolites specifically related to 
obesity and diabetes via metabolomic profiling. No other published work has reported on the 
association between maternal metabolites and child risk of ASD. More importantly, our study 
sheds light on potential maternal biomarkers in conjunction with obesity and diabetes and fetal 
sex on offspring risk of ASD.  
As this study is the first of its kind to explore the association between maternal metabolites and 
child ASD, there were some limitations. The primary limitation of our study was that BCAAs 
were only measured at one time-point using maternal blood samples collected 24-72 hours post-
delivery. Along with the physical stress associated with delivery, mothers experience changes in 
protein and hormone homeostasis, as well as medications during the peri-partum period. Amino 
acid concentrations at this time may not be reflective of a steady-state condition. Additionally, 
the measurement was taken in a non-fasted state. It is uncertain to what degree our observed 
maternal BCAA association with ASD was affected by the timing and the events peri-partum. 
While it is known that children with ASD were more likely to be born preterm, the associations 
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remained after adjusting for preterm birth. Other limitations include the lack of data as to the 
BCAA status of the children at the time of ASD diagnosis, whether there was a family history of 
ASD, as well as additional medical histories from both parents. The BBC enrolment also 
spanned across the transition from the American Psychiatric Association’s Diagnostic and 
Statistical Manual fourth edition (DSM-IV) to the fifth edition (DSM-5) and from ICD-9 to ICD-
10. Since the definition of ASD changed during this time, there may be inconsistencies in 
diagnoses between these two periods. While we adjusted for known risk factors, we cannot 
exclude the possibility of residual confounding.  
The results from this study may not be generalizable to other populations since our study 
population consisted of predominantly urban, low-income minorities. However, our study helps 
fill a major knowledge gap since this population is mostly under-represented in ASD research. A 
larger sample size would have also facilitated further sex-specific and more detailed dose-
response analyses. Our grouping of BCAAs was based on the exploration of the functional 
relationship between the maternal BCAA score and child ASD risk, as shown in Figure 4-1. Our 
data suggest an overall monotonic positive association, and thus our cutoff at the median was a 
compromise between the desire for precision and the limitation of sample size.  
Of note, BCAA metabolite concentrations have mostly been reported as reduced in ASD subjects 
compared to TD controls.15,16 While this may seem to contradict our findings, the maternal 
metabolome is not necessarily reflective of the metabolome of the child. There is no literature 
reporting on the outcome of offspring ASD in association with the maternal metabolome. 
Extrapolating from the “Barker Hypothesis” of early origins of disease, it is possible that high 
concentrations of BCAAs in the womb may cue the developing fetus to prepare for a similar 
external environment – an unlikely scenario.37 Another possible mechanism for reduced BCAAs 
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in individuals with ASD could be a mutation in the branched chain ketoacid dehydrogenase 
kinase (BCKDK), the rate-limiting enzyme in BCAA catabolism.38 Additionally, sensitivity to 
certain tastes and textures often results in poor diet quality among the ASD population and may 
explain the altered concentrations.39  
Conversely, others have demonstrated a two-fold increase in concentrations of BCAA and 
greater mTOR activity in rabbit embryos of dams with insulin resistance and elevated circulating 
BCAAs compared to embryos of healthy dams. This research team concluded the BCAA 
composition of the blastocyst was reflective of maternal plasma and urine BCAA 
concentrations.27 Another link between BCAAs and ASD is via the gut microbiome. Specific 
bacteria in the gut are able to synthesize BCAAs de novo – individuals with ASD are known to 
have a distinctly atypical gut microflora composition, and this could contribute to altered BCAA 
concentrations.40 
This study raises more questions than it could answer, and it will hopefully stimulate more 
clinical and mechanistic research in this area. Future studies may consider additional time-points 
for metabolite measurement, including preconception and early pregnancy to avoid the influence 
of factors associated with the stress of delivery. It would be ideal to simultaneously examine 
paired maternal and child cord blood metabolome in relation to child ASD risk. The examination 
of plasma sampled at additional time-points during early childhood will also provide us with a 
greater understanding of the changes in BCAA concentrations as the disorder manifests.  
The findings of this study provide important insight into the role of the BCAAs in the pathway 
between maternal ob/DM and child risk of ASD. Mothers with obesity or diabetes with abnormal 
cholesterol or other metabolic conditions may be at an even greater risk for development of child 
ASD when combined with elevated BCAA concentrations. However, BCAAs almost certainly 
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will not tell the entire story. As illustrated in Supplemental Figure 4-7, BCAA levels in the 
plasma are significantly associated with those of several other amino acids. Further study is 
required to explore the role of these additional amino acids in the pathway from maternal ob/DM 
to child risk of ASD. Of course, other pathways are tightly linked to amino acid metabolism as 
well. For example, lipid metabolites may also play an integral role in these pathways. Thus, this 
present study is a powerful entry point to the metabolomic exploration of ASD pathophysiology.  
This study also lends further support that ASD is potentially predictable and preventable. For 
example, investigators from a large-scale metabolomics study recently reported dysregulation of 
amino acid/BCAA metabolism in close to 17% of their ASD subjects and were also able to 
identify metabotypes of ASD with over 90% sensitivity and specificity.41 Thus, there is potential 
for similarly identifying maternal metabotypes at risk for a child with ASD, especially those with 
the added risk factors of ob/DM and a male fetus. This will greatly enhance our ability to detect 
children at high risk of ASD at the earliest possible developmental windows, when interventions 
may be most cost-effective.  
Conclusions 
In this prospective birth cohort study, we found joint associations between maternal ob/DM and 
elevated maternal plasma BCAAs and between child male sex and elevated maternal plasma 
BCAAs on child risk of ASD. These additive or synergistic effects suggest elevated maternal 
BCAA concentrations may further increase risk of child ASD in the setting of maternal ob/DM 
and/or male fetuses. Additional metabolomic studies on maternal and cord plasma BCAAs are 
warranted to confirm and better understand mechanistic pathways underlying these joint 
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Table 4-1. Maternal and child characteristics by child autism spectrum disorder (ASD) status 
(Typically Developing (TD) vs. ASD) in the Boston Birth Cohort 







Maternal age (years), mean (SD)b 28.21 (6.52) 27.93 (6.52) 29.95 (6.25) 0.008 
Nulliparous, n (%) 379 (43.87) 344 (44.39) 35 (39.33) 0.362 
Race or ethnicity, n (%)c    0.110 
   Black 611 (70.72) 557 (71.87) 54 (61.67)  
   White 35 (4.05) 30 (3.87) 5 (5.62)  
   Hispanic 161 (18.63) 137 (17.68) 24 (26.97)  
   Other 57 (6.60) 51 (6.58) 6 (6.74)  
Maternal education, n (%)    0.986 
   Below college degree 741 (85.76) 666 (89.54) 75 (84.27)  
   College degree or above 117 (13.54) 105 (13.55) 12 (13.48)  
   Missing  6 (0.69) 4 (0.52) 2 (2.25)  
Maternal BMI, n (%)     
   Mean (SD) 26.56 (6.60) 26.38 (6.41) 28.18 (7.97) 0.018 
   Normal weight (<25 kg/m2) 406 (46.99) 372 (48.00) 34 (38.20) 0.009 
   Overweight (25 - <30 kg/m2) 218 (25.23) 200 (25.81) 18 (20.22)  
   Obese (≥30 kg/m2) 202 (23.38) 171 (22.06) 31 (34.83)  
   Missing  38 (4.40) 32 (4.13) 6 (6.74)  
Maternal Diabetesd    0.050 
   No diabetes 771 (89.24) 649 (90.14) 73 (82.95)  
   Diabetes 93 (10.76) 71 (9.86) 15 (17.05)  
Maternal smoking, n (%)e    0.587 
   Never 730 (84.49) 658 (84.90) 72 (80.90)  
   Quit 55 (6.37) 48 (6.19) 7 (7.87)  
   Continuous 69 (7.99) 60 (7.74) 9 (10.11)   
   Missing  10 (1.16) 9 (1.16) 1 (1.12)  
Child’s, n (%)    <0.0001 
   Male 396 (45.83) 330 (42.58) 66 (74.16)  
   Female 468 (54.17) 445 (57.42) 23 (25.84)  
Gestational age, n (%)    <0.0001 
   Term (≥37 weeks) 736 (85.19) 670 (86.45) 66 (74.16)  
   Late preterm (34-36 weeks) 68 (7.87) 64 (8.26) 4 (4.49)  
   Early preterm (<34 weeks) 60 (6.94) 41 (5.29) 19 (21.35)  
Birthweight    0.036 
   ≥2,500 grams 702 (81.25) 637 (82.19) 65 (73.03)  
   <2,500 grams 162 (18.75) 138 (17.81) 24 (26.97)  
Leucine (above median), n (%) 432 (50.00) 382 (49.29) 50 (56.18) 0.218 
Isoleucine (above median), n (%) 432 (50.00) 386 (49.81) 46 (51.69) 0.737 
Valine (above median), n (%) 432 (50.00) 376 (48.52) 52 (58.43) 0.093 
BCAA score (above median), n 
(%) 
432 (50.00) 382 (49.29) 50 (56.18) 0.171 
SD, standard deviation 
aP-values were obtained from chi-square or t-test; missing values for categorical variables were incorporated with largest sized group 
bMaternal age at time of delivery 
cBlack includes self- reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
dType II diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking six months prior to conception or during pregnancy; some smoking 
includes mothers who smoked at some point in the window of six months prior to conception to delivery but did not smoke throughout 
that window; continuous is defined as mothers that smoked starting six months prior to and throughout pregnancy 
 
 69 
Table 4-2. Association of maternal plasma branched-chain amino acids (BCAAs) and risk of 
child autism spectrum disorder (ASD) - joint effect with maternal obesity/diabetes (ob/DM) 
  Leucine below median Leucine above median   
Maternal obesity/DM   N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DMa 
No ob/DM 26/297 1.00 (Reference) 28/317 0.97 (0.54, 1.74) 1.01 (0.58, 1.77) 
Any ob/DM 13/135 0.91 (0.43, 1.93) 22/115 2.30 (1.18, 4.67) 2.22 (1.06, 4.64) 
OR (95% CI) ob/DM 
within strata of 
BCAAa   1.11 (0.55, 2.23)   2.44 (1.33, 4.47)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (0.004, 0.18); P = 0.039   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.59 (0.98 to 6.89); P = 0.056 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DMa 
No ob/DM 28/306 1.00 (Reference) 26/308 0.85 (0.47, 1.52) 0.92 (0.52, 1.60) 
Any ob/DM 15/126 1.04 (0.51, 2.14) 20/134 1.81 (0.93, 3.52) 1.42 (0.69, 2.93) 
OR (95% CI) ob/DM 
within strata of 
BCAAa   1.34 (0.69, 2.61)   2.09 (1.11, 3.90)   
Measure of interaction on additive scale: RERI (95% CI) = 0.07 (-0.02, 0.16); P = 0.135  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.04 (0.78 to 5.39); P = 0.148 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DMa 
No ob/DM 27/304 1.00 (Reference) 27/310 0.92 (0.51, 1.66) 0.98 (0.56, 1.71) 
Any ob/DM 10/128 0.67 (0.30, 1.50) 25/122 2.57 (1.34, 4.90) 3.04 (1.39, 6.64) 
OR (95% CI) ob/DM 
within strata of 
BCAAa   0.87 (0.41, 1.85)   2.70 (1.50, 4.88)   
Measure of interaction on additive scale: RERI (95% CI) = 0.14 (0.05, 0.22); P = 0.003   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.17 (1.50 to 11.60); P = 0.006 
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DMa 
No ob/DM 26/304 1.00 (Reference) 28/310 1.05 (0.58, 2.04) 1.06 (0.61, 1.86) 
Any ob/DM 13/134 0.96 (0.46, 2.04) 22/116 2.35 (1.21, 4.55) 2.18 (1.04, 4.55) 
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OR (95% CI) ob/DM 
within strata of 
BCAAa   1.15 (0.57, 2.31)   2.36 (1.29, 4.32)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (-0.004, 0.18); P = 0.061   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.33 (0.88 to 6.18); P = 0.090 
Note: ORs Adjusted for maternal age, race/ethnicity, education, parity, smoking status, child’s, and gestational age/birthweight unless 




Table 4-3. Association of maternal plasma branched-chain amino acids (BCAAs) and risk of 
child autism spectrum disorder (ASD) - joint effect with child’s 
  Leucine below median Leucine above median   
Child’s sex  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of sexa 
Female 13/240 1.00 (Reference) 10/228 0.81 (0.34, 1.93) 0.80 (0.34, 1.86) 
Male 26/192 2.77 (1.35, 5.69) 40/204 4.88 (2.47, 9.66) 1.56 (0.91, 2.67) 
OR (95% CI) sex 
within strata of 
BCAAa   2.73 (1.36, 5.48)   5.32 (2.58, 10.95)   
Measure of interaction on additive scale: RERI (95% CI) = 0.08 (0.001, 0.16); P = 0.048  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.18 (0.77, 6.14); P = 0.142 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of sexa 
Female 15/233 1.00 (Reference) 8/235 0.47 (0.19, 1.17) 0.51 (0.21, 1.23) 
Male 28/199 2.39 (1.21, 4.72) 38/197 3.73 (1.94, 7.18) 1.46 (0.86, 2.49) 
OR (95% CI) sex 
within strata of 
BCAAa   2.38 (1.23, 4.60)   6.78 (3.08, 14.93)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (0.01, 0.17); P = 0.030  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 3.29 (1.14, 9.52); P = 0.028 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of sexa 
Female 11/233 1.00 (Reference) 12/235 0.98 (0.41, 2.33) 1.09 (0.47, 2.51) 
Male 26/199 2.94 (1.38, 6.25) 40/197 5.51 (2.68, 11.32) 1.70 (0.99, 2.91) 
OR (95% CI) sex 
within strata of 
BCAAa   3.03 (1.46, 6.31)   4.73 (2.41, 9.31)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (<-0.001, 0.16); P = 0.051  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.91 (0.68, 5.35); P = 0.219 
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of sexa 
Female 13/240 1.00 (Reference) 10/228 0.76 (0.32, 1.81) 0.80 (0.34, 1.86) 
Male 26/198 2.61 (1.28, 5.34) 40/198 4.91 (2.48, 9.69) 1.67 (0.97, 2.87) 
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OR (95% CI) sex 
within strata of 
BCAAa   2.64 (1.32, 5.29)   5.52 (2.68, 11.37)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (0.01, 0.17); P = 0.025  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.48 (0.88, 7.03); P = 0.087 
Note: ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking status, and gestational 





Figure 4-1. Association of maternal plasma branched-chain amino acid (BCAA) score with risk 




a. association of maternal plasma BCAA score with risk of ASD in children in the overall sample, b. association of maternal plasma BCAA score 
with risk of ASD in male children, c. association of maternal plasma BCAA score with risk of ASD in female children, d. association of maternal 
plasma BCAA score with risk of ASD in children by obesity/DM status in the overall sample, e. association of maternal plasma BCAA score 






Figure 4-2. Joint association of maternal plasma branched-chain amino acid (BCAA) score, 





Supplemental Table 4-1. List of ICD-9 and ICD-10 codes for the diagnosis of each 
developmental disorder 
Developmental disorder ICD-9 codes ICD-10 codes 
ASD 299.0, 299.00, 299.01, 299.8, 
299.80, 299.81, 299.9, 299.90, 
299.91 
F84.0, F84.8, F84.9 
ADHD 314.0, 314.00, 314.01, 314.1, 
314.2, 314.8, 314.9 
F90, F90.0, F90.1, F90.2, F90.8, 
F90.9 
Developmental delays 315.0, 315.9 F81.0, R48.0, F81.81, F81.2, 
F81.89, F80.1, F80.2, H93.25, 
F80.4, F80.81, F80.0, F80.82, 
F80.89, F82, F88, F81.9, F89 





Supplemental Table 4-2. Maternal and child characteristics between participants excluded and 
included in the analysis 
Characteristics Total, N (%) Excluded, N (%) Included, N (%) P-valuea 
Total 3138 (100.00) 2274 (72.47) 864 (27.53)  
Maternal age (years), mean (SD)b 28.64 (6.50) 28.64 (6.48) 28.21 (6.51) 0.094 
Nulliparous, n (%) 1337 (42.61) 958 (42.13) 379 (43.87) 0.379 
Race or ethnicity, n (%)c    <0.0001 
   Black 1998 (63.67) 1387 (60.99) 611 (70.72)  
   White 227 (7.23) 192 (8.44) 35 (4.05)  
   Hispanic 701 (22.34) 540 (23.75) 161 (18.63)  
   Other 212 (6.76) 155 (6.82) 57 (6.60)  
Maternal education, n (%)    0.973 
   Below college degree 2690 (85.72) 1949 (85.71) 741 (85.76)  
   College degree or above 426 (13.58) 309 (13.59) 117 (13.54)  
   Missing 22 (0.70) 16 (0.70) 6 (0.69)  
Maternal BMI, n (%)     
   Mean (SD) 26.58 (6.65) 26.59 (6.67) 26.56 (6.60) 0.918 
   Normal weight (<25) 1452 (46.27) 1046 (46.00) 406 (46.99) 0.842 
   Overweight (25 - <30) 813 (25.90) 595 (26.17) 218 (25.23)  
   Obese (≥30) 703 (22.40) 501 (22.03) 202 (23.38)  
   Missing 170 (5.42) 132 (5.80) 38 (4.40)  
Maternal Diabetesd    0.099 
   No diabetes 2751 (87.67) 1980 (89.68) 771 (89.24)  
   Diabetes 387 (12.33) 294 (12.93) 93 (10.76)  
Maternal smoking, n (%)e     
   Never 2542 (81.01) 1812 (79.68) 730 (84.49) 0.001 
   Quit 241 (7.68) 186 (8.18) 55 (6.37)  
   Continuous 336 (10.71) 267 (11.74) 69 (7.99)  
   Missing 19 (0.61) 9 (0.40)  10 (1.16)  
Child’s, n (%)    0.001 
   Male 1583 (50.45) 1187 (52.20) 396 (45.83)  
   Female 1555 (49.55) 1087 (47.80) 468 (54.17)  
Gestational age, n (%)    0.001 
   Term (≥37 weeks) 2448 (78.01) 1712 (75.29) 736 (85.19)  
   Late preterm (34-36 weeks) 306 (9.75) 238 (10.47) 68 (7.87)  
   Early preterm (<34 weeks) 384 (12.24) 324 (14.25) 60 (6.94)  
Birthweight    <0.0001 
   ≥2,500 grams 2275 (72.50) 1573 (69.17) 702 (81.25)  
   <2,500 grams 863 (27.50) 701 (30.83) 162 (18.75)  
SD, standard deviation 
aP-values were obtained from chi-square or t-tests; missing values for categorical variables incorporated with largest sized group 
bMaternal age at time of delivery 
cBlack includes self-reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
dType II diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking six months prior to conception or during pregnancy; some smoking 
includes mothers who smoked at some point in the window of six months prior to conception to delivery but did not smoke throughout 




Supplemental Table 4-3. Maternal and child characteristics by maternal plasma branched-
chained amino acid (BCAA) score in the Boston Birth Cohort 
Maternal and child characteristics Low score (N=438)a High score (N=426) P-valueb 
ASD, n (%) 39 (8.90) 50 (11.74) 0.171 
Maternal age (years), mean (SD)c 28.16 (6.67) 28.25 (6.37) 0.833 
Nulliparous, n (%) 197 (44.98) 182 (42.72) 0.504 
Race or ethnicity, n (%)d   0.112 
   Black 296 (67.58) 315 (73.94)  
   White 16 (3.65) 19 (4.46)  
   Hispanic 93 (21.23) 68 (15.96)  
   Other 33 (7.53) 24 (5.63)  
Maternal education, n (%)   0.737 
   Below college degree 373 (85.16) 368 (86.38)  
   College degree or above 61 (13.93) 56 (13.15)  
   Missing (n=6) 4 (0.91) 2 (0.47)  
Maternal BMI, n (%)    
   Mean (SD) 26.68 (6.76) 26.44 (6.44) 0.596 
   Normal weight (<25 kg/m2) 205 (46.80) 201 (47.18) 0.933 
   Overweight (25 - <30 kg/m2) 109 (24.89) 109 (25.59)  
   Obese (≥30 kg/m2) 108 (24.66) 94 (22.07)  
   Missing (n=38) 16 (3.65) 22 (5.16)  
Maternal Diabetes   0.397 
   No diabetes 387 (88.36) 384 (90.14)  
   Diabetes 51 (11.64) 42 (9.86)  
Maternal smoking, n (%)e   0.839 
   Never 366 (83.56) 364 (85.45)  
   Quit 30 (6.85) 25 (5.87)  
   Continuous 35 (7.99) 34 (7.98)   
   Missing (n=10) 7 (1.60) 3 (0.70)  
Child’s, n (%)   0.707 
   Male 198 (45.21) 198 (46.48)  
   Female 240 (54.79) 228 (53.52)  
Gestational age, n (%)   0.068 
   Term (≥37 weeks) 383 (87.44) 353 (82.86)  
   Late preterm (34, 36 weeks) 33 (7.53) 35 (8.22)  
   Early preterm (<34 weeks) 22 (5.02) 38 (8.92)  
Birthweight   0.586 
   ≥2,500 grams 359 (81.96) 343 (80.52)  
   <2,500 grams 79 (18.04) 83 (19.48)  
SD, standard deviation 
aScore derived from factor analysis as the average score of the three BCAAs (leucine, isoleucine, and valine); low is below median and 
high is above median 
bP-values were obtained from chi-square or t-test; missing values for categorical variables incorporated with largest sized group 
cMaternal age at time of delivery 
dBlack includes self, reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
eNever smokers were defined as mothers with no history of smoking six months prior to conception or during pregnancy; some smoking 
includes mothers who smoked at some point in the window of six months prior to conception and delivery but did not smoke throughout 




Supplemental Table 4-4. Maternal and child characteristics by maternal plasma branched-chain 
amino acid (BCAA) score in the Boston Birth Cohort among males 
Maternal and child characteristics Low score (N=198)a High score (N=198) P-valueb 
ASD, n (%) 26 (13.13) 40 (20.20) 0.059 
Maternal age (years), mean (SD)c 27.98 (6.77) 28.25 (6.48) 0.685 
Nulliparous, n (%) 94 (47.47) 87 (43.94) 0.480 
Race or ethnicity, n (%)d   0.270 
   Black 130 (65.66) 146 (73.74)  
   White 8 (4.04) 8 (4.04)  
   Hispanic 41 (20.71) 33 (16.67)  
   Other 19 (9.60) 11 (5.56)  
Maternal education, n (%)   0.884 
   Below college degree 169 (85.35) 170 (85.86)  
   College degree or above 27 (13.64) 28 (14.14)  
   Missing (n=2) 2 (1.01) 0 (0.00)  
Maternal BMI, n (%)    
   Mean (SD) 26.09 (6.20) 26.25 (6.20) 0.802 
   Normal weight (<25) 95 (47.98) 92 (46.46) 0.897 
   Overweight (25 - <30) 55 (27.78) 54 (27.27)  
   Obese (≥30) 42 (21.21) 41 (20.71)  
   Missing (n=17) 6 (3.03) 11 (5.56)  
Maternal Diabetes   0.294 
   No diabetes 169 (85.35) 176 (88.89)  
   Diabetes 29 (14.65) 22 (11.11)  
Maternal smoking, n (%)e   0.711 
   Never 167 (84.34) 172 (86.87)  
   Quit 14 (7.07) 13 (6.57)  
   Continuous 16 (8.08) 12 (6.06)   
   Missing (n=2) 1 (0.51) 1 (0.51)  
Gestational age, n (%)   0.581 
   Term (≥37 weeks) 171 (86.36) 168 (84.85)  
   Late preterm (34 - 36 weeks) 16 (8.08) 14 (7.07)  
   Early preterm (<34 weeks) 11 (5.56) 16 (8.08)  
Birthweight   0.292 
   ≥2,500 grams 159 (80.30) 343 (80.52)  
   <2,500 grams 39 (19.70) 83 (19.48)  
SD, standard deviation 
aScore derived from factor analysis as the average score of the three BCAAs (leucine, isoleucine, and valine); low is below median and 
high is above median 
bP-values were obtained from chi-square or t-test; missing values for categorical variables incorporated with largest sized group 
cMaternal age at time of delivery 
dBlack includes self, reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
eNever smokers were defined as mothers with no history of smoking six months prior to conception or during pregnancy; some smoking 
includes mothers who smoked at some point in the window of six months prior to conception and delivery but did not smoke throughout 





Supplemental Table 4-5. Association between maternal plasma branched-chain amino acid 
(BCAA) score and risk of child autism spectrum disorder (ASD), where BCAA score was 
analyzed as linear, in tertiles, and binary  
BCAA 
ASD OR (95% 
CI)a 
ASD OR (95% 
CI)b 
Leucine   
Linear 1.11 (0.89, 1.38) 1.12 (0.88, 1.42) 
Tertiles   
T1 (N= 288) Reference Reference 
T2 (N= 288) 1.04 (0.59, 1.83) 0.89 (0.49, 1.61) 
T3 (N= 288) 1.44 (0.84, 2.45) 1.38 (0.78, 2.43) 
Binaryc 1.32 (0.85, 2.05) 1.40 (0.87, 2.24) 
Isoleucine   
Linear 1.13 (0.90, 1.41) 1.14 (0.89, 1.44) 
Tertiles   
T1 (N= 288) Reference Reference 
T2 (N= 288) 0.78 (0.45, 1.37) 0.68 (0.37, 1.23) 
T3 (N= 288) 1.19 (0.71, 2.00) 1.16 (0.67, 2.01) 
Binaryc 1.08 (0.70, 1.67) 1.11 (0.69, 1.76) 
Valine   
Linear 1.08 (0.87, 1.35) 1.10 (0.87, 1.41) 
Tertiles   
T1 (N= 288) Reference Reference 
T2 (N= 288) 0.85 (0.48, 1.49) 0.91 (0.50, 1.64) 
T3 (N= 288) 1.24 (0.73, 2.08) 1.27 (0.73, 2.20) 




Linear 1.11 (0.89, 1.39) 1.12 (0.88, 1.43) 
Tertiles   
T1 (N= 288) Reference Reference 
T2 (N= 288) 0.96 (0.55, 1.69) 0.82 (0.45, 1.49) 
T3 (N= 288) 1.38 (0.81, 2.34) 1.31 (0.75, 2.29) 
Binaryc 1.36 (0.87, 2.12) 1.44 (0.90, 2.30) 
aUnadjusted analysis 
bAdjusted for maternal age, race, parity, education, smoking, obesity/DM status, child’s, and birthweight/gestational age 





Supplemental Table 4-6. Mediation analysis – maternal plasma branched-chain amino acid 
(BCAA) score as a mediator in the relationship between maternal obesity/diabetes (ob/DM) and 
risk of child ASD  
Total N=720; 
ASD=88 
Total Effect, OR  
(95% CI) 
Model 1  
No ob/DM Reference 
Any ob/DM 1.69 (1.07, 2.66) 
Model 2  
No ob/DM Reference 
Any ob/DM 1.69 (1.07, 2.67) 
Model 3  
No ob/DM Reference 
Any ob/DM 1.51 (0.93, 2.47) 
Model 4  
No ob/DM Reference 
Any ob/DM 1.53 (0.94, 2.50) 
Model 1 Unadjusted  
Model 2 Adjusted for continuous BCAA score variable 
Model 3 Adjusted for maternal age, race, parity, education, smoking, child’s, and gestational age/birthweight 





Supplemental Table 4-7. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child ASD - joint effect with maternal obesity/diabetes (ob/DM) 
  Leucine below median Leucine above median   
Maternal ob/DM 
   N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 26/297 1.00 (Reference) 28/317 1.01 (0.58, 1.77) 1.01 (0.58, 1.77) 
Any ob/DM 13/135 1.11 (0.55, 2.23) 22/115 2.47 (1.33, 4.56) 2.22 (1.06, 4.64) 
OR (95% CI) ob/DM 
within strata of BCAA   1.11 (0.55, 2.23)   2.44 (1.33, 4.47)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (-0.004, 0.19); P = 0.060  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.59 (0.98 to 6.89); P = 0.056 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 28/306 1.00 (Reference) 26/308 0.92 (0.52, 1.60) 0.92 (0.52, 1.60) 
Any ob/DM 15/126 1.34 (0.69, 2.61) 20/134 1.91 (1.03, 3.54) 1.42 (0.69, 2.93) 
OR (95% CI) ob/DM 
within strata of BCAA   1.34 (0.69, 2.61)   2.09 (1.11, 3.90)   
Measure of interaction on additive scale: RERI (95% CI) = 0.05 (-0.05, 0.15); P = 0.319  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.04 (0.78 to 5.39); P = 0.148 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 27/304 1.00 (Reference) 27/310 0.98 (0.56, 1.71) 0.98 (0.56, 1.71) 
Any ob/DM 10/128 0.87 (0.41, 1.85) 25/122 2.64 (1.46, 4.78) 3.04 (1.39, 6.64) 
OR (95% CI) ob/DM 
within strata of BCAA   0.87 (0.41, 1.85)   2.70 (1.50, 4.88)   
Measure of interaction on additive scale: RERI (95% CI) = 0.13 (0.03, 0.22); P = 0.009   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.17 (1.50 to 11.60); P = 0.006 
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 26/304 1.00 (Reference) 28/310 1.06 (0.61, 1.86) 1.06 (0.61, 1.86) 
Any ob/DM 13/134 1.15 (0.57, 2.31) 22/116 2.50 (1.35, 4.62) 2.18 (1.04, 4.55) 
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OR (95% CI) ob/DM 
within strata of BCAA   1.15 (0.57, 2.31)   2.36 (1.29, 4.32)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (-0.01, 0.19); P = 0.079  






Supplemental Table 4-8. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) - joint effect with maternal 
obesity/diabetes (ob/DM), where the analyses were limited to males 
  Leucine below median Leucine above median   
Maternal ob/DM   N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 17/132 1.00 (Reference) 22/150 1.16 (0.59, 2.30) 1.16 (0.59, 2.30) 
Any ob/DM 9/60 1.19 (0.50, 2.86) 18/54 3.38 (1.58, 7.24) 2.83 (1.14, 7.02) 
OR (95% CI) ob/DM 
within strata of BCAA   1.19 (0.50, 2.86)   2.91 (1.41, 6.00)   
Measure of interaction on additive scale: RERI (95% CI) = 0.17 (-0.01, 0.34); P = 0.063  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.44 (0.78, 7.58); P = 0.124 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 17/139 1.00 (Reference) 22/143 1.30 (0.66, 2.58) 1.30 (0.66, 2.58) 
Any ob/DM 11/60 1.61 (0.70, 3.69) 16/54 3.02 (1.39, 6.55) 1.88 (0.78, 4.51) 
OR (95% CI) ob/DM 
within strata of BCAA   1.61 (0.70, 3.69)   2.32 (1.10, 4.85)   
Measure of interaction on additive scale: RERI (95% CI) = 0.08 (-0.09, 0.26); P = 0.364  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.44 (0.47, 4.36); P = 0.522 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 18/141 1.00 (Reference) 21/141 1.20 (0.61, 2.36) 1.20 (0.61, 2.36) 
Any ob/DM 8/58 1.09 (0.47, 2.68) 19/56 3.51 (1.67, 7.37) 3.21 (1.27, 8.13) 
OR (95% CI) ob/DM 
within strata of BCAA   1.09 (0.47, 2.68)   2.93 (1.43, 6.04)   
Measure of interaction on additive scale: RERI (95% CI) = 0.18 (0.01, 0.35); P = 0.041  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.68 (0.85, 8.48); P = 0.139 
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 17/138 1.00 (Reference) 22/144 1.28 (0.68, 2.54) 1.28 (0.65, 2.54) 
Any ob/DM 9/60 1.26 (0.53, 3.00) 18/54 3.56 (1.35, 1.66) 2.83 (1.14, 7.02) 
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OR (95% CI) ob/DM 
within strata of BCAA   1.26 (0.53, 3.00)   2.78 (1.34, 5.73)   
Measure of interaction on additive scale: RERI (95% CI) = 0.15 (-0.02, 0.33); P = 0.084  





Supplemental Table 4-9. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) - joint effect with maternal 
obesity/diabetes (ob/DM), where the analyses were limited to females 
  Leucine below median Leucine above median   
Maternal ob/DM   N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 17/132 1.00 (Reference) 22/150 0.65 (0.22, 1.86) 0.65 (0.22, 1.86) 
Any ob/DM 9/60 0.98 (0.29, 3.28) 18/54 1.22 (0.36, 4.10) 1.25 (0.30, 5.20) 
OR (95% CI) ob/DM 
within strata of BCAA   0.98 (0.29, 3.28)   1.88 (0.51, 6.91)   
Measure of interaction on additive scale: RERI (95% CI) = 0.03 (-0.06, 0.12); P = 0.510  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.93 (0.33, 11.40); P = 0.171 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 17/139 1.00 (Reference) 22/143 0.35 (0.11, 1.13) 0.35 (0.11, 1.13) 
Any ob/DM 11/60 0.91 (0.28, 2.98) 16/54 0.86 (0.26, 2.80) 0.94 (0.23, 3.92) 
OR (95% CI) ob/DM 
within strata of BCAA   0.91 (0.28, 2.98)   2.44 (0.59, 10.04)   
Measure of interaction on additive scale: RERI (95% CI) = 0.04 (-0.05, 0.13); P = 0.410  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.67 (0.42, 16.84); P = 0.297 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 18/141 1.00 (Reference) 21/141 0.63 (0.22, 1.81) 0.63 (0.22, 1.81) 
Any ob/DM 8/58 0.50 (0.11, 2.39) 19/56 1.71 (0.58, 5.01) 3.40 (0.66, 17.48) 
OR (95% CI) ob/DM 
within strata of BCAA   0.50 (0.11, 2.39)   2.72 (0.84, 8.75)   
Measure of interaction on additive scale: RERI (95% CI) = 0.08 (-0.01, 0.17); P = 0.078  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 5.40 (0.77, 37.89); P = 0.090 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 17/138 1.00 (Reference) 22/144 0.65 (0.23, 1.88) 0.65 (0.23, 1.88) 
Any ob/DM 9/60 1.00 (0.30, 3.35) 18/54 1.20 (0.36, 4.06) 1.21 (0.29, 5.04) 
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OR (95% CI) ob/DM 
within strata of BCAA   1.00 (0.30, 3.35)   1.84 (0.50, 6.75)   
Measure of interaction on additive scale: RERI (95% CI) = 0.03 (-0.06, 0.12); P = 0.541  





Supplemental Table 4-10. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) - joint effect with maternal 
obesity/diabetes (ob/DM) (neither, either, or both) 
  Leucine below median Leucine above median 
Maternal ob/DM 
   N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
Neither ob/DM 26/297 1.00 (Reference) 28/317 1.01 (0.58, 1.77) 
Either ob/DM 8/109 0.83 (0.36, 1.88) 16/96 2.08 (1.07, 4.08) 
Both ob/DM  5/26 2.48 (0.86, 7.13)  6/19 4.81 (1.69, 13.72) 
  Isoleucine below median Isoleucine above median 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
Neither ob/DM 28/306 1.00 (Reference) 26/308 0.92 (0.52, 1.60) 
Either ob/DM 10/104 1.06 (0.49, 2.26) 14/101 1.60 (0.81, 3.17) 
Both ob/DM  5/22 2.92 (1.00, 8.51)  6/23 3.50 (1.28, 9.61) 
  Valine below median Valine above median 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
Neither ob/DM 27/304 1.00 (Reference) 27/310 0.98 (0.56, 1.71) 
Either ob/DM 6/104 0.63 (0.25, 1.57) 18/101 2.22 (1.17, 4.24) 
Both ob/DM  4/24 2.05 (0.65, 6.44)  7/21 5.13 (1.91, 13.80) 
  BCAA score below median BCAA score above median 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
Neither ob/DM 26/304 1.00 (Reference) 28/310 1.06 (0.61, 1.86) 
Either ob/DM 8/109 0.85 (0.37, 1.93) 16/96 2.14 (1.09, 4.18) 





Supplemental Table 4-11. Association between child’s sex and risk of child autism spectrum 
disorder (ASD) – joint effect with maternal obesity/diabetes (ob/DM) 
  No maternal ob/DM Any maternal ob/DM   
Child’s sex  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 ob/DM within  
strata of sex* 
Female 13/240 1.00 (Reference) 10/228 1.15 (0.47, 2.85) 1.32 (0.55, 3.19) 
Male 26/198 3.54 (1.89, 6.65) 40/198 6.01 (3.00, 12.03) 1.93 (1.12, 3.35) 
OR (95% CI) sex 
within strata of 
ob/DM*   3.39 (1.83, 6.30)   4.97 (2.16, 11.44)   
Measure of interaction on additive scale: RERI (95% CI) = 0.07 (-0.03, 0.16); P = 0.165  





Supplemental Table 4-12. Association of maternal plasma branched-chain amino acids (BCAAs) 
and risk of other child developmental disorders (DD) - joint effect with maternal obesity/diabetes 
(ob/DM) 
 
  Leucine score below median Leucine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 188/464 1.00 (Reference) 180/464 0.98 (0.75, 1.29) 0.99 (0.75, 1.31) 
Any ob/DM 80/203 0.92 (0.65, 1.31) 98/190 1.53 (1.07, 2.19) 1.86 (1.41, 2.46) 
OR (95% CI) ob/DM 
within strata of BCAA   0.89 (0.62, 1.28)   1.56 (1.09, 2.23)   
Measure of interaction on additive scale: RERI (95% CI) = 0.14 (0.02, 0.26); P = 0.019   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.70 (1.03 to 2.79); P = 0.038 
  Isoleucine score below median Isoleucine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 195/472 1.00 (Reference) 173/456 0.90 (0.68, 1.19) 0.90 (0.68, 1.19) 
Any ob/DM 80/191 0.96 (0.67, 1.37) 98/202 1.32 (0.93, 1.87) 1.37 (0.90, 2.10) 
OR (95% CI) ob/DM 
within strata of BCAA   0.94 (0.65, 1.36)   1.46 (1.03, 2.06)   
Measure of interaction on additive scale: RERI (95% CI) = 0.10 (-0.02, 0.22); P = 0.093   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.53 (0.93 to 2.52); P = 0.095 
  Valine score below median Valine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 197/472 1.00 (Reference) 171/456 0.87 (0.66, 1.15) 0.88 (0.66, 1.16) 
Any ob/DM 80/198 0.91 (0.64, 1.29) 98/195 1.36 (0.95, 1.94) 1.49 (0.98, 2.28) 
OR (95% CI) ob/DM 
within strata of BCAA   0.90 (0.63, 1.30)   1.55 (1.09, 2.21)   
Measure of interaction on additive scale: RERI (95% CI) = 0.14 (0.02, 0.26); P = 0.018   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.72 (1.04 to 2.83); P = 0.034 
  BCAA score below median BCAA score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 190/468 1.00 (Reference) 178/460 0.97 (0.74, 1.28) 0.98 (0.74, 1.29) 
Any ob/DM 79/200 0.92 (0.65, 1.31) 99/193 1.50 (1.05, 2.13) 1.60 (1.05, 2.45) 
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OR (95% CI) ob/DM 
within strata of BCAA   0.89 (0.61, 1.28)   2.36 (1.29, 4.32)   
Measure of interaction on additive scale: RERI (95% CI) = 0.14 (0.02, 0.25); P = 0.021   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.67 (1.02 to 2.75); P = 0.043 





Supplemental Table 4-13. Association of maternal plasma branched-chain amino acids (BCAAs) 
and risk of other child developmental disorders (DD) - joint effect with maternal obesity/diabetes 
(ob/DM), among male children 
 
  Leucine score below median Leucine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 118/234 1.00 (Reference) 98/225 1.35 (0.99, 1.83) 0.86 (0.58, 1.27) 
Any ob/DM 48/99 1.52 (0.99, 2.34) 56/98 2.49 (1.58, 3.91) 1.47 (0.79, 2.34) 
OR (95% CI) ob/DM 
within strata of BCAA   0.89 (0.54, 1.47)   1.85 (1.10, 3.11)   
Measure of interaction on additive scale: RERI (95% CI) = 0.19 (0.03, 0.36); P = 0.024  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.98 (0.98 to 4.03); P = 0.059 
  Isoleucine score below median Isoleucine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 126/247 1.00 (Reference) 90/212 1.25 (0.92, 1.71) 0.76 (0.51, 1.13) 
Any ob/DM 51/100 1.63 (1.06, 2.50) 53/91 2.22 (1.42, 3.49) 1.28 (0.69, 2.37) 
OR (95% CI) ob/DM 
within strata of BCAA   0.93 (0.56, 1.53)   1.75 (1.04, 2.93)   
Measure of interaction on additive scale: RERI (95% CI) = 0.16 (-0.01, 0.33); P = 0.065   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.84 (0.91 to 3.74); P = 0.091 
  Valine score below median Valine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 128/251 1.00 (Reference) 88/208 1.25 (0.91, 1.70) 0.76 (0.51, 1.13) 
Any ob/DM 53/103 1.72 (1.13, 2.63) 51/88 2.09 (1.32, 3.32) 1.11 (0.60, 2.05) 
OR (95% CI) ob/DM 
within strata of BCAA   0.97 (0.60, 1.59)   1.65 (0.97, 2.81)   
Measure of interaction on additive scale: RERI (95% CI) = 0.15 (-0.02, 0.32); P = 0.077   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.65 (0.81 to 3.36); P = 0.164 
  BCAA score below median BCAA score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 120/241 1.00 (Reference) 96/218 1.38 (1.01, 1.87) 0.89 (0.60, 1.32) 
Any ob/DM 48/99 1.51 (0.98, 2.33) 56/92 2.51 (1.59, 3.95) 1.48 (0.79, 2.74) 
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OR (95% CI) ob/DM 
within strata of BCAA   0.91 (0.55, 1.49)   1.83 (1.08, 3.07)   
Measure of interaction on additive scale: RERI (95% CI) = 0.18 (0.01, 0.35); P = 0.033   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.93 (0.95 to 3.92); P = 0.069 





Supplemental Table 4-14. Association of maternal plasma branched-chain amino acids (BCAAs) 
and risk of other child developmental disorders (DD) - joint effect with maternal obesity/diabetes 
(ob/DM), among female children 
  Leucine score below median Leucine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 70/230 1.00 (Reference) 83/239 0.66 (0.50, 0.90) 1.21 (0.81, 1.82) 
Any ob/DM 32/104 0.51 (0.32, 0.80) 42/98 0.87 (0.56, 1.34) 1.67 (0.91, 3.08) 
OR (95% CI) ob/DM 
within strata of BCAA   0.95 (0.55, 1.63)   1.30 (0.78, 2.15)   
Measure of interaction on additive scale: RERI (95% CI) = 0.08 (-0.07, 0.24); P = 0.305  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.42 (0.69 to 2.90); P = 0.342 
  Isoleucine score below median Isoleucine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 69/225 1.00 (Reference) 83/244 0.63 (0.46, 0.85) 1.12 (0.75, 1.67) 
Any ob/DM 29/91 0.54 (0.33, 0.86) 45/111 0.77 (0.50, 1.16) 1.33 (0.71, 2.49) 
OR (95% CI) ob/DM 
within strata of BCAA   0.99 (0.56, 1.75)   1.21 (0.74, 1.98)   
Measure of interaction on additive scale: RERI (95% CI) = 0.05 (-0.10, 0.21); P = 0.507  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.28 (0.62 to 2.63); P = 0.501 
  Valine score below median Valine score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 69/221 1.00 (Reference) 83/248 0.60 (0.44, 0.82) 1.04 (0.70, 1.56) 
Any ob/DM 27/95 0.45 (0.28, 0.73) 47/107 0.87 (0.57, 1.32) 1.93 (1.04, 3.58) 
OR (95% CI) ob/DM 
within strata of BCAA   0.83 (0.46, 1.49)   1.45 (0.89, 2.36)   
Measure of interaction on additive scale: RERI (95% CI) = 0.13 (-0.02, 0.29); P = 0.095  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.83 (0.88 to 3.79); P = 0.104 
  BCAA score below median BCAA score above median   
  
N other DD/ 
Total OR (95% CI) 
N other DD/ 
Total OR (95% CI) 
OR (95% CI)  
BCAA within  
strata of ob/DM 
No ob/DM 70/227 1.00 (Reference) 82/242 0.63 (0.47, 0.86) 1.14 (0.76, 1.71) 
Any ob/DM 31/101 0.51 (0.33, 0.81) 43/101 0.83 (0.54, 1.28) 1.62 (0.88, 2.98) 
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OR (95% CI) ob/DM 
within strata of BCAA   0.93 (0.53, 1.63)   1.30 (0.80, 2.18)   
Measure of interaction on additive scale: RERI (95% CI) = 0.09 (-0.07, 0.25); P = 0.269  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.41 (0.69 to 2.88); P = 0.347 











3,163 mother-infant pairs with EMR records of well-child and specialty visits 
1,933 typically developing children; 150 children with ASD; 1080 cases of  
other developmental disabilities (DD) 
    
864 mother-infant pairs  
   775 typically developing children 
   89 children with ASD with or without other DD 
1202 excluded for missing 
metabolite measurement  









a. correlation between leucine and valine, b. correlation between leucine and isoleucine, c. correlation between 




Supplemental Figure 4-3. Distribution of maternal plasma branched-chain amino acids (BCAA) 
score overall and by child’s sex 
 
 





Supplemental Figure 4-4. Maternal plasma branched-chain amino acids (BCAAs) stratified by 





Supplemental Figure 4-5. Association of maternal plasma branched-chain amino acids (BCAAs) 
with risk of child ASD, overall and by child’s sex 
 
 
a. association between relative abundance in maternal plasma leucine and probability of ASD diagnosis in children, 
b. association between relative abundance in maternal plasma leucine and probability of ASD diagnosis by child’s 
sex, c. association between relative abundance in maternal plasma isoleucine and probability of ASD diagnosis, d. 
association between relative abundance in maternal plasma isoleucine and probability of ASD diagnosis by child’s 
sex, e. association between relative abundance in maternal plasma valine and probability of ASD diagnosis, f. 




Supplemental Figure 4-6. Joint association of maternal plasma branched-chain amino acid 






Supplemental Figure 4-7. Manhattan plot of associations between branched-chain amino acid 






CHAPTER 5 MATERNAL DYSLIPIDEMIA, PLASMA 
BRANCHED-CHAIN AMINO ACIDS, AND THE RISK OF 






We and others have shown that maternal obesity and diabetes and elevated branched-chain 
amino acids (BCAAs) are risk factors of child Autism Spectrum Disorder (ASD). In contrast to 
the well-observed association of obesity and diabetes with ASD, the role of maternal 
dyslipidemia in ASD has not been well-studied. We aimed to examine the joint associations of 
maternal plasma cholesterols and BCAAs on child ASD risk and to determine whether these 
associations differed by child’s. 
Methods 
We analyzed data from 829 mother-infant pairs, a subset of the Boston Birth Cohort with 
pertinent data. Maternal plasma cholesterols were measured using standard clinical methods and 
BCAAs were measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in 
samples collected 24-72 hours postpartum. A composite BCAA score was created using factor 
analysis and dichotomized at the median, and specific cholesterol subtypes were dichotomized 
using clinical cut-points (HDL-C <50 mg/dl, TC 240 mg/dl, LDL-C 160, non-HDL-C 190 
mg/dl). Logistic regression was used to explore the joint association of maternal cholesterols and 
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BCAA with child ASD among the overall sample and by sex, adjusting for important 
covariables, including maternal obesity and diabetes.  
Results 
Maternal plasma cholesterols by themselves were not associated with ASD. There was evidence 
of low maternal high-density lipoprotein cholesterol (HDL-C, <50 mg/dl) enhancing the effect of 
male sex on the risk of ASD, though tests for interaction were not significant. Among mothers 
with low HDL-C, high maternal BCAA score was associated with higher risk of child ASD (OR 
4.67, 95% CI 1.33, 16.36). This association was consistent with significant interactions of all 
three BCAAs with HDL-C on the risk of child ASD. Compared to mothers with high HDL-C, 
low BCAAs, and a female child, mothers with low HDL-C, elevated BCAAs, and a male child 
were at the highest risk for child ASD (OR 4.78, 95% CI 2.12, 10.78) among all other 
combinations. Elevated risks associated with non-HDL and low-density lipoprotein cholesterols 
were not as robust.  
Conclusions 
In this US urban, low income prospective birth cohort, our findings suggest that low maternal 
HDL-C, high maternal plasma BCAAs, and male sex can jointly increase child risk of ASD. 
Additional studies are necessary to understand the mechanisms behind maternal HDL-C and 





Autism Spectrum Disorders (ASDs) present a wide array of symptoms characterized by impaired 
social interaction, deficits in communication, and restricted and stereotyped behaviors and 
interests.1 ASD is a complex disorder and its etiology and underlying mechanisms remain 
unknown. While genetics is believed to play an important role, there are many environmental 
factors that have been associated with ASD.2 
Cholesterols, within normal range, play important roles in brain function, mainly in regulating 
cell membrane permeability and the formation of synapses. Twenty-five percent of bodily 
cholesterol is found in the brain with 70% of brain cholesterol incorporated into myelin, the 
protective sheath for neuronal axons.3 Maternal circulating cholesterols can be transported across 
the placenta and play important roles during fetal neurodevelopment.4 For example, they are 
essential components of cellular membranes and also precursors for steroid hormones in the 
fetus. Disruptions in the level of certain cholesterols can result in adverse birth outcomes, 
including pre-term birth.5 Abnormal maternal HDL-C and triglycerides measured post-delivery 
have been linked to attention deficit hyperactive disorder (ADHD) in children, the most common 
co-occurring condition with ASD.6 However, there are no studies reporting on the association 
between maternal dyslipidemia and development of ASD in children.  
We and others have previously shown that maternal obesity and diabetes contribute to an 
elevated risk of the child developing ASD, especially among male children.7-9 Dyslipidemia is 
highly associated with obesity and diabetes and contributes to all definitions of the metabolic 
syndrome.10 About a quarter of US women of reproductive age have higher than normal low-
density lipoprotein cholesterol (LDL-C) levels (130 mg/dl) and 13% have lower than normal 
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high-density lipoprotein cholesterol (HDL-C) levels (<40 mg/dl).11 The goal of this study was to 
examine the independent and joint effects of maternal dyslipidemia, branched-chain amino acids 
(BCAAs), and child’s sex on child risk of ASD.  
The BCAAs – leucine, isoleucine, and valine – are essential amino acids making up 
approximately a third of essential amino acids in muscle and are also involved in cellular 
signaling and modulation of glucose homeostasis and body weight.12 Elevated levels have also 
been shown to predict type 2 diabetes mellitus13 and are linked with increased risk of an 
atherogenic profile.14 BCAAs are also associated with cholesterol metabolism.15,16 Plasma 
cholesterol increased in patients with sepsis when given large dose of BCAAs, while other amino 
acids, fat, and glucose did not have an impact.15 However, only a few studies exist on BCAA-
ASD associations and with small sample sizes.17-19 Further, there is a lack of inter-generational 
studies examining the joint association of maternal lipid profile and BCAA with child ASD. 
We therefore examined whether maternal dyslipidemia is associated with the risk of ASD and 
sought to clarify whether maternal dyslipidemia can interact with BCAAs to affect child risk of 
ASD. As there is a sex disparity in the prevalence of ASD, we also investigated whether the 
associations differed by sex of the child. 
METHODS 
Participants and Data Collection 
This study analyzed the existing data from the Boston Birth Cohort (BBC), an ongoing 
prospective cohort study at the Boston Medical Center (BMC) initiated in 1998. In the parent 
study, mother-infant pairs were recruited at birth using a rolling enrollment and followed up 
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from birth up to 21 years of age. The current study includes children followed up between 2004 – 
2017. Detailed recruitment and follow-up procedures have been previously published.8 The 
Johns Hopkins Bloomberg School of Public Health and the Boston University Medical Center 
Institutional Review Boards (IRB) approved the recruitment, follow-up studies, and protocols.  
Briefly, at the time of enrolment, 24-72 hours post-partum, written informed consent was 
obtained from all participants. Mothers with multiple gestations or who became pregnant due to 
in vitro fertilization were excluded from the analysis as were babies with chromosomal 
abnormalities or major birth defects. Maternal blood was collected at the time of enrolment in a 
non-fasted state. Maternal and newborn prenatal and perinatal information were obtained via a 
maternal postpartum questionnaire interview and medical record review. Child postnatal 
information was obtained via child follow-up questionnaires completed by maternal interviews 
and child medical record review. 
Of 3,163 mother-infant pairs in the BBC who were enrolled at birth and followed postnatally at 
the BMC, 829 (86 children with ASD and 743 typically developing (TD) children) who had 
complete data of the key variables were included in the analyses (Supplemental Figure 5-1). 
Electronic Medical Records (EMR) were used to define ASD case status as per primary and 
secondary diagnoses using ICD-9 or ICD-10 codes (Supplemental Table 5-1). Specifically, ASD 
was defined for children who were ever diagnosed with autism (299.00), Asperger syndrome 
(299.80), and/or pervasive developmental disorder - not otherwise specified (299.90). Though a 
systematic screening for ASD was not conducted, all children were evaluated by highly 
experienced staff at the BMC autism evaluation program who are in regular communication with 
primary care physicians at the medical center. Attention deficit hyperactivity disorder (ADHD), 
developmental delays, or intellectual disabilities without an ASD diagnosis were classified as 
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other developmental disorders. Children with no ASD or other developmental disorders were 
classified as typically developing (TD). Given the focus of this study, children with other 
developmental disabilities other than ASD were excluded from the analyses. Our study sample 
further excluded mothers missing key covariates and cholesterol measurements.  
Serum total cholesterol (TC), HDL-C, and triglycerides were measured using standard clinical 
methods.20 LDL-C was calculated using the Friedewald equation.21 As the accuracy of TC, LDL-
C, and TG are dependent on a fasted blood sample, this analysis focused mainly on maternal 
HDL-C. Quantitative profiling of maternal plasma metabolites, including the BCAAs, was 
conducted by the Harvard-MIT Broad Institute Metabolite Profiling Laboratory using liquid 
chromatography tandem mass spectrometry (LC-MS/MS).  
Statistical Analysis 
Clinical and demographic characteristics for both mother and child were compared for the ASD 
and TD groups using the t-test and chi-squared test for continuous and categorical variables, 
respectively. For major covariates, missing values were combined into the largest group. 
Metabolite intensity levels were inverse-normally transformed for all subsequent analyses and 
metabolite values below the limit of detection were imputed with one-half the limit of detection. 
A BCAA score variable was created based on factor analysis of all three BCAAs using the 
Anderson-Rubin Method.22 We explored the association between maternal dyslipidemia and 
child risk of ASD using logistic regression and further assessed for joint effects with sex and 
maternal plasma BCAAs, independently and altogether. Plasma HDL-C was evaluated in the 
main analysis because it is unaffected in a non-fasted state, unlike the other cholesterols. For 
joint effects and effect modification analyses, the reference category was the combination of high 
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HDL-C with female sex (or below median maternal BCAA levels) and was compared to three 
other groups: 2. low HDL-C with female sex (or below median BCAAs) 3. high HDL-C with 
male sex (or above median BCAAs with), and 4. low HDL-C with male sex (or above median 
BCAAs). The relative excess risk due to interaction (RERI) was used to show departure from the 
additive effects of BCAAs and HDL-C or sex.23 Tests for multiplicative interaction were also 
conducted. All analyses were conducted using Stata v14.0 (Stata Corporation, College Station, 
TX, USA). 
To define dyslipidemia, the cholesterol variables were dichotomized by their clinical cut-offs. 
The cut-off used for HDL-C was <50 mg/dl, for TC was 240 mg/dl, and for LDL-C was 160 
mg/dl.24,25 The non-HDL-C variable was created by subtracting HDL-C from TC and using a 
clinical cut-point of 190 mg/dl.25  
Key maternal covariates in this analysis included: age at delivery (<20, 20-20, 30 and older), 
race-ethnicity (black, white, Hispanic, or other), smoking during pregnancy (“never smoked,” 
“ever smoked,” or “continuous smoking” within three months prior to conception), parity 
(nulliparous vs multiparous), education (“high school or less” vs “some college or more”), 
obesity/diabetes mellitus (ob/DM) (categorized into 1. no obesity (BMI 30 kg/m2), no type 2 
diabetes mellitus or gestational diabetes (DM, collectively); 2. either obesity or DM; 3. both 
obesity and DM). Key child covariates included: sex (female vs male), and gestational age and 
birthweight (categorized into 1. full term (37 weeks of gestation) and non-low birth weight 
(non-LBW; 2500g); 2. full term and LBW; 3. preterm and non-LBW; 4. preterm and LBW). 
RESULTS 
In total, 829 mother-infant pairs were included in this study consisting of 86 children with ASD 
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and 743 TD children. Table 5-1 presents maternal and child characteristics by child ASD status. 
Mothers with ASD children were approximately two years older (p=0.01) and more obese 
(p=0.01) than mothers with TD children. They were also more likely to have diabetes, though 
this difference was marginally significant (p=0.05). There was a 3:1 male to female ratio in the 
prevalence of ASD (p<0.0001) and ASD children had shorter gestation (p<0.0001) and lower 
birth weight (p=0.04) than their TD counterparts. When considered by themselves, maternal 
cholesterol levels, BCAA levels, smoking, race/ethnicity, parity, or education were not 
associated with child ASD risk. To evaluate potential selection bias of the study sample, 
Supplemental Table 5-2 compares maternal and child characteristics for included and excluded 
participants; there were significantly more black mothers included in the study than other race 
(p<0.0001) and fewer mothers who had ever smoked or continued to smoke (p=0.001). A 
significantly greater number of infants included in the study were female (p<0.01), born full term 
(≥37 weeks) (p<0.0001), and at a normal weight (>2500 g) (p<0.0001). There were no 
significant in maternal and child characteristics by level of maternal HDL-C (Supplemental 
Table 5-3) and maternal cholesterols did not significantly vary by ASD case status 
(Supplemental Figure 5-2). 
Maternal cholesterols had joint effects with child’s sex on child risk of ASD, even after 
adjustment for pertinent covariables, including maternal age, race/ethnicity, education, parity, 
obesity/diabetes, smoking status, gestational age, and birthweight (Table 5-2). The effect of 
HDL-C, non-HDL-C, and LDL-C on child risk of ASD all differed by child’s. Males whose 
mothers had low HDL-C were at highest risk of ASD (odds ratio (OR): 4.20; 95% CI 2.02, 8.73), 
followed by males whose mothers had high HDL-C (OR: 3.70; 95% CI 2.05, 6.67), compared to 
females whose mothers had high HDL-C. Further, the risk of child ASD was higher for males 
 
 110 
than females more so among mothers with low HDL-C than with high HDL-C (crude OR: 5.57; 
95% CI 1.81, 17.11 vs crude OR: 3.53; 95% CI 1.99, 6.23, respectively). A similar pattern was 
found for elevated LDL-C and non-HDL-C for crude stratified ORs by child’s. However, 
assessment of maternal cholesterol-infant sex interactions on additive and multiplicative scales 
were not significant for any of these cholesterol measures. 
Maternal HDL-C also modified the effect of maternal plasma BCAAs on child risk of ASD 
(Table 5-3). Among mothers with low levels of HDL-C, the crude OR for the effect of high 
BCAA score on ASD risk was over four-fold (OR 4.67; 95% CI: 1.33, 16.36). For isoleucine, 
this effect was over six-fold and for valine over seven-fold. Assessment of BCAA-HDL-C 
interactions were significant on the additive scale (BCAA score RERI 0.12; 95% CI: 0.03, 0.20) 
and multiplicative scale (BCAA score OR: 6.13; 95% CI: 1.42, 26.42) across all three BCAAs. 
Sensitivity analyses showed consistent results (Supplemental Tables 5-4 – 5-5). Analyses on TC, 
LDL-C, and non-HDL-C are also presented (Supplemental Tables 5-6 – 5-14), manifesting 
similar trends, but not as robust as HDL-C. 
Finally, we examined the joint effect of HDL-C, BCAA, and child’s sex on child ASD risk. 
Figure 5-1 illustrates the association of maternal HDL-C levels with child risk of ASD, stratified 
by maternal plasma BCAA status as defined by the BCAA score, among the overall sample, and 
among males and females, respectively. Most notably, in mothers with high BCAA scores, the 
risk of ASD was higher with lower HDL-C concentrations, decreasing steadily as HDL-C 
increased. This pattern was more exaggerated among male children. Figure 5-2 displays similar 
patterns for the other cholesterol measures. The group with all three exposures combined – males 
whose mothers had a high BCAA score and low HDL-C – had the greatest risk of ASD, 
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To our knowledge, this is the first study of this kind in US urban, low income prospective birth 
cohort. We found that low maternal HDL-C, high maternal plasma BCAA concentrations, and 
male sex can additively or multiplicatively increase child risk of ASD. This study extends 
previous studies by us and others on the role of maternal metabolic factors in child ASD. 
Interpretation 
Though the role of maternal obesity and diabetes in child ASD has received increasing attention 
due to accumulating evidence, there is a lack of studies linking maternal cholesterols to ASD. 
However, as reviewed below, it is biologically plausible that abnormal maternal cholesterols may 
affect the risk of child ASD. While cholesterols are be formed de novo by the fetus, maternal 
cholesterols are also transported via placenta, at least during the first trimester, and enter fetal 
circulation.4 A recent meta analyses of maternal dyslipidemia reported that both low and high 
levels of cholesterol were associated with preterm birth,5 which is also highly associated with 
ASD.26,27 Low maternal cholesterol has also been linked with low birthweight and 
microcephaly.28 In cases of maternal hypercholesterolemia, fetal cholesterols also become 
elevated, and this increased exposure has been shown to predispose the offspring to 
atherosclerosis later in life.29 Elevated maternal cholesterol has been consistently linked with 
adverse adult offspring outcomes, including atherosclerosis and cardiovascular disease,30 which 
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are co-occurring conditions in individuals with ASD.31 It is possible that selective diets and food 
sensitivities in ASD could partially account for the pathophysiology of these inflammatory 
conditions.32  
Adequate levels of cholesterol are necessary for proper membrane myelination during fetal 
development. Reduced levels of myelin have been seen in individuals with Fragile X syndrome, 
a disorder closely related to ASD.33 However, there is inconsistent evidence for altered 
cholesterol levels in ASD individuals; some studies have found higher total and LDL-C levels 
among ASD individuals while others report normal or lower cholesterol compared to 
controls.34,35 This may be due to the differing subtypes and etiologies of ASD.  
Genetic defects of cholesterol biosynthesis have severe impacts on development and survival of 
the fetus.35 Smith–Lemli–Opitz Syndrome (SLOS) is a milder genetic disorder characterized by a 
defect in cholesterol synthesis and is associated with autistic traits. One study reported around 
20% of children with ASD had hypocholesterolemia.36 Abnormal cholesterol metabolism in 
SLOS and ASD may lead to dysfunction in serotonin signaling, as cholesterol modulates the 
activity of serotonin, especially in its transport. Serotonin has been implicated in altered social 
behaviors characteristic of SLOS and ASD. A mouse model for SLOS supports this finding.37 A 
recent study also found that adult rats prenatally exposed to valproic acid to induce autistic-like 
traits had sex-specific differences in brain cholesterol metabolism compared to unexposed rats.38 
With the exception of vitamin D, all steroid hormones are formed from cholesterol precursors. 
Steroids have been implicated in the etiology of anxiety and mood disorders as well as ASD.36 
There is growing literature on maternal vitamin D deficiency during pregnancy and ASD.39,40 
Serotonin, oxytocin, and vasopressin all contain a vitamin D response element (VDRE).40 The 
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genes encoding production of each require vitamin D to activate them. All three of these 
hormones are also modulated by cholesterol. Although cholesterol is not a precursor for vitamin 
D, they are both derived from the same molecule, 7-dehydrocholesterol (7DHC).33 The 7DHC 
reductase gene (DHCR7) is the same as that implicated in SLOS. Gillberg et al. (2017) 
hypothesized there may be an association between ASD and this “branching point,” possibly 
explaining the links between ASD and cholesterol and ASD and vitamin D.33 Pregnant women 
with inadequate levels of 25-hydroxyvitamin D during the first trimester had significantly 
increased TC, LDL-C, and TC/HDL-C ratio compared to pregnant women with sufficient levels 
of the vitamin.41 
It is a well-observed phenomenon that there is a profound sex disparity in ASD, with male to 
female ratio of 3:1.42 However, the underlying reasons and mechanisms for the sex difference are 
poorly understood. In the present study, for the first time, we showed that the effect of low 
maternal HDL-C on child ASD risk was most pronounced in male children. This link between 
cholesterol and sex is supported by a study that reported estrogen is able to compensate for 
insufficient maternal vitamin D, potentially rescuing female fetuses from developing psychiatric 
disorders, including ASD.40 Thus, our finding puts forth new indications for future research. 
This study demonstrated that maternal cholesterols by themselves were not associated with child 
risk of ASD. However, HDL-C, non-HDL-C, and LDL-C did modify maternal effect of BCAAs 
on child ASD risk with significant additive and multiplicative interactions.  
BCAAs are highly correlated with obesity and T2DM and predictive of T2DM.13,43 Yet, there is 
limited evidence linking cholesterol and BCAAs. One study showed plasma cholesterol levels 
increased in septic patients given a large dose of BCAAs, while other amino acids, fat, and 
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glucose were not impacted.15 This suggests BCAA metabolites contribute to cholesterol 
synthesis in an inflammatory state. Both BCAA and lipid metabolism involve the tricarboxylic 
acid (TCA) cycle in the mitochondria and are thus dependent on the proper functioning of each 
other. Disturbances in lipid metabolism have been shown to yield elevated serum concentrations 
of BCAAs.16 These disturbances in energy metabolism have the potential to cause oxidative 
stress and inflammation. BCAAs, especially leucine, are inducers of mammalian target of 
rapamycin (mTOR), an important kinase involved in cell growth, protein synthesis, and energy 
balance.44 Thus, together with low HDL-C levels and child male sex, BCAAs have the potential 
to increase the risk of child ASD. Our results showed that male children whose mothers had low 
HDL-C levels and low BCAA concentrations, were not at significant risk compared to the 
reference group (female children whose mothers had high HDL-C levels and low BCAA 
concentrations) (Supplemental Figure 5-3). However, male children whose mothers had low 
HDL-C levels and high BCAA concentrations had a significantly increased risk, suggesting 
elevated BCAA concentrations are key factors in increasing the risk under these conditions. This 
analysis was unadjusted for key covariates and conducted as exploratory research. 
Strengths and Limitations 
This is a relatively large, prospective, longitudinal, and inter-generational study design coupled 
with maternal biomarkers of lipids and BCAAs. It is the first to examine the joint effects of 
maternal cholesterol and metabolites on the risk of her child developing ASD. This study also 
brought to light potential biomarkers associated with sex differences observed in ASD. 
Limitations of this study include a one-time post-delivery measurement of maternal BCAAs and 
cholesterols in a non-fasted state. Apart from HDL-C, cholesterol measurements in a non-fasted 
state are not as reliable, especially triglycerides, which we did not analyze. Though our sample 
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size was among the largest for a prospective study of its kind, we were not able to examine 
stratified odds ratios adjusted for pertinent covariables. We caution the number of cases is very 
small in certain category and the observed associations may not be reliable. As such, our findings 
should be regarded as hypothesis-generating and warrant further investigation and confirmation. 
Implications for future research 
While most current research on BCAAs in ASD has shown reduced levels in ASD cases versus 
controls, we are not aware of any that have examined the prospective effect of maternal BCAAs 
on child risk of ASD. The developmental origins of health and disease model asserts that in a 
womb environment of plenty, the fetus adapts to expect a similar postnatal environment.45 Thus, 
fetuses exposed to excess levels of BCAAs in the womb may express fewer circulating 
concentrations postnatally. Other possible explanations of lower concentrations of BCAAs 
among individuals with ASD include food sensitivities and poor diet quality leading to 
insufficient intake of certain nutrients,32 and possible mutations in the branched chain ketoacid 
dehydrogenase kinase (BCKDK), a key enzyme in BCAA catabolism.46 Future studies including 
both maternal plasma measurements during specific trimesters of pregnancy as well as cord 
blood and postnatal child plasma cholesterols and BCAAs may help clarify the inter-generational 
link of cholesterols and BCAAs with child ASD risk. 
Conclusions 
The results of this longitudinal, prospective birth cohort study showed that while maternal 
plasma cholesterols were not associated with the risk of child ASD, they had a joint effect with 
child’s sex on this risk. Low HDL-C and elevated maternal plasma BCAAs jointly increased the 
risk as well and together with child male sex, the three factors together had the greatest effect on 
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the risk of child development of ASD. Future studies with larger sample sizes and additional 
time points for HDL-C and BCAAs throughout pregnancy, from fetal cord blood, and during 
early childhood may further elucidate the role of maternal and fetal/child cholesterols and 
BCAAs in the risk of child ASD.  
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Table 5-1. Maternal and child characteristics by child autism spectrum disorder (ASD) status 
(Typically Developing (TD) vs. ASD) in the Boston Birth Cohort 
 
Maternal Characteristics Total (N=829) TD (N=743) ASD (N=86) P-valuea 
Age (years), mean (SD)b 28.29 (6.51) 28.09 (6.51) 30.00 (6.34) 0.010 
   25 298 (35.95) 274 (36.88) 24 (27.91) 0.257 
   26-35 390 (47.04) 344 (46.30) 46 (53.49)  
   ≥36 141 (17.01) 125 (16.82) 16 (18.60)  
Nulliparous, n (%) 362 (43.67) 327 (44.01) 35 (40.70) 0.344 
Race or ethnicity, n (%)c    0.089 
   Black 585 (70.57) 533 (71.74) 52 (60.47)  
   White 33 (3.98) 28 (3.77) 5 (5.81)  
   Hispanic 156 (18.82) 132 (17.77) 24 (27.91)  
   Other 55 (6.63) 50 (6.73) 5 (5.81)  
Education, n (%)    0.991 
   Below college degree 707 (85.28) 635 (85.46) 72 (83.72)  
   College degree or above 116 (13.99) 104 (14.00) 12 (13.95)  
   Missing  6 (0.72) 4 (0.54) 2 (2.33)  
Pre-pregnancy BMI, n (%)     
   Mean (SD) 26.57 (6.59) 26.41 (6.42) 27.96 (7.91) 0.046 
   Normal weight (<25 kg/m2) 388 (46.80) 354 (47.64) 34 (39.53) 0.019 
   Overweight (25 - <30 kg/m2) 210 (25.33) 193 (25.98) 17 (19.77)  
   Obese (≥30 kg/m2) 194 (23.40) 165 (22.21) 29 (33.72)  
   Missing  37 (4.46) 31 (4.17) 6 (6.98)  
Diabetes, n (%)d    0.053 
   No diabetes 736 (88.78) 665 (89.50) 71 (82.56)  
   Diabetes 93 (10.76) 78 (10.50) 15 (17.44)  
Smoking, n (%)e    0.665 
   Never 702 (84.68) 632 (85.06) 70 (81.40)  
   Quit 54 (6.51) 47 (6.33) 7 (8.14)  
   Continuous 64 (7.72) 56 (7.54) 8 (9.30)   
   Missing  9 (1.09) 8 (1.08) 1 (1.16)  
Total cholesterol, mean (SD) 218.38 (59.45) 218.54 (59.90) 216.97 (55.74) 0.818 
High cholesterol (≥240 mg/dl), n (%) 260 (31.36) 235 (31.63) 25 (29.07) 0.628 
LDL cholesterol, mean (SD) 125.72 (40.41) 125.74 (40.74) 125.55 (37.75) 0.968 
High LDL (≥160 mg/dl), n (%) 146 (17.61) 134 (18.03) 12 (13.95) 0.347 
HDL cholesterol, mean (SD) 62.77 (17.98) 63.08 (18.26) 60.02 (15.16) 0.135 
Low HDL (<50 mg/dl), n (%) 201 (24.25) 179 (24.09) 22 (25.58) 0.760 
Leucine (above median), n (%) 416 (50.18) 368 (49.53) 48 (55.81) 0.270 
Isoleucine (above median), n (%) 417 (50.30) 372 (50.07) 45 (52.33) 0.692 
Valine (above median), n (%) 416 (50.18) 366 (49.26) 50 (58.14) 0.119 
BCAA score (above median), n (%) 410 (49.46) 362 (48.72) 48 (55.81) 0.213 
Child Characteristics Total (N=829) TD (N=743) ASD (N=86) P-valuea 
Sex, n (%)    <0.0001 
   Male 381 (45.96) 317 (42.66) 64 (74.42)  
   Female 448 (54.04) 426 (57.34) 22 (25.58)  
Gestational age, n (%)    <0.0001 
   Term (≥37 weeks) 709 (85.52) 645 (86.81) 64 (74.42)  
   Late preterm (34-36 weeks) 64 (7.72) 60 (8.08) 4 (4.65)  
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   Early preterm (<34 weeks) 56 (6.76) 38 (5.11) 18 (20.93)  
Birth weight, n (%)    0.036 
   ≥2,500 grams 676 (81.54) 613 (82.50) 63 (73.26)  
   <2,500 grams 153 (18.46) 130 (17.50) 23 (26.74)  
SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein 
aP-values were obtained from χ2 tests or t-tests; missing values for categorical variables were incorporated into the largest group 
bMaternal age at time of delivery 
cBlack includes self-reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
dType 2 diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking three months prior to conception or during pregnancy; some 
smoking includes mothers who smoked at some point in the window of three months prior to conception to delivery but did not smoke 






Table 5-2. Joint association of maternal plasma cholesterols and child’s sex on the risk of child 
autism spectrum disorder (ASD) 
 




ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 HDL-C within  
strata of Sexa 
Female 18/345 1.00 (ref) 4/103 0.67 (0.22-2.09) 0.73 (0.24-2.22) 
Male 46/283 3.70 (2.05-6.67) 18/98 4.20 (2.02-8.73) 1.16 (0.64-2.11) 
OR (95% CI) Sex 
within strata of HDL-Ca   3.53 (1.99-6.23)   5.57 (1.81-17.11)   
Measure of interaction on additive scale: RERI (95% CI) = 0.03 (-0.06-0.13); P = 0.499  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.69 (0.46-6.19); P = 0.431 
  Non-HDL-C (<190 mg/dl)  Non-HDL-C (≥190 mg/dl)   
  
N 
ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 Non-HDL-C 
within  
strata of Sexa 
Female 19/358 1.00 (ref) 3/90 0.64 (0.18-2.26) 0.62 (0.18-2.13) 
Male 54/307 4.14 (2.34-7.33) 10/74 2.77 (1.17-6.52) 0.73 (0.35-1.52) 
OR (95% CI) Sex 
within strata of Non-
HDL-Ca   3.81 (2.20-6.58)   4.53 (1.20-17.13)   
Measure of interaction on additive scale: RERI (95% CI) = -0.03 (-0.13-0.07); P = 0.536  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.04 (0.24-4.53); P = 0.958 
  LDL-C (<160 mg/dl)  LDL-C (≥160 mg/dl)   
  
N 
ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 LDL-C within  
strata of Sexa 
Female 19/368 1.00 (ref) 3/80 0.77 (0.22-2.71) 0.72 (0.21, 2.48) 
Male 55/315 4.23 (2.40-7.46) 9/66 2.94 (1.21-7.11) 0.75 (0.35, 1.60) 
OR (95% CI) Sex 
within strata of LDL-Ca   3.89 (2.25-6.71)   4.05 (1.05-15.64)   
Measure of interaction on additive scale: RERI (95% CI) = -0.03 (-0.13-0.07); P = 0.536  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.91 (0.20-4.01); P = 0.896 
HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol 
ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking status, gestational age, and birthweight 
unless otherwise noted 




Table 5-3. Joint association of maternal plasma branched-chain amino acids (BCAAs) and high-
density lipoprotein cholesterol (HDL-C) on the risk of child autism spectrum disorder (ASD) 
 
  Leucine below median Leucine above median   
Maternal HDL-C  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL-Ca 
High HDL-C  35/336 1.00 (ref) 29/292 0.98 (0.56-1.70) 0.95 (0.56-1.59) 
Low HDL-C 3/77 0.27 (0.07-0.97) 19/124 1.56 (0.81-2.99) 4.46 (1.27-15.63) 
OR (95% CI) HDL-C 
within strata of BCAAa   0.35 (0.10-1.16)   1.64 (0.88-3.05)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (0.03-0.20); P = 0.007   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 5.95 (1.38-25.72); P = 0.017 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL-Ca 
High HDL-C 39/338 1.00 (ref) 25/290 0.73 (0.41-1.27) 0.72 (0.43-1.23) 
Low HDL-C 2/74 0.16 (0.03-0.74) 20/127 1.40 (0.74-2.64) 6.73 (1.53-29.68) 
OR (95% CI) HDL-C 
within strata of BCAAa   0.21 (0.05-0.90)   1.98 (1.06-3.72)   
Measure of interaction on additive scale: RERI (95% CI) = 0.15 (0.07-0.23); P = <0.001   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 12.21 (2.23-66.77); P = 0.004 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL-Ca 
High HDL-C 34/336 1.00 (ref) 30/292 1.06 (0.61-1.85) 1.02 (0.61-1.71) 
Low HDL-C 2/77 0.17 (0.04-0.80) 20/124 1.73 (0.91-3.30) 7.21 (1.64-31.79) 
OR (95% CI) HDL-C 
within strata of BCAAa   0.24 (0.06-1.01)   1.70 (0.91-3.09)   
Measure of interaction on additive scale: RERI (95% CI) = 0.13 (0.05-0.21); P = 0.002   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 9.50 (1.78-50.88); P = 0.009 
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL-Ca 
High HDL-C  35/340 1.00 (ref) 29/288 1.00 (0.57-1.74) 0.98 (0.58-1.64) 
Low HDL-C 3/79 0.26 (0.07-0.96) 19/122 1.61 (0.84-3.10) 4.67 (1.33-16.36) 
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OR (95% CI) HDL-C 
within strata of BCAAa   0.34 (0.10-1.15)   1.65 (0.88-3.09)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (0.03-0.20); P = 0.006   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 6.13 (1.42-26.42); P = 0.015 
  HDL-C, high-density lipoprotein cholesterol  
  Note: Low HDL-C <50 mg/dl 
ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking status, gestational age, and birthweight 
unless otherwise noted  




Figure 5-1. Association of maternal HDL levels with risk of child autism spectrum disorder 
(ASD), stratified by maternal plasma branched-chain amino acid (BCAA) status defined by 
BCAA score, among overall sample, and among males and females, respectively 
 




Figure 5-2. Association of maternal total cholesterol, non-HDL cholesterol, and LDL levels with 
risk of child autism spectrum disorder (ASD), stratified by maternal plasma branched-chain 
amino acid (BCAA) status defined by BCAA score, among overall sample, and among males 




a. association of maternal TC with risk of child ASD by maternal plasma BCAA score in the overall sample, b. association of maternal TC with 
risk of ASD in male children by maternal plasma BCAA score, c. association of maternal TC with risk of ASD in female children by maternal 
plasma BCAA score, d. association of maternal non-HDL cholesterol with child risk of ASD by maternal plasma BCAA score in the overall 
sample, e. association of maternal non-HDL cholesterol with risk of ASD in male children by maternal plasma BCAA score, f. association of 
maternal non-HDL cholesterol with risk of ASD in female children by maternal plasma BCAA score, g. association of maternal LDL cholesterol 
with child risk of ASD by maternal plasma BCAA score in the overall sample, h. association of maternal LDL cholesterol with risk of ASD in 
male children by maternal plasma BCAA score, i. association of maternal LDL cholesterol with risk of ASD in female children by maternal 










3,163 mother-infant pairs with EMR records of well-child and specialty visits 
1,933 neurotypical children; 150 children with ASD; 1080 cases of other 
developmental disabilities (DD)   
829 mother-infant pairs 
   743 neurotypical children 
   86 children with ASD with or without other DD 
1202 excluded due to missing 
metabolite measurement  
1080 excluded 
due to other DDs 
35 excluded due to missing 
lipid measurement  




Supplemental Figure 5-2. Maternal cholesterols by child case status (autism spectrum disorder 
(ASD) and typically developing (TD) children) 
 
 
a. Maternal high-density lipoprotein cholesterol (HDL-C) by ASD status b. Maternal total cholesterol by ASD status c. Maternal non- high-
density lipoprotein cholesterol (non-HDL-C) by ASD status d. Maternal low-density lipoprotein cholesterol (LDL-C) by ASD status  





Supplemental Figure 5-3. Joint association of maternal plasma branched-chain amino acid 
(BCAA) score, maternal high-density lipoprotein cholesterol (HDL-C) status and child’s sex on 






Supplemental Table 5-1. List of ICD-9 and ICD-10 codes for the diagnosis of each 
developmental disorder 
 
Developmental disorder ICD-9 codes ICD-10 codes 
ASD 299.0, 299.00, 299.01, 299.8, 
299.80, 299.81, 299.9, 299.90, 
299.91 
F84.0, F84.8, F84.9 
ADHD 314.0, 314.00, 314.01, 314.1, 
314.2, 314.8, 314.9 
F90, F90.0, F90.1, F90.2, F90.8, 
F90.9 
Developmental delays 315.0-315.9 F81.0, R48.0, F81.81, F81.2, 
F81.89, F80.1, F80.2, H93.25, 
F80.4, F80.81, F80.0, F80.82, 
F80.89, F82, F88, F81.9, F89 





Supplemental Table 5-2. Maternal and child characteristics of Boston Birth Cohort participants 
excluded and included in the analysis 
 
Characteristics Total, N (%) Excluded, N (%) Included, N (%) P-valuea 
Total 3138 (100.00) 2309 (73.58) 829 (26.42)  
Maternal age (years), mean (SD)b 28.64 (6.50) 28.60 (6.48) 28.29 (6.51) 0.234 
Nulliparous, n (%) 1337 (42.61) 975 (42.23) 362 (43.67) 0.472 
Race or ethnicity, n (%)c    <0.0001 
   Black 1998 (63.67) 1413 (61.20) 585 (70.57)  
   White 227 (7.23) 194 (8.40) 33 (3.98)  
   Hispanic 701 (22.34) 545 (23.60) 156 (18.82)  
   Other 212 (6.76) 156 (6.80) 55 (6.63)  
Maternal education, n (%)    0.683 
   Below college degree 2690 (85.72) 1983 (85.88) 707 (85.28)  
   College degree or above 426 (13.58) 310 (13.43) 116 (13.99)  
   Missing 22 (0.70) 16 (0.69) 6 (0.72)  
Maternal BMI, n (%)     
   Mean (SD) 26.58 (6.65) 26.59 (6.67) 26.57 (6.59) 0.950 
   Normal weight (<25 kg/m2) 1452 (46.27) 1064 (46.08) 388 (46.80) 0.898 
   Overweight (25 - <30 kg/m2) 813 (25.90) 603 (26.12) 210 (25.33)  
   Obese (≥30 kg/m2) 703 (22.40) 509 (22.04) 194 (23.40)  
   Missing 170 (5.42) 133 (5.76) 37 (4.46)  
Maternal Diabetes, n (%)d    0.255 
   No diabetes 2751 (87.67) 2015 (87.27) 736 (88.78)  
   Diabetes 387 (12.33) 294 (12.73) 93 (11.22)  
Maternal smoking, n (%)e     
   Never 2542 (81.01) 1840 (79.69) 702 (84.68) 0.001 
   Quit 241 (7.68) 187 (8.10) 54 (6.51)  
   Continuous 336 (10.71) 272 (11.78) 64 (7.72)  
   Missing 19 (0.61) 10 (0.43)  9 (1.09)  
Child’s, n (%)    0.003 
   Male 1583 (50.45) 1202 (52.06) 381 (45.96)  
   Female 1555 (49.55) 1107 (47.94) 448 (54.04)  
Gestational age, n (%)    <0.0001 
   Term (≥37 weeks) 2448 (78.01) 1739 (75.31) 709 (85.52)  
   Late preterm (34-36 weeks) 306 (9.75) 242 (10.48) 64 (7.72)  
   Early preterm (<34 weeks) 384 (12.24) 328 (14.21) 56 (6.76)  
Birthweight, n (%)    <0.0001 
   ≥2,500 grams 2275 (72.50) 1599 (69.25) 676 (81.54)  
   <2,500 grams 863 (27.50) 710 (30.75) 153 (18.46)  
SD, standard deviation 
aP-values were obtained from χ2 tests or t-tests; missing values for categorical variables were incorporated into the largest group 
bMaternal age at time of delivery 
cBlack includes self-reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
dType 2 diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking three months prior to conception or during pregnancy; some 
smoking includes mothers who smoked at some point in the window of three months prior to conception to delivery but did not smoke 




Supplemental Table 5-3. Maternal and child characteristics by maternal plasma high-density 
lipoprotein cholesterol (HDL-C) levels in the Boston Birth Cohort 
 





ASD, n (%) 64 (10.19) 22 (10.95) 0.760 
Maternal age (years), mean (SD)c 28.34 (6.57) 28.13 (6.36) 0.682 
Nulliparous, n (%) 271 (43.15) 91 (45.27) 0.598 
Race or ethnicity, n (%)d   0.198 
   Black 439 (69.90) 146 (72.64)  
   White 24 (3.82) 9 (4.48)  
   Hispanic 120 (19.11) 36 (17.91)  
   Other 45 (7.17) 10 (4.98)  
Maternal education, n (%)   0.096 
   Below college degree 528 (84.08) 179 (89.05)  
   College degree or above 95 (15.13) 21 (10.45)  
   Missing (n=6) 5 (0.80) 1 (0.50)  
Maternal BMI, n (%)    
   Mean (SD) 26.45 (6.55) 26.97 (6.73) 0.342 
   Normal weight (<25 kg/m2) 302 (48.09) 86 (42.79) 0.326 
   Overweight (25 - <30 kg/m2) 152 (24.20) 58 (28.86)  
   Obese (≥30 kg/m2) 146 (23.25) 48 (23.88)  
   Missing 28 (4.46) 9 (4.48)  
Maternal Diabetes, n (%)e   0.056 
   No diabetes 565 (89.97) 171 (85.07)  
   Diabetes 63 (10.03) 30 (14.93)  
Maternal smoking, n (%)f   0.305 
   Never 539 (85.83) 163 (81.09)  
   Quit 37 (5.89) 17 (8.46)  
   Continuous 46 (7.32) 18 (8.96)   
   Missing 6 (0.96) 3 (1.49)  
Child’s, n (%)   0.361 
   Male 283 (45.06) 98 (48.76)  
   Female 345 (54.94) 103 (51.24)  
Gestational age, n (%)   0.968 
   Term (≥37 weeks) 536 (85.35) 173 (86.07)  
   Late preterm (34-36 weeks) 49 (7.80) 15 (7.46)  
   Early preterm (<34 weeks) 43 (6.86) 13 (6.47)  
Birthweight, n (%)   0.287 
   ≥2,500 grams 507 (80.73) 169 (84.08)  
   <2,500 grams 121 (19.27) 32 (15.92)  
SD, standard deviation 
aScore derived from factor analysis as the average score of the three BCAAs (leucine, isoleucine, and valine) 
bP-values were obtained from χ2 tests or t-tests; missing values for categorical variables incorporated with largest sized group 
cMaternal age at time of delivery 
dBlack includes self-reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
eType 2 diabetes mellitus and/or gestational diabetes mellitus 
fNever smokers were defined as mothers with no history of smoking three months prior to conception or during pregnancy; some 
smoking includes mothers who smoked at some point in the window of three months prior to conception to delivery but did not smoke 





Supplemental Table 5-4. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal high-
density lipoprotein (HDL-C) 
  Leucine below median Leucine above median   
Maternal HDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  35/336 1.00 (ref) 29/292 0.95 (0.56-1.59) 0.95 (0.56-1.59) 
Low HDL 3/77 0.35 (0.10-1.16) 19/124 1.56 (0.85-2.84) 4.46 (1.27-15.63) 
OR (95% CI) HDL 
within strata of BCAA   0.35 (0.10-1.16)   1.64 (0.88-3.05)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (0.03-0.21); P = 0.010  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.71 (1.21-18.28); P = 0.025 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  39/338 1.00 (ref) 25/290 0.72 (0.43-1.23) 0.72 (0.43-1.23) 
Low HDL 2/74 0.21 (0.05-0.90) 20/127 1.43 (0.80-2.57) 6.73 (1.53-29.68) 
OR (95% CI) HDL 
within strata of BCAA   0.21 (0.05-0.90)   1.98 (1.06-3.72)   
Measure of interaction on additive scale: RERI (95% CI) = 0.16 (0.07-0.25); P = <0.001  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 9.30 (1.93-44.96); P = 0.006 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  34/336 1.00 (ref) 30/292 1.02 (0.61-1.71) 1.02 (0.61-1.71) 
Low HDL 2/77 0.24 (0.06-1.01) 20/124 1.67 (0.87-3.19) 7.21 (1.64-31.79) 
OR (95% CI) HDL 
within strata of BCAA   0.24 (0.06-1.01)   1.70 (0.91-3.09)   
Measure of interaction on additive scale: RERI (95% CI) = 0.13 (0.05-0.22); P = 0.003  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 7.09 (1.47-34.13); P = 0.015 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  35/340 1.00 (ref) 29/288 0.98 (0.58-1.64) 0.98 (0.58-1.64) 
Low HDL 3/79 0.34 (0.10-1.15) 19/122 1.61 (0.88-2.93) 4.67 (1.33-16.36) 
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OR (95% CI) HDL 
within strata of BCAA   0.34 (0.10-1.15)   1.65 (0.88-3.09)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (0.03-0.21); P = 0.009   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.79 (1.23-18.60); P = 0.024 




Supplemental Table 5-5. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of male child autism spectrum disorder (ASD) – joint effect with maternal 
high-density lipoprotein (HDL-C) 
  Leucine below median Leucine above median   
Maternal HDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  23/151 1.00 (ref) 23/132 1.17 (0.62-2.21) 1.17 (0.62-2.21) 
Low HDL 2/33 0.36 (0.08-1.60) 16/65 1.82 (0.89-3.73) 5.06 (1.09-23.54) 
OR (95% CI) HDL 
within strata of BCAA   0.36 (0.08-1.60)   1.55 (0.75-3.18)   
Measure of interaction on additive scale: RERI (95% CI) = 0.16 (0.005-0.32); P = 0.043  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.31 (0.82-22.71); P = 0.085 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  25/158 1.00 (ref) 21/125 1.07 (0.57-2.03) 1.07 (0.57-2.03) 
Low HDL 1/32 0.17 (0.02-1.32) 17/66 1.85 (0.92-3.71) 10.78 (1.36-84.92) 
OR (95% CI) HDL 
within strata of BCAA   0.17 (0.02-1.32)   1.72 (0.83-3.54)   
Measure of interaction on additive scale: RERI (95% CI) = 0.22 (0.07-0.37); P = 0.004  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 10.01 (1.15-86.95); P = 0.037 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  23/156 1.00 (ref) 23/127 1.28 (0.68-2.41) 1.28 (0.68-2.41) 
Low HDL 2/35 0.35 (0.08-1.56) 16/63 1.97 (0.96-4.04) 5.62 (1.21-26.09) 
OR (95% CI) HDL 
within strata of BCAA   0.35 (0.08-1.56)   1.54 (0.75-3.18)   
Measure of interaction on additive scale: RERI (95% CI) = 0.16 (0.005-0.32); P = 0.043  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.39 (0.83-23.12); P = 0.081 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of HDL 
High HDL  23/156 1.00 (ref) 23/127 1.28 (0.68-2.41) 1.28 (0.68-2.41) 
Low HDL 2/34 0.36 (0.08-1.61) 16/64 1.93 (0.94-3.95) 5.33 (1.15-24.79) 
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OR (95% CI) HDL 
within strata of BCAA   0.36 (0.08-1.61)   1.51 (0.73-3.11)   
Measure of interaction on additive scale: RERI (95% CI) = 0.16 (-0.001-0.32); P = 0.051   
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 4.17 (0.79-21.97); P = 0.092 




Supplemental Table 5-6. Adjusted association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal total 
cholesterol (TC) 
  Leucine below median Leucine above median   
Maternal TC 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TCa 
Low TC  23/275 1.00 (ref) 38/294 1.88 (1.05-3.37) 1.63 (0.94-2.81) 
High TC 15/138 1.70 (0.81-3.57) 10/122 1.12 (0.49-2.54) 0.73 (0.32-1.70) 
OR (95% CI) TC within 
strata of BCAAa   1.34 (0.67-2.65)   0.60 (0.29-1.25)   
Measure of interaction on additive scale: RERI (95% CI) = -0.09 (-0.17- <-0.001); P = 0.050  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.35 (0.12-1.02); P = 0.053 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TCa 
Low TC  25/271 1.00 (ref) 36/298 1.41 (0.79-2.49) 1.35 (0.79-2.32) 
High TC 16/141 1.42 (0.70-2.89) 9/119 0.92 (0.40-2.14) 0.64 (0.27-1.50) 
OR (95% CI) TC within 
strata of BCAAa   1.26 (0.65-2.45)   0.60 (0.28-1.28)   
Measure of interaction on additive scale: RERI (95% CI) = -0.06 (-0.15-0.02); P = 0.149  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.46 (0.16-1.35); P = 0.158 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TCa 
Low TC  22/281 1.00 (ref) 39/288 2.16 (1.20-3.89) 1.84 (1.06-3.20) 
High TC 14/132 1.78 (0.83-3.89) 11/128 1.28 (0.57-2.84) 0.79 (0.35-1.82) 
OR (95% CI) TC within 
strata of BCAAa   1.40 (0.69-2.83)   0.60 (0.30-1.21)   
Measure of interaction on additive scale: RERI (95% CI) = -0.09 (-0.18- -0.003); P = 0.043  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.33 (0.11-10.97); P = 0.044 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TCa 
Low TC  23/280 1.00 (ref) 38/289 1.94 (1.08-3.48) 1.69 (0.98-2.92) 
High TC 15/139 1.71 (0.81-3.57) 10/121 1.14 (0.50-2.60) 0.74 (0.32-1.73) 
OR (95% CI) TC within 
strata of BCAAa   1.35 (0.68-2.68)   0.60 (0.29-1.24)   
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Measure of interaction on additive scale: RERI (95% CI) = -0.09 (-0.17- <-0.001); P = 0.049  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.35 (0.12-1.01); P = 0.052  
Note: High total cholesterol ≥240 mg/dl; ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking 
status, gestational age, and birthweight unless otherwise noted.  




Supplemental Table 5-7. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal total 
cholesterol (TC) 
  Leucine below median Leucine above median   
Maternal TC 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  23/275 1.00 (ref) 38/294 1.63 (0.94-2.81) 1.63 (0.94-2.81) 
High TC 15/138 1.34 (0.67-2.65) 10/122 0.98 (0.45-2.12) 0.73 (0.32-1.70) 
OR (95% CI) TC within 
strata of BCAA   1.34 (0.67-2.65)   0.60 (0.29-1.25)   
Measure of interaction on additive scale: RERI (95% CI) = -0.07 (-0.16-0.01); P = 0.104  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.45 (0.17-1.23); P = 0.119 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  25/271 1.00 (ref) 36/298 1.35 (0.79-2.32) 1.35 (0.79-2.32) 
High TC 16/141 1.26 (0.65-2.45) 9/119 0.81 (0.36-1.78) 0.64 (0.27-1.50) 
OR (95% CI) TC within 
strata of BCAA   1.26 (0.65-2.45)   0.60 (0.28-1.28)   
Measure of interaction on additive scale: RERI (95% CI) = -0.06 (-0.15-0.02); P = 0.134  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.47 (0.17-1.30); P = 0.147 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  22/281 1.00 (ref) 39/288 1.84 (1.06-3.20) 1.84 (1.06-3.20) 
High TC 14/132 1.40 (0.69-2.83) 11/128 1.11 (0.52-2.36) 0.79 (0.35-1.82) 
OR (95% CI) TC within 
strata of BCAA   1.40 (0.69-2.83)   0.60 (0.30-1.21)   
Measure of interaction on additive scale: RERI (95% CI) = -0.08 (-0.16-0.01); P = 0.084  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.43 (0.16-1.16); P = 0.097 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  23/280 1.00 (ref) 38/289 1.69 (0.98-2.92) 1.69 (0.98-2.92) 
High TC 15/139 1.35 (0.68-2.68) 10/121 1.01 (0.46-2.19) 0.74 (0.32-1.73) 
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OR (95% CI) TC within 
strata of BCAA   1.35 (0.68-2.68)   0.60 (0.29-1.24)   
Measure of interaction on additive scale: RERI (95% CI) = -0.07 (-0.16-0.01); P = 0.094  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.44 (0.16-1.20); P = 0.109  
Note: High total cholesterol ≥240 mg/dl 
Supplemental Table 5-8. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of male child autism spectrum disorder (ASD) – joint effect with maternal 
total cholesterol (TC) 
  Leucine below median Leucine above median   
Maternal TC 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  15/129 1.00 (ref) 30/141 2.05 (1.05-4.02) 2.05 (1.05-4.02) 
High TC 10/55 1.69 (0.71-4.04) 9/56 1.46 (0.60-3.56) 0.86 (0.32-2.32) 
OR (95% CI) TC within 
strata of BCAA   1.69 (0.71-4.04)   0.71 (0.31-1.61)   
Measure of interaction on additive scale: RERI (95% CI) = -0.12 (-0.28-0.05); P = 0.163  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.42 (0.13-1.39); P = 0.155 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  15/129 1.00 (ref) 30/141 2.05 (1.05-4.02) 2.05 (1.05-4.02) 
High TC 11/61 1.67 (0.72-3.90) 8/50 1.45 (0.57-3.66) 0.87 (0.32-2.35) 
OR (95% CI) TC within 
strata of BCAA   1.67 (0.72-3.90)   0.70 (0.30-1.66)   
Measure of interaction on additive scale: RERI (95% CI) = -0.12 (-0.28-0.05); P = 0.166  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.42 (0.13-1.41); P = 0.160 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  15/135 1.00 (ref) 30/135 2.29 (1.17-4.48) 2.29 (1.17-4.48) 
High TC 10/56 1.74 (0.73-4.15) 9/55 1.57 (0.64-3.83) 0.90 (0.33-2.42) 
OR (95% CI) TC within 
strata of BCAA   1.74 (0.73-4.15)   0.68 (0.30-1.56)   
Measure of interaction on additive scale: RERI (95% CI) = -0.13 (-0.29-0.04); P = 0.135  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.39 (0.12-1.30); P = 0.127 
  BCAA below median BCAA above median   
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  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of TC 
Low TC  15/134 1.00 (ref) 30/136 2.25 (1.15-4.40) 2.25 (1.15-4.40) 
High TC 10/56 1.72 (0.72-4.11) 9/55 1.55 (0.64-3.79) 0.90 (0.33-2.42) 
OR (95% CI) TC within 
strata of BCAA   1.72 (0.72-4.11)   0.69 (0.30-1.57)   
Measure of interaction on additive scale: RERI (95% CI) = -0.12 (-0.29-0.04); P = 0.143  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.40 (0.12-1.33); P = 0.134 
  Note: High total cholesterol ≥240 mg/dl 
Supplemental Table 5-9. Adjusted association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal low-
density lipoprotein (LDL-C) 
  Leucine below median Leucine above median   
Maternal LDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDLa 
Low LDL  32/330 1.00 (ref) 42/353 1.37 (0.81-2.30) 1.26 (0.77-2.05) 
High LDL 6/83 0.75 (0.28-1.99) 6/63 0.96 (0.37-2.54) 1.35 (0.41-4.41) 
OR (95% CI) LDL 
within strata of BCAAa   0.73 (0.29-1.80)   0.78 (0.32-1.92)   
Measure of interaction on additive scale: RERI (95% CI) = -0.01 (-0.11-0.09); P = 0.843  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.94 (0.24-3.61); P = 0.924 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDLa 
Low LDL  35/331 1.00 (ref) 39/352 1.08 (0.64-1.80) 1.05 (0.65-1.71) 
High LDL 6/81 0.65 (0.25-1.70) 6/65 0.86 (0.33-2.24) 1.27 (0.39-4.14) 
OR (95% CI) LDL 
within strata of BCAAa   0.68 (0.27-1.67)   0.82 (0.33-2.01)   
Measure of interaction on additive scale: RERI (95% CI) = 0.01 (-0.08-0.11); P = 0.789  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.23 (0.33-4.77); P = 0.760 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDLa 
Low LDL  30/336 1.00 (ref) 44/347 1.66 (0.98-2.80) 1.48 (0.91-2.42) 
High LDL 6/77 0.93 (0.35-2.48) 6/69 0.95 (0.36-2.51) 1.13 (0.35-3.67) 
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OR (95% CI) LDL 
within strata of BCAAa   0.86 (0.35-2.15)   0.66 (0.27-1.61)   
Measure of interaction on additive scale: RERI (95% CI) = -0.04 (-0.14-0.06); P = 0.402  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.62 (0.16-2.41); P = 0.490 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDLa 
Low LDL  32/336 1.00 (ref) 42/347 1.42 (0.84-2.38) 1.31 (0.80-2.13) 
High LDL 6/83 0.77 (0.29-2.02) 6/63 0.98 (0.37-2.58) 1.35 (0.41-4.41) 
OR (95% CI) LDL 
within strata of BCAAa   0.74 (0.30-1.83)   0.76 (0.31-1.88)   
Measure of interaction on additive scale: RERI (95% CI) = -0.01 (-0.11-0.08); P = 0.796  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.90 (0.23-3.49); P = 0.884  
ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking status, gestational 
age, and birthweight unless otherwise noted.  
aStratified ORs are unadjusted  




Supplemental Table 5-10. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal low-
density lipoprotein (LDL-C)  
  Leucine below median Leucine above median   
Maternal LDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  32/330 1.00 (ref) 42/353 1.26 (0.77-2.05) 1.26 (0.77-2.05) 
High LDL 6/83 0.73 (0.29-1.80) 6/63 0.98 (0.39-2.45) 1.35 (0.41-4.41) 
OR (95% CI) LDL 
within strata of BCAA   0.73 (0.29-1.80)   0.78 (0.32-1.92)   
Measure of interaction on additive scale: RERI (95% CI) = 0.001 (-0.10-0.10); P = 0.986  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.07 (0.30-3.86); P = 0.913 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  35/331 1.00 (ref) 39/352 1.05 (0.65-1.71) 1.05 (0.65-1.71) 
High LDL 6/81 0.68 (0.27-1.67) 6/65 0.86 (0.35-2.14) 1.27 (0.39-4.14) 
OR (95% CI) LDL 
within strata of BCAA   0.68 (0.27-1.67)   0.82 (0.33-2.01)   
Measure of interaction on additive scale: RERI (95% CI) = 0.01 (-0.09-0.12); P = 0.800  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.21 (0.34-4.33); P = 0.773 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  30/336 1.00 (ref) 44/347 1.48 (0.91-2.42) 1.48 (0.91-2.42) 
High LDL 6/77 0.86 (0.35-2.15) 6/69 0.97 (0.39-2.43) 1.13 (0.35-3.67) 
OR (95% CI) LDL 
within strata of BCAA   0.86 (0.35-2.15)   0.66 (0.27-1.61)   
Measure of interaction on additive scale: RERI (95% CI) = -0.03 (-0.13-0.07); P = 0.580  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.76 (0.21-2.73); P = 0.675 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  32/336 1.00 (ref) 42/347 1.31 (0.80-2.13) 1.31 (0.80-2.13) 
High LDL 6/83 0.74 (0.30-1.83) 6/63 1.00 (0.40-2.50) 1.35 (0.41-4.41) 
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OR (95% CI) LDL 
within strata of BCAA   0.74 (0.30-1.83)   0.76 (0.31-1.88)   
Measure of interaction on additive scale: RERI (95% CI) = -0.003 (-0.11-0.10); P = 0.752  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.03 (0.29-3.71); P = 0.961 
  Note: High LDL ≥160 mg/dl 
Supplemental Table 5-11. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of male child autism spectrum disorder (ASD) – joint effect with maternal 
low-density lipoprotein (LDL-C) 
  Leucine below median Leucine above median   
Maternal LDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  21/149 1.00 (ref) 34/166 1.57 (0.87-2.85) 1.57 (0.87-2.85) 
High LDL 4/35 0.79 (0.25-2.46) 5/31 1.17 (0.41-3.39) 1.49 (0.36-6.13) 
OR (95% CI) LDL 
within strata of BCAA   0.79 (0.25-2.46)   0.75 (0.27-2.09)   
Measure of interaction on additive scale: RERI (95% CI) = -0.02 (-0.20-0.17); P = 0.859  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.95 (0.20-4.40); P = 0.947 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  22/154 1.00 (ref) 33/161 1.55 (0.86-2.80) 1.55 (0.86-2.80) 
High LDL 4/36 0.75 (0.27-2.09) 5/30 1.20 (0.42-3.47) 1.60 (0.39-6.59) 
OR (95% CI) LDL 
within strata of BCAA   0.75 (0.27-2.09)   0.78 (0.28-2.18)   
Measure of interaction on additive scale: RERI (95% CI) = -0.01 (-0.19-0.18); P = 0.945  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.03 (0.22-4.79); P = 0.966 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  21/158 1.00 (ref) 34/157 1.80 (0.99-3.27) 1.80 (0.99-3.27) 
High LDL 4/33 0.90 (0.29-2.82) 5/33 1.16 (0.40-3.35) 1.29 (0.31-5.32) 
OR (95% CI) LDL 
within strata of BCAA   0.90 (0.29-2.82)   0.65 (0.23-1.80)   
Measure of interaction on additive scale: RERI (95% CI) = -0.05 (-0.24-0.13); P = 0.572  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.72 (0.15-3.33); P = 0.672 
  BCAA below median BCAA above median   
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  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of LDL 
Low LDL  21/155 1.00 (ref) 34/160 1.72 (0.95-3.12) 1.72 (0.95-3.12) 
High LDL 4/35 0.82 (0.26-2.57) 5/31 1.23 (0.42-3.55) 1.49 (0.36-6.13) 
OR (95% CI) LDL 
within strata of BCAA   0.82 (0.26-2.57)   0.71 (0.25-1.99)   
Measure of interaction on additive scale: RERI (95% CI) = -0.03 (-0.22-0.16); P = 0.752  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.87 (0.19-4.02); P = 0.854 




Supplemental Table 5-12. Adjusted association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal non-
high-density lipoprotein (non-HDL-C) 
  Leucine below median Leucine above median   
Maternal non-HDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDLa 
Low non-HDL 31/324 1.00 (ref) 42/341 1.46 (0.86-2.47) 1.33 (0.81-2.17) 
High non-HDL 7/89 0.83 (0.33-2.10) 6/75 0.79 (0.30-2.07) 1.02 (0.33-3.17) 
OR (95% CI) non-HDL 
within strata of BCAAa   0.81 (0.34-1.90)   0.62 (0.25-1.51)   
Measure of interaction on additive scale: RERI (95% CI) = -0.04 (-0.13-0.06); P = 0.437  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.65 (0.18-2.41); P = 0.523 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDLa 
Low non-HDL 34/326 1.00 (ref) 39/339 1.15 (0.68-1.93) 1.12 (0.69-1.82) 
High non-HDL 7/86 0.72 (0.29-1.81) 6/78 0.69 (0.27-1.81) 0.94 (0.30-2.93) 
OR (95% CI) non-HDL 
within strata of BCAAa   0.76 (0.33-1.78)   0.64 (0.26-1.57)   
Measure of interaction on additive scale: RERI (95% CI) = -0.01 (-0.11-0.08); P = 0.751  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.84 (0.23-3.08); P = 0.789 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDLa 
Low non-HDL 29/329 1.00 (ref) 44/336 1.72 (1.02-2.93) 1.56 (0.95-2.56) 
High non-HDL 7/84 0.94 (0.37-2.40) 6/80 0.83 (0.32-2.18) 0.89 (0.29-2.78) 
OR (95% CI) non-HDL 
within strata of BCAAa   0.94 (0.40-2.23)   0.54 (0.22-1.31)   
Measure of interaction on additive scale: RERI (95% CI) = -0.05 (-0.15-0.04); P = 0.292  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.52 (0.14-1.92); P = 0.239 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDLa 
Low non-HDL 31/331 1.00 (ref) 42/334 1.52 (0.90-2.56) 1.39 (0.85-2.27) 
High non-HDL 7/88 0.85 (0.34-2.14) 6/76 0.80 (0.30-2.09) 0.99 (0.32-3.09) 
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OR (95% CI) non-HDL 
within strata of BCAAa   0.84 (0.36-1.97)   0.60 (0.24-1.46)   
Measure of interaction on additive scale: RERI (95% CI) = -0.04 (-0.13-0.05); P = 0.385  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.62 (0.17-2.29); P = 0.474 
ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking status, gestational 
age, and birthweight unless otherwise noted.  
aStratified ORs are unadjusted  





Supplemental Table 5-13. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of child autism spectrum disorder (ASD) – joint effect with maternal non-
high-density lipoprotein (non-HDL-C) 
  Leucine below median Leucine above median   
Maternal non-HDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 31/324 1.00 (ref) 42/341 1.33 (0.81-2.17) 1.33 (0.81-2.17) 
High non-HDL 7/89 0.81 (0.34-1.90) 6/75 0.83 (0.33-2.05) 1.02 (0.33-3.17) 
OR (95% CI) non-HDL 
within strata of BCAA   0.81 (0.34-1.90)   0.62 (0.25-1.51)   
Measure of interaction on additive scale: RERI (95% CI) = -0.03 (-0.12-0.07); P = 0.592  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.77 (0.22-2.65); P = 0.675 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 34/326 1.00 (ref) 39/339 1.12 (0.69-1.82) 1.12 (0.69-1.82) 
High non-HDL 7/86 0.76 (0.33-1.78) 6/78 0.72 (0.29-1.77) 0.94 (0.30-2.93) 
OR (95% CI) non-HDL 
within strata of BCAA   0.76 (0.33-1.78)   0.64 (0.26-1.57)   
Measure of interaction on additive scale: RERI (95% CI) = -0.02 (-0.11-0.08); P = 0.754  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.84 (0.24-2.90); P = 0.786 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 29/329 1.00 (ref) 44/336 1.56 (0.95-2.56) 1.56 (0.95-2.56) 
High non-HDL 7/84 0.94 (0.40-2.23) 6/80 0.84 (0.34-2.09) 0.89 (0.29-2.78) 
OR (95% CI) non-HDL 
within strata of BCAA   0.94 (0.40-2.23)   0.54 (0.22-1.31)   
Measure of interaction on additive scale: RERI (95% CI) = -0.05 (-0.15-0.04); P = 0.292  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.57 (0.17-1.98); P = 0.377 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 31/331 1.00 (ref) 42/334 1.39 (0.85-2.27) 1.39 (0.85-2.27) 
High non-HDL 7/88 0.84 (0.36-1.97) 6/76 0.83 (0.33-2.06) 0.99 (0.32-3.09) 
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OR (95% CI) non-HDL 
within strata of BCAA   0.84 (0.36-1.97)   0.60 (0.24-1.46)   
Measure of interaction on additive scale: RERI (95% CI) = -0.03 (-0.13-0.06); P = 0.502  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.71 (0.21-2.46); P = 0.592 
ORs adjusted for maternal age, race/ethnicity, education, parity, obesity/diabetes, smoking status, gestational 
age, and birthweight unless otherwise noted.  





Supplemental Table 5-14. Crude association of maternal plasma branched-chain amino acids 
(BCAAs) and risk of male child autism spectrum disorder (ASD) – joint effect with maternal 
non-high-density lipoprotein (non-HDL-C)  
  Leucine below median Leucine above median   
Maternal non-HDL 
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 20/147 1.00 (ref) 34/160 1.71 (0.94-3.14) 1.71 (0.94-3.14) 
High non-HDL 5/37 0.99 (0.35-2.85) 5/37 0.99 (0.35-2.85) 1.00 (0.26-3.79) 
OR (95% CI) non-HDL 
within strata of BCAA   0.99 (0.35-2.85)   0.58 (0.21-1.60)   
Measure of interaction on additive scale: RERI (95% CI) = -0.08 (-0.25-0.10); P = 0.397  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.58 (0.14-2.52); P = 0.471 
  Isoleucine below median Isoleucine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 21/152 1.00 (ref) 33/155 1.69 (0.93-3.07) 1.69 (0.93-3.07) 
High non-HDL 5/38 0.95 (0.33-2.69) 5/36 1.01 (0.35-2.88) 1.06 (0.28-4.04) 
OR (95% CI) non-HDL 
within strata of BCAA   0.95 (0.33-2.69)   0.60 (0.22-1.65)   
Measure of interaction on additive scale: RERI (95% CI) = -0.07 (-0.24-0.11); P = 0.456  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.63 (0.15-2.72); P = 0.537 
  Valine below median Valine above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 20/153 1.00 (ref) 34/154 1.88 (1.03-3.45) 1.88 (1.03-3.45) 
High non-HDL 5/38 1.01 (0.35-2.88) 5/36 1.07 (0.37-3.08) 1.06 (0.28-4.04) 
OR (95% CI) non-HDL 
within strata of BCAA   1.01 (0.35-2.88)   0.57 (0.21-1.58)   
Measure of interaction on additive scale: RERI (95% CI) = -0.08 (-0.26-0.09); P = 0.360  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.56 (0.13-2.44); P = 0.445 
  BCAA below median BCAA above median   
  N ASD/Total OR (95% CI) N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of non-HDL 
Low non-HDL 20/153 1.00 (ref) 34/154 1.88 (1.03-3.45) 1.88 (1.03-3.45) 
High non-HDL 5/37 1.04 (0.36-2.98) 5/37 1.04 (0.36-2.98) 1.00 (0.26-3.79) 
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OR (95% CI) non-HDL 
within strata of BCAA   1.04 (0.36-2.98)   0.55 (0.20-1.52)   
Measure of interaction on additive scale: RERI (95% CI) = -0.09 (-0.28-0.09); P = 0.319  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 0.53 (0.12-2.29); P = 0.396 




CHAPTER 6 MATERNAL MULTIPLE METABOLIC 
DISORDERS, PLASMA BRANCHED-CHAIN AMINO ACIDS, 
AND THE RISK OF CHILD AUTISM SPECTRUM DISORDER: 




Obesity and diabetes are known risk factors for ASD and are associated with branched-chain 
amino acids (BCAAs). However, the association of maternal multiple metabolic disorders 
(MMD) alone or in combination with BCAAs, with child ASD has not been well-studied. 
Bringing several lines of research under a life course framework, we examined joint associations 
of maternal MMD and BCAAs on child ASD using a prospective birth cohort design.  
Methods 
We analyzed 829 mother-infant pairs (including 86 ASD) from the Boston Birth Cohort. Based 
on pre-pregnancy overweight or obesity, type 2 or gestational diabetes, high-density lipoprotein 
cholesterol (HDL<50mg/dl), and hypertensive disorders, mothers were grouped into MMD 
(score>3) or no MMD (score<3). Liquid chromatography-tandem mass spectrometry was used to 
quantify maternal postpartum plasma BCAAs and factor analysis was used to create a composite 
BCAA score. Logistic regression was used to examine additive and interactive associations of 
maternal MMD and BCAAs on child ASD risk, adjusting for pertinent covariates. Differential 




The median composite MMD score was 1 (IQR: 0-2). Mothers with an MMD score >3 were at a 
significantly greater risk for having a child with ASD (crude OR: 2.03 95% CI: 1.11-3.71), 
though this significance was lost upon adjustment with pertinent variables. Maternal high MMD 
score and high BCAA score synergistically increased the risk of ASD (adjusted OR: 3.20, 95% 
CI: 1.65-6.18; p for interaction= 0.019) and the association was more pronounced among male 
children (crude OR: 4.53, 95% CI: 2.02-10.16). The highest ASD risk was among children with 
all three risk factors – male sex, high MMD score, and high BCAA score (crude OR: 12.20, 95% 
CI: 4.89-30.46) compared to children without any of these factors. A similar, yet weaker, 
association was observed among children with other developmental disorders (adjusted OR: 
3.30, 95% CI: 1.78-6.12). 
Conclusion 
Maternal MMD and elevated plasma BCAAs synergistically increased the child risk of ASD, 
especially among males, providing new evidence on multiple early life maternal metabolic 





Autism spectrum disorders (ASDs) are defined by core abnormalities in social interaction and 
communication and by the presence of restricted or repetitive interests and behaviors.1 The 
causes of ASD remains largely unknown, but both genetics and the environment are believed to 
contribute to its etiology.2 
We and others have shown maternal obesity and diabetes are associated with child risk of ASD.3-
5 It is well-observed that in a given individual, multiple metabolic disorders tend to co-exist. For 
example, metabolic syndrome is a loosely defined term for co-occurring cardio-metabolic 
conditions,6 and typically comprises elevated blood pressure, dyslipidemia, hyperglycemia, and 
central obesity. Metabolic syndrome is highly prevalent among adults in countries with Western 
diets.7-9 Among US women, the prevalence of metabolic syndrome was close to 35% between 
2007-2012, up from 26% during 1988-1994.10 The role of maternal multiple metabolic disorders 
in child ASD risk has not been well-studied and is worth investigation. For example, the 
prevalence of pre-pregnancy hypertension was significantly greater among mothers who had 
children with ASD, and together with obesity and diabetes, pre-pregnancy hypertension was 
associated with a higher likelihood of having a child with ASD.11 Given the well-observed co-
occurring of multiple cardiometabolic disorders in the population, it would be important to 
consider both individual components as well as multiple metabolic disorders (MMD) as a whole 
in relation to ASD. 
Leucine, isoleucine, and valine are essential amino acids that constitute the branched-chain 
amino acids (BCAAs). These key macronutrients make up about a third of muscle protein and 
are also important cellular signaling molecules.12 Higher circulating concentrations of BCAAs 
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are known to be associated with diabetes, in particular, and are predictive of incident type 2 
diabetes.13 A few studies have also reported associations between BCAAs and individuals with 
ASD in children; however, the studies were most cross-sectional in design and findings were 
mostly inconsistent.14-16 Given the increasing prevalence of MMD among women of 
reproductive age and the association of their individual components with BCAAs and ASD, there 
is a strong scientific premise to investigate whether maternal MMD and BCAAs can jointly 
increase child risk of ASD.  
However, there is a lack of studies on the prospective association between maternal MMD, 
BCAAs and child risk of ASD. In this study, we brought together several lines of research to 
address these important questions using a prospective birth cohort design. Three key aspects of 
this research are addressed in this study: the role of maternal MMD in child’s risk of ASD; 
whether maternal MMD and BCAAs additively or interactively increase the child risk of ASD; 
and whether the associations differ by child’s, given the striking sex difference observed in ASD 
prevalence. 
METHODS 
Participants and Data Collection 
The Boston Birth Cohort (BBC) is an ongoing prospective birth cohort study, recruiting mothers 
from the Boston Medical Center since 1998. The current analysis is based on data from this 
dataset between 2004-2017. Starting from 2004, children were followed from birth, with a mean 
follow-up period of 9.1 years. Briefly, mothers were approached 24-72 hours post-partum and 
informed consent was obtained upon enrolment. Additional recruitment details have been 
previously published.3 Exclusion criteria included multiple deliveries, pregnancies due to in vitro 
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fertilization, and babies born with major birth defects or chromosomal abnormalities. The Johns 
Hopkins Bloomberg School of Public Health and the Boston University Medical Center 
Institutional Review Boards (IRB) reviewed and approved the initial and follow-up studies.  
Of 3,163 mothers enrolled in the Boston Birth Cohort (BBC), 829 mother-infant pairs were 
included in this study. Maternal and infant medical records were reviewed and abstracted and 
mothers were interviewed in person using a standardized questionnaire. Follow-up information 
on each child was obtained through child medical records as well as maternal interviews during 
well-child visits. Maternal blood was collected during enrolment in a non-fasted state and 
fractionated at the Boston Medical Center. Quantitative profiling of maternal plasma metabolites 
was conducted at the Harvard-Massachusetts Institute of Technology (MIT) Broad Institute 
Metabolite Profiling Laboratory using liquid chromatography tandem mass spectrometry (LC-
MS/MS). The present study was limited to mothers who had metabolite measurements and no 
missing covariates (Supplemental Figure 6-1). 
Outcome  
While there was no systematic screening for ASD, all children were evaluated by highly trained 
medical staff at the Boston Medical Center autism evaluation program who communicate 
regularly with the medical center primary care physicians. ASD was defined using ICD-9 and 
ICD-10 primary and secondary diagnoses from electronic medical records (EMR) (Table 3-3). 
Children who were ever diagnosed with autism (299.00), Asperger syndrome (299.80), and/or 
pervasive developmental disorder - not otherwise specified (299.90) were defined as ASD cases. 
Children without ASD but with attention deficit hyperactivity disorder (ADHD), intellectual 
disabilities, or developmental delays were classified as having other developmental disorders and 
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were excluded from the present analysis. Children without ASD or other developmental 
disorders were classified as typically developing (TD). 
Exposures 
Metabolic syndrome is defined by at least three criteria of the following: hyperglycemia or 
insulin resistance, obesity or high waist circumference, dyslipidemia (high triglycerides and low 
HDL), and hypertension.17 Based on availability of data and previous findings from the BBC, we 
developed a multiple metabolic disorders (MMD) score based on the following: 
- Pre-gestational overweight (body mass index ≥ 25 and <30 kg/m2) – 1 point  
OR pre-gestational obesity (BMI ≥30 kg/m2) – 2 points 
- Gestational diabetes mellitus (GDM; ICD-9 codes: 648.00 or 648.03) – 1 point 
OR pre-gestational type 2 diabetes (ICD-9 codes: 250.00–250.93) – 2 points 
- Hypertensive disorder (from EMR) (any one of the following: eclampsia, pre-eclampsia, 
chronic hypertension, gestational hypertension, or hemolysis elevated liver enzymes low 
platelet count (HELLP) syndrome)18 – 1 point  
- HDL-C <50 mg/dl – 1 point 
In considering the functional relationship between the MMD score and ASD risk (Figure 6-1), in 
the subsequent analyses, we grouped subjects into a MMD (score ≥3) vs no MMD (score <3).  
Covariates  
Maternal covariates included age at delivery; race-ethnicity (black, white, Hispanic, or other); 
smoking during pregnancy (“never smoked,” “ever smoked,” or “continuous smoking” three 
months prior to conception); parity (nulliparous vs multiparous), and education (“high school or 
less” vs “some college or more”). Child covariates included child’s sex (female vs male); and 
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gestational age and birthweight (categorized into four groups: 1. full term (37 completed weeks 
of gestation) and non-low birthweight (non-LBW; 2500g); 2. full term and LBW; 3. preterm 
and non-LBW; and 4. preterm and LBW). 
Statistical analysis 
Maternal and child demographic and clinical characteristics were compared by ASD case status 
t-tests and chi-squared tests for continuous and categorical variables, respectively. Missing 
values were incorporated with the largest category for main covariates. Undetected metabolite 
values were imputed with one-half the limit of detection. Metabolite levels were inverse-
normally transformed to produce standardized distributions. Factor analysis on the three BCAAs 
was conducted to create a BCAA score using the Anderson Rubin Method.19  
Multivariate logistic regression was used to explore the relationship of all the factors included in 
our criteria for MMD with ASD. We then explored the joint associations of the BCAAs with 
MMD. For this analysis, the reference category was defined as children whose mothers did not 
have MMD and had below median concentrations of BCAAs. This group was compared to the 
three other combinations with the doubly-exposed group being children whose mothers had both 
MMD and above median concentrations of BCAAs. Additive interaction was assessed by 
relative excess risk due to interaction (RERI).20 Multiplicative interaction was also assessed. All 
analyses were conducted using Stata v14.0 (Stata Corporation, College Station, TX, USA). 
RESULTS  
Of 3,163 mothers enrolled in the Boston Birth Cohort (BBC), 829 mother-infant pairs from a 
predominantly urban, low-income, minority population were included in the present study. 
Maternal and child characteristics by ASD case status have been previously published for this 
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population and are thus included as a supplementary table with an added comparison of maternal 
hypertensive disorders (Supplemental Table 6-1). Mothers with ASD children were older 
(p=0.01) and more obese (p=0.02) than mothers with TD children. Apart from BMI and a 
marginally significant difference in diabetes (p=0.05), no other MMD component was 
significantly different between these groups of mothers. More ASD children were male 
(p<0.0001) and had shorter gestation (p<0.0001) and lower birthweight (p=0.04) compared to 
TD children. Maternal and child characteristics for included and excluded participants are 
compared in (Supplemental Table 6-2). 
Univariate logistic regression analysis revealed maternal obesity and type 2 diabetes as 
significantly associated with child ASD risk, while the other MMD components were not 
associated (Table 6-1). Maternal obesity remained significant after adjusting for potential 
confounders (adjusted odds ratio (aOR): 1.77, 95% CI: 1.02-3.08). When analyzed categorically, 
the odds ratio for three or more MMD components on the risk of child ASD was significant (OR: 
2.03, 95% CI: 1.11-3.71), however this association lost significance when adjusted for potential 
confounders.  
Compared to children born to mothers without MMD and with below median BCAA 
concentrations, children born to mothers with MMD and above median BCAA concentrations 
were significantly more at risk of developing ASD (BCAA score aOR: 2.87, 95% CI: 1.40 – 
5.89) (Table 6-2). This was true for each individual BCAA. There was also evidence of additive 
and multiplicative interactions for these associations (BCAA score p for additive interaction = 
0.02; p for multiplicative interaction = 0.03). This association was greater among male children 
than the overall effect (crude BCAA score aOR: 4.53, 95% CI: 2.02-10.16), while no effect was 
observed among females (Table 6-3). There was also significant additive interaction for the 
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association among males (p for interaction =0.02). The greatest effect was observed for the group 
of males whose mothers had MMD and above median BCAA concentrations compared to the 
reference group: females with mothers without MMD and with below median BCAA 
concentrations (crude OR: 12.20, 95% CI: 4.89-30.46). Compared to obesity and/or diabetes 
alone, additional components of the MMD add considerably to this risk (Supplemental Figure 6-
2). 
Maternal BCAAs alone were not associated with other developmental disorders (DD) (data not 
shown), and MMD was significantly associated with other DD (p<0.01, data not shown) 
however, it lost significance upon adjustment of key variables. Joint associations were observed 
between maternal MMD and BCAAs on the risk of other DD (BCAA score OR 1.77, 95% CI 
1.16, 2.70, p for interaction = 0.03) and was reflective of all three BCAAs (Supplemental Table 
6-3). As found in ASD, there was a sex difference observed for other DD as well (Supplemental 
Tables 6-4 - 6-5), with males at a higher risk than females (BCAA score OR 2.39 95% CI 1.35, 
4.22). Significant interactions were observed for leucine and isoleucine. The risk for other DD 
was the highest when all three risk factors were combined – male sex, maternal MMD, and 
above median maternal BCAAs – adjusted for key covariates (Supplemental Figure 6-3). 
DISCUSSION 
Main findings 
Several components of maternal MMD have been implicated in the pathophysiology of ASD, 
including obesity and waist circumference, insulin resistance, and hypertension. However, prior 
studies were mostly focused on one or a few components of MMD, thus were unable to examine 
their joint effects on ASD. This study has simultaneously considered four maternal metabolic 
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disorders: overweight or obesity, gestational diabetes/diabetes, low HDL, and hypertensive 
disorders. We found that MMD was indeed significantly associated with risk of ASD in our 
unadjusted analyses, but not after adjustment with potential confounders. More importantly, we 
revealed that MMD and BCAAs had a significant synergistic joint effect on child risk of ASD 
after adjusting for relevant covariates. When stratified by sex of the child, the synergistic effect 
was most pronounced among males and was insignificant in females. With all three risk factors 
combined – male child, elevated maternal BCAAs, and maternal MMD – the risk of ASD was 
the greatest. A similar trend was observed for children with other DD, however, the effect was 
not as strong. 
Interpretation 
There is evidence that components of MMD often co-exist and influence each other and are thus 
difficult to tease apart. Obesity and large waist circumference are predictors of diabetes and 
cardiovascular disease,21,22 and dyslipidemia may lead to gestational diabetes and pre-eclampsia 
during pregnancy.23 In turn, insulin may alter cholesterol metabolism and biosynthesis in 
trophoblast cells of obese women.24 Further still, maternal preeclampsia is associated with 
increases in cholesterol in both mother and fetus.25,26 
Maternal MMD components are characterized by oxidative stress and inflammation. As with 
acute infections, in these chronic conditions, inflammatory mediators are known to cross the 
placenta during pregnancy.27 Growing evidence links maternal immune activation (MIA) to child 
ASD and it is suggested this is due to epigenetic changes.28 For example, oxidative stress 
induced by metabolic conditions like diabetes and high cholesterol results in the accumulation of 
free radicals, including reactive oxygen species (ROS),29,30 which can alter DNA methylation of 
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the fetus.31,32 Obesity can also alter the transcriptome of the placenta during early gestation, 
leading to energy imbalances and mitochondrial dysfunction.24,33 One theory posits the 
combination of genetics and environmental risk factors causing oxidative stress in early life give 
rise to schizophrenia.34 Myelin, for example, is highly susceptible to oxidative stress and 
required for optimal brain development and function.34 Abnormal myelin formation is also 
characteristic of ASD.35 Furthermore, elevated BCAA concentrations also increase ROS via 
activation of the mammalian target of rapamycin (mTOR) signaling pathway.36 This can lead to 
abnormal beta oxidation and potentially mitochondrial dysfunction, and is thought to be linked to 
ASD etiology.37,38 Thus, it is possible the effects of maternal oxidative stress paired with the 
genetic makeup of the fetus could lead to the development of ASD. Epigenetic changes are also 
seen in cases of preterm birth, a condition highly associated with ASD.39,40 There is evidence of 
significantly reduced mRNA levels of brain derived neurotrophic factor (BDNF) and nerve 
growth factor (NGF) – both implicated in ASD etiology – in cord plasma of preterm neonates 
compared to their full term counterparts.41 Because the etiology of ASD has been associated with 
both genetic and environmental risk factors, epigenetic changes during fetal development are an 
important area of scientific inquiry.42 
Though we cannot directly identify the proximal source of high levels of maternal plasma 
BCAAs, we do know they are associated with the mothers’ metabolic condition.13,43 It is possible 
that excess protein consumption may be a contributing factor, and it has been shown that 
reducing dietary BCAA intake is associated with lower circulating levels.44 Red meat and 
poultry, specifically, are consistently reported to be associated with obesity, inflammation, and 
diabetes.44-46 In a study with over 38,000 subjects, high intake of animal protein was associated 
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with a two-fold increased risk of incident type 2 diabetes.47 Another study reported subjects who 
underwent a six-week pescatarian fast had reduced levels of all three BCAAs compared to their 
baseline.44 Valine levels were reduced by almost 20% at the end of the six-week period. A 
randomized crossover control study showed that within 48 hours, a vegan diet not only reduced 
levels of total BCAAs, it significantly reduced insulin, HOMA-IR, triglycerides, and total 
cholesterol to HDL-C ratio.48 Several animal studies have also shed light on chemical and 
physiological effects of reducing dietary BCAAs, including decreased repetitive self-grooming 
behavior and mTOR activity, improved glucose tolerance, and rapid fat loss in mice.49,50 
Furthermore, growing pigs fed an optimal BCAA ratio (Leu:Ile:Val = 1:0.75:0.75 to 1:0.25:0.25) 
within a restricted protein diet exhibited a shift from fatty acid synthesis to fatty acid oxidation in 
the liver compared to the control group.51 Taken together, these reports highlight the positive 
effects of a reduced BCAA diet and call for additional dietary intervention studies in subjects 
with MMD components.  
Strengths and Limitations 
Our study leveraged a relatively large intergenerational prospective birth cohort. Maternal 
circulating BCAAs were quantified using metabolomic profiling. It is the first to evaluate the 
joint effects of MMD with maternal metabolites on child risk of ASD. More importantly, this 
study brings forth potential maternal biomarkers of child ASD in concert with maternal MMD 
and the male fetus. Our study also consisted of an urban, low-income minority group, often 
under-represented in ASD research.  
The primary limitation of our study was that the blood draw was conducted at one time-point 
post-delivery and taken in a non-fasted state. Maternal lipids and BCAA metabolites were 
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measured from the plasma. The peri-partum period is a time of metabolic flux and mothers may 
experience shifts in protein and hormone homeostasis. There may also be changes in medications 
during this time. It is unknown how this peri-partum period may have affected circulating amino 
acid concentrations and our observed associations between maternal BCAAs and child risk of 
ASD. Another limitation was due to the enrolment period for the BBC spanning across the 
transition from the American Psychiatric Association’s Diagnostic and Statistical Manual fourth 
edition (DSM-IV) to the fifth edition (DSM-5) and ICD-9 to ICD-10. The diagnostic criteria for 
ASD were redefined, which may have resulted in inconsistencies in diagnoses across the two 
periods. Our study findings may not be generalizable to the larger US population since the study 
participants came from a predominantly urban, low-income, minority population. Though our 
study is the largest metabolomics study of its kind, the sample size was insufficient for detailed 
stratified analysis. Therefore, we view our findings as hypothesis-generating and call for further 
research in this area.  
Implications for future research 
Most previous studies on BCAAs in ASD have been in ASD individuals using a cross-sectional 
design and report decreased concentrations compared to TD individuals.15,16 However, our 
research, conducted in mothers, reports the opposite. Though this finding awaits confirmation of 
future studies, we posit that this dissonance may be explained by the developmental origins of 
health and disease model.52 BCAAs along with other amino acids are transferred across the 
placental barrier to provide nutrients to the growing fetus and lower levels of BCAA uptake were 
observed in pregnancies complicated by intrauterine growth restriction.53 BCAA uptake, in 
particular, was reported to be significantly lower in babies born small for gestational age 
compared to normal birthweight babies. Gürke et al., 2015 found that rabbit embryos of dams 
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with insulin resistance and elevated BCAA levels had a two-fold increase in BCAA 
concentrations as well as increased mTOR activity.54 
Therefore, if the fetus is exposed to elevated concentrations of BCAAs, it is likely to read it as a 
signal of excess in the postnatal environment and thus be programmed to lower its BCAA 
metabolism. Other possible explanations of lower BCAA concentrations among individuals with 
ASD include, mutations in the branched chain ketoacid dehydrogenase kinase (BCKDK),55 a key 
enzyme in BCAA metabolism, poor diet quality as a cause of sensitivities to certain tastes and 
textures,56 and abnormal gut flora that can produce BCAAs de novo, as an altered gut 
microbiome has been associated with ASD.57  
Future studies may consider performing measurements of MMD components and plasma at 
several timepoints, including preconception and throughout pregnancy as well as plasma from 
cord blood and during early childhood. Comparing maternal and cord metabolites may help fill 
the gaps in our knowledge. If our findings are confirmed, BCAAs may serve as potential early 
biomarkers in high risk pregnancies with maternal MMD and a male fetus. One study reported 
over 90% sensitivity and specificity in predicting specific metabotypes of ASD using 
biomarkers; thus, identifying maternal metabotypes may be a useful next step in early risk 
prevention.58 Finally, this study focused on BCAAs while other metabolites remain to be 
explored. 
Conclusion 
In this longitudinal prospective birth cohort study, we found that maternal MMD was associated 
with child risk of ASD. Maternal MMD also had joint and synergistic effects with maternal 
plasma BCAA concentrations, and when stratified by sex, these effects only remained in males. 
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Our findings are considered preliminary and hypotheses generating and warrant further studies 
with larger sample size and additional timepoints to clarify the role of maternal MMD, maternal 
BCAAs, and sex differences in the pathway from in-utero metabolic environment to child 
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Table 6-1. Individual components of maternal multiple metabolic disorders (MMD) and 






OR (95% CI) 
Adjusted  
ORb (95% CI) 
Diabetes    
No Diabetes 1.00 (ref) 1.00 (ref) 
GDM  1.39 (0.47-4.08) 1.06 (0.33-3.37) 
T2DM 2.02 (1.01-4.05) 1.73 (0.83-3.62) 
Obesity   
Normal weight 1.00 (ref) 1.00 (ref) 
Overweight 0.92 (0.50-1.68) 0.74 (0.39-1.42) 
Obese 1.86 (1.12-3.08) 1.77 (1.02-3.08) 
HDL <50 
mg/dl 1.08 (0.65-1.81) 
1.05 (0.61-1.80) 
Hypertension 1.01 (0.54-1.89) 0.70 (0.35-1.39) 
MMD Score   
0 1.00 (ref) 1.00 (ref) 
1 0.91 (0.48-1.71) 0.71 (0.36-1.38) 
2 1.01 (0.53-1.93) 1.04 (0.52-2.08) 
3+ 2.03 (1.11-3.71) 1.47 (0.75-2.86) 
Test for trendc p = 0.215 p = 0.268 
aUnivariate logistic regression  
bORs adjusted for maternal age, race/ethnicity, education, parity, smoking status, and child’s, gestational age, and birthweight 





Table 6-2. Adjusted joint association of maternal multiple metabolic disorders (MMD) and 
branched-chain amino acids (BCAAs) with risk of child autism spectrum disorder (ASD) 
  Leucine below median  Leucine above median   
  N ASD/Total  OR (95% CI) 
 
N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  30/335 1.00 (ref)  31/347 0.95 (0.55-1.65) 1.00 (0.59-1.69) 
MMD  8/78 0.77 (0.32-1.88)  17/69 2.85 (1.39-5.86) 2.86 (1.15-7.13) 
OR (95% CI) 
MMD within 
strata of BCAA*   1.16 (0.51-2.64) 
 
  3.33 (1.72-6.45)   
Measure of interaction on additive scale: RERI (95% CI) = 0.14 (0.03-0.25); P = 0.012 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 3.87 (1.25-11.57); P = 0.019 
  Isoleucine below median  Isoleucine above median   
  N ASD/Total OR (95% CI) 
 
N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  33/343 1.00 (ref)  28/339 0.81 (0.46-1.41) 0.85 (0.50-1.43) 
MMD  8/69 0.81 (0.33-1.97)  17/78 2.24 (1.11-4.53) 2.13 (0.85-5.29) 
OR (95% CI) 
MMD within 
strata of BCAA*   1.23 (0.54-2.80) 
 
  3.10 (1.60-6.00)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (0.02-0.23); P = 0.025 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 3.41 (1.11-6.93); P = 0.033 
  Valine below median  Valine above median   
  N ASD/Total OR (95% CI) 
 
N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  28/337 1.00 (ref)  33/345 1.16 (0.66-2.01) 1.17 (0.69-1.98) 
MMD  8/76 0.87 (0.36-2.13)  17/71 3.09 (1.50-6.39) 2.68 (1.07-6.67) 
OR (95% CI) 
MMD within 
strata of BCAA*   1.30 (0.57-2.97) 
 
  2.98 (1.55-5.72)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (0.01-0.23); P = 0.029 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 3.08 (0.99-9.48); P = 0.050 
  BCAA below median  BCAA above median   
  N ASD/Total OR (95% CI) 
 
N ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  30/342 1.00 (ref)  31/340 1.02 (0.59-1.78) 1.04 (0.62-1.77) 
MMD  8/77 0.82 (0.34-1.99)  17/70 2.87 (1.40-5.89) 2.77 (1.11-6.90) 
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OR (95% CI) 
MMD within 
strata of BCAA*   1.21 (0.53-2.74) 
 
  3.20 (1.65-6.18)   
Measure of interaction on additive scale: RERI (95% CI) = 0.13 (0.02-0.24); P = 0.019 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 3.45 (1.12-10.63); P = 0.031 
  RERI Relative excess risk due to interaction; maternal metabolic syndrome defined as a score of ≥3 
Note: ORs adjusted for maternal age, race/ethnicity, education, parity, smoking status, and gestational age/birthweight unless 





Table 6-3. Crude joint association of maternal multiple metabolic disorders (MMD) and 
branched-chain amino acids (BCAAs) with risk of child autism spectrum disorder (ASD) among 
male and female children 
 Males  
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) 
N 
ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD 
No MMD  30/342 1.00 (ref) 31/340 1.23 (0.65-2.33) 1.23 (0.65-2.33) 
MMD  8/77 1.04 (0.36-2.98) 17/70 4.53 (2.02-10.16) 4.36 (1.38-13.76) 
OR (95% CI) MMD 
within strata of BCAA   1.04 (0.36-2.98)   3.69 (1.68-8.12)   
Measure of interaction on additive scale: RERI (95% CI) = 0.25 (0.04-0.45); P = 0.021  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 3.55 (0.95-13.24); P = 0.059 
 Females  
  BCAA score below median BCAA score above median   
  N ASD/Total OR (95% CI) 
N 
ASD/Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD 
No MMD  10/189 1.00 (ref) 7/186 0.70 (0.26-1.88) 0.70 (0.26-1.88) 
MMD  3/40 1.45 (0.38-5.53) 2/33 1.15 (0.24-5.53) 0.80 (0.12-5.07) 
OR (95% CI) MMD 
within strata of BCAA   1.45 (0.38-5.53)   1.65 (0.33-8.31)   
Measure of interaction on additive scale: RERI (95% CI) = 0.001 (-0.12-0.12); P = 0.989  
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.14 (0.14-9.27); P = 0.905 
RERI Relative excess risk due to interaction 








Figure 6-1.  Joint association of maternal multiple metabolic disorders (MMD), BCAA score, 




(n, % ASD); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ***p ≤ 0.0001, 






Supplemental Table 6-1. Maternal and child characteristics by child autism spectrum disorder 
status (typically developing (TD) vs. ASD) in the Boston Birth Cohort 
 
Maternal Characteristics Total (N=829) TD (N=743) ASD (N=86) P-valuea 
Age (years), n (%)b     
Mean (SD) 28.29 (6.51) 28.09 (6.51) 30.00 (6.34) 0.010 
   25 298 (35.95) 274 (36.88) 24 (27.91) 0.257 
   26-35 390 (47.04) 344 (46.30) 46 (53.49)  
   ≥36 141 (17.01) 125 (16.82) 16 (18.60)  
Nulliparous, n (%) 362 (43.67) 327 (44.01) 35 (40.70) 0.344 
Race or ethnicity, n (%)c    0.089 
   Black 585 (70.57) 533 (71.74) 52 (60.47)  
   White 33 (3.98) 28 (3.77) 5 (5.81)  
   Hispanic 156 (18.82) 132 (17.77) 24 (27.91)  
   Other 55 (6.63) 50 (6.73) 5 (5.81)  
Education, n (%)    0.991 
   Below college degree 707 (85.28) 635 (85.46) 72 (83.72)  
   College degree or above 116 (13.99) 104 (14.00) 12 (13.95)  
   Missing  6 (0.72) 4 (0.54) 2 (2.33)  
Pre-pregnancy BMI, n (%)     
   Mean (SD) 26.57 (6.59) 26.41 (6.42) 27.96 (7.91) 0.046 
   Normal weight (<25 kg/m2) 388 (46.80) 354 (47.64) 34 (39.53) 0.019 
   Overweight (25 - <30 kg/m2) 210 (25.33) 193 (25.98) 17 (19.77)  
   Obese (≥30 kg/m2) 194 (23.40) 165 (22.21) 29 (33.72)  
   Missing  37 (4.46) 31 (4.17) 6 (6.98)  
Diabetes, n (%)d    0.053 
   No diabetes 736 (88.78) 665 (89.50) 71 (82.56)  
   Diabetes 93 (10.76) 78 (10.50) 15 (17.44)  
Smoking, n (%)e    0.665 
   Never 702 (84.68) 632 (85.06) 70 (81.40)  
   Quit 54 (6.51) 47 (6.33) 7 (8.14)  
   Continuous 64 (7.72) 56 (7.54) 8 (9.30)   
   Missing  9 (1.09) 8 (1.08) 1 (1.16)  
HDL cholesterol, mean (SD) 62.77 (17.98) 63.08 (18.26) 60.02 (15.16) 0.135 
Low HDL (<50 mg/dl), n (%) 201 (24.25) 179 (24.09) 22 (25.58) 0.760 
Hypertensive disorders, n (%)f 124 (14.96) 111 (14.94) 13 (15.12) 0.965 
Leucine (above median), n (%) 416 (50.18) 368 (49.53) 48 (55.81) 0.270 
Isoleucine (above median), n (%) 417 (50.30) 372 (50.07) 45 (52.33) 0.692 
Valine (above median), n (%) 416 (50.18) 366 (49.26) 50 (58.14) 0.119 
BCAA score (above median), n (%) 410 (49.46) 362 (48.72) 48 (55.81) 0.213 
Child Characteristics Total (N=829) TD (N=743) ASD (N=86) P-valuea 
Sex, n (%)    <0.0001 
   Male 381 (45.96) 317 (42.66) 64 (74.42)  
   Female 448 (54.04) 426 (57.34) 22 (25.58)  
Gestational age, n (%)    <0.0001 
   Term (≥37 weeks) 709 (85.52) 645 (86.81) 64 (74.42)  
   Late preterm (34-36 weeks) 64 (7.72) 60 (8.08) 4 (4.65)  
   Early preterm (<34 weeks) 56 (6.76) 38 (5.11) 18 (20.93)  
Birth weight, n (%)    0.036 
   ≥2,500 grams 676 (81.54) 613 (82.50) 63 (73.26)  
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   <2,500 grams 153 (18.46) 130 (17.50) 23 (26.74)  
SD, standard deviation; LDL, low-density lipoprotein; HDL, high-density lipoprotein 
aP-values were obtained from χ2 tests or t-tests; missing values for categorical variables were incorporated into the largest group 
bMaternal age at time of delivery 
cBlack includes self- reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
dType 2 diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking six months prior to conception or during pregnancy; some smoking 
includes mothers who smoked at some point in the window of six months prior to conception to delivery but did not smoke throughout 
that window; continuous is defined as mothers that smoked starting six months prior to and throughout pregnancy 
fHypertension defined by any one of the following: eclampsia, pre-eclampsia, chronic hypertension, gestational hypertension, or 





Supplemental Table 6-2. Maternal and child characteristics of Boston Birth Cohort participants 
excluded and included in the analysis 
 
Characteristics Total, N (%) Excluded, N (%) Included, N (%) P-valuea 
Total 3138 (100.00) 2309 (73.58) 829 (26.42)  
Maternal age (years), mean (SD)b 28.64 (6.50) 28.60 (6.48) 28.29 (6.51) 0.234 
Nulliparous, n (%) 1337 (42.61) 975 (42.23) 362 (43.67) 0.472 
Race or ethnicity, n (%)c    <0.0001 
   Black 1998 (63.67) 1413 (61.20) 585 (70.57)  
   White 227 (7.23) 194 (8.40) 33 (3.98)  
   Hispanic 701 (22.34) 545 (23.60) 156 (18.82)  
   Other 212 (6.76) 156 (6.80) 55 (6.63)  
Maternal education, n (%)    0.683 
   Below college degree 2690 (85.72) 1983 (85.88) 707 (85.28)  
   College degree or above 426 (13.58) 310 (13.43) 116 (13.99)  
   Missing 22 (0.70) 16 (0.69) 6 (0.72)  
Maternal BMI, n (%)     
   Mean (SD) 26.58 (6.65) 26.59 (6.67) 26.57 (6.59) 0.950 
   Normal weight (<25 kg/m2) 1452 (46.27) 1064 (46.08) 388 (46.80) 0.898 
   Overweight (25 - <30 kg/m2) 813 (25.90) 603 (26.12) 210 (25.33)  
   Obese (≥30 kg/m2) 703 (22.40) 509 (22.04) 194 (23.40)  
   Missing 170 (5.42) 133 (5.76) 37 (4.46)  
Maternal Diabetes, n (%)d    0.255 
   No diabetes 2751 (87.67) 2015 (87.27) 736 (88.78)  
   Diabetes 387 (12.33) 294 (12.73) 93 (11.22)  
Maternal smoking, n (%)e     
   Never 2542 (81.01) 1840 (79.69) 702 (84.68) 0.001 
   Quit 241 (7.68) 187 (8.10) 54 (6.51)  
   Continuous 336 (10.71) 272 (11.78) 64 (7.72)  
   Missing 19 (0.61) 10 (0.43)  9 (1.09)  
Child’s, n (%)    0.003 
   Male 1583 (50.45) 1202 (52.06) 381 (45.96)  
   Female 1555 (49.55) 1107 (47.94) 448 (54.04)  
Gestational age, n (%)    <0.0001 
   Term (≥37 weeks) 2448 (78.01) 1739 (75.31) 709 (85.52)  
   Late preterm (34-36 weeks) 306 (9.75) 242 (10.48) 64 (7.72)  
   Early preterm (<34 weeks) 384 (12.24) 328 (14.21) 56 (6.76)  
Birthweight, n (%)    <0.0001 
   ≥2,500 grams 2275 (72.50) 1599 (69.25) 676 (81.54)  
   <2,500 grams 863 (27.50) 710 (30.75) 153 (18.46)  
SD, standard deviation 
aP-values were obtained from χ2 tests or t-tests; missing values for categorical variables were incorporated into the largest group 
bMaternal age at time of delivery 
cBlack includes self-reported Black, African American, Haitian, Cape Verdean, and Caribbean race and ethnicities; other includes Asian 
and Pacific Islander races 
dType 2 diabetes mellitus and/or gestational diabetes mellitus 
eNever smokers were defined as mothers with no history of smoking three months prior to conception or during pregnancy; some 
smoking includes mothers who smoked at some point in the window of three months prior to conception to delivery but did not smoke 








3,163 mother-infant pairs with EMR records of well-child and specialty visits 
1,933 neurotypical children; 150 children with ASD; 1080 cases of other 
developmental disabilities (DD)   
829 mother-infant pairs 
   743 neurotypical children 
   86 children with ASD with or without other DD 
1202 excluded due to missing 
metabolite measurement  
1080 excluded 
due to other DDs 
35 excluded due to missing 
lipid measurement  




Supplemental Table 6-3. Adjusted joint association of maternal multiple metabolic disorders 
(MMD) and branched-chain amino acids (BCAAs) with risk of other child developmental 
disorders (Other DD) 
 
  Leucine below median  Leucine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD 
No MMD  209/518 1.00 (ref)  50/122 0.97 (0.75-1.26) 0.98 (0.75-1.28) 
MMD  193/505 0.93 (0.61-1.42)  69/119 1.88 (1.23-2.88) 1.93 (1.12-3.33) 
OR (95% CI) 
MMD within 
strata of BCAA   0.88 (0.57-1.37) 
 
  2.00 (1.30-3.06)   
Measure of interaction on additive scale: RERI (95% CI) = 0.19 (0.05-0.33); P = 0.007 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.09 (1.15-3.78); P = 0.015 
  Isoleucine below median  Isoleucine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD 
No MMD  219/528 1.00 (ref)  45/106 0.87 (0.67-1.14) 0.87 (0.67-1.14) 
MMD  183/495 0.90 (0.58-1.41)  74/135 1.61 (1.08-2.41) 1.75 (1.01-3.03) 
OR (95% CI) 
MMD within 
strata of BCAA   0.84 (0.53-1.33) 
 
  1.88 (1.25-2.81)   
Measure of interaction on additive scale: RERI (95% CI) = 0.17 (0.03-0.31); P = 0.018 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.05 (1.13-3.72); P = 0.018 
  Valine below median  Valine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD 
No MMD  215/522 1.00 (ref)  52/120 0.89 (0.69-1.16) 0.90 (0.69-1.17) 
MMD  187/501 0.98 (0.64-1.50)  67/121 1.62 (1.06-2.47) 1.62 (0.94-2.79) 
OR (95% CI) 
MMD within 
strata of BCAA   0.96 (0.62-1.48) 
 
  1.85 (1.21-2.83)   
Measure of interaction on additive scale: RERI (95% CI) = 0.16 (0.02-0.30); P = 0.025 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.85 (1.03-3.35); P = 0.041 
  BCAA below median  BCAA above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD 
No MMD  209/521 1.00 (ref)  51/120 0.98 (0.75-1.27) 0.99 (0.76-1.28) 
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MMD  193/502 0.99 (0.65-1.51)  68/121 1.77 (1.16-2.70) 1.76 (1.02-3.01) 
OR (95% CI) 
MMD within 
strata of BCAA   0.94 (0.61-1.45) 
 
  1.87 (1.22-2.86)   
Measure of interaction on additive scale: RERI (95% CI) = 0.15 (0.02-0.29); P = 0.030 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.83 (1.02-3.32); P = 0.044 
RERI: Relative excess risk due to interaction; No MMD: score <3; MMD: score ≥3 




Supplemental Table 6-4. Adjusted joint association of maternal multiple metabolic disorders 
(MMD) and branched-chain amino acids (BCAAs) with risk of other child developmental 
disorders (Other DD), among males 
  Leucine below median  Leucine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  130/258 1.00 (ref)  29/61 1.27 (0.74-2.19) 0.77 (0.54-1.09) 
MMD  105/240 1.33 (0.99-1.78)  36/58 2.45 (1.39-4.32) 1.81 (0.87-3.75) 
OR (95% CI) 
MMD within 
strata of BCAA*   0.89 (0.51-1.56) 
 
  2.10 (1.17-3.79)   
Measure of interaction on additive scale: RERI (95% CI) = 0.21 (0.01-0.41); P = 0.036 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.28 (0.98-5.31); P = 0.055 
  Isoleucine below median  Isoleucine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  140/273 1.00 (ref)  28/58 1.27 (0.73-2.21) 0.69 (0.49-0.99) 
MMD  95/225 1.21 (0.90-1.64)  37/61 2.27 (1.31-3.92) 1.65 (0.80-3.42) 
OR (95% CI) 
MMD within 
strata of BCAA*   0.89 (0.50-1.56) 
 
  2.11 (1.18-3.76)   
Measure of interaction on additive scale: RERI (95% CI) = 0.21 (0.02-0.41); P = 0.034 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.43 (1.05-5.65); P = 0.038 
  Valine below median  Valine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  141/275 1.00 (ref)  32/64 1.40 (0.83-2.37) 0.69 (0.49-0.99) 
MMD  94/223 1.19 (0.88-1.62)  33/55 2.14 (1.20-3.81) 1.50 (0.72-3.11) 
OR (95% CI) 
MMD within 
strata of BCAA*   0.95 (0.55-1.64) 
 
  2.06 (1.13-3.76)   
Measure of interaction on additive scale: RERI (95% CI) = 0.19 (-0.01-0.39); P = 0.059 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.10 (0.90-4.88); P = 0.085 
  BCAA below median  BCAA above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  131/264 1.00 (ref)  30/62 1.33 (0.78-2.27) 0.81 (0.57-1.16) 
MMD  104/234 1.37 (1.02-1.85)  35/57 2.39 (1.35-4.22) 1.70 (0.82-3.52) 
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OR (95% CI) 
MMD within 
strata of BCAA*   0.95 (0.55-1.67) 
 
  1.99 (1.10-3.60)   
Measure of interaction on additive scale: RERI (95% CI) = 0.18 (-0.02-0.38); P = 0.071 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 2.02 (0.87-4.65); P = 0.102 
RERI: Relative excess risk due to interaction; No MMD: score <3; MMD: score ≥3 
Note: ORs adjusted for maternal age, race/ethnicity, education, parity, smoking status, and gestational age/birthweight unless otherwise 






Supplemental Table 6-5. Adjusted joint association of maternal multiple metabolic disorders 
(MMD) and branched-chain amino acids (BCAAs) with risk of other child developmental 
disorders (Other DD), among females 
  Leucine below median  Leucine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  79/260 1.00 (ref)  21/61 0.63 (0.36-1.10) 1.14 (0.79-1.65) 
MMD  88/265 0.67 (0.50-0.90)  33/61 1.34 (0.78-2.30) 2.24 (1.08-4.66) 
OR (95% CI) 
MMD within 
strata of BCAA*   1.20 (0.67-2.17) 
 
  2.37 (1.35-4.17)   
Measure of interaction on additive scale: RERI (95% CI) = 0.17 (-0.02-0.36); P = 0.083 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.77 (0.76-4.11); P = 0.188 
  Isoleucine below median  Isoleucine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  79/255 1.00 (ref)  17/48 0.65 (0.35-1.21) 1.08 (0.75-1.56) 
MMD  88/270 0.63 (0.47-0.84)  37/74 1.13 (0.69-1.86) 1.82 (0.86-3.85) 
OR (95% CI) 
MMD within 
strata of BCAA*   1.22 (0.64-2.34) 
 
  2.07 (1.23-3.49)   
Measure of interaction on additive scale: RERI (95% CI) = 0.13 (-0.06-0.32); P = 0.190 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.66 (0.70-3.93); P = 0.250 
  Valine below median  Valine above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  74/247 1.00 (ref)  20/56 0.67 (0.37-1.20) 1.18 (0.81-1.70) 
MMD  93/278 0.65 (0.48-0.87)  34/66 1.18 (0.70-1.99) 1.91 (0.92-3.97) 
OR (95% CI) 
MMD within 
strata of BCAA*   1.30 (0.71-2.39) 
 
  2.11 (1.23-3.64)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (-0.07-0.31); P = 0.208 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.49 (0.64-3.50); P = 0.355 
  BCAA below median  BCAA above median   
  
N Other DD/ 
Total OR (95% CI) 
 
N Other DD/ 
Total OR (95% CI) 
OR (95% CI) 
 BCAA within  
strata of MMD* 
No MMD  78/257 1.00 (ref)  21/58 0.68 (0.38-1.19) 1.14 (0.79-1.65) 
MMD  89/268 0.65 (0.48-0.87)  33/64 1.20 (0.70-2.04) 1.88 (0.91-3.88) 
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OR (95% CI) 
MMD within 
strata of BCAA*   1.30 (0.72-2.37) 
 
  2.14 (1.23-3.72)   
Measure of interaction on additive scale: RERI (95% CI) = 0.12 (-0.07-0.32); P = 0.201 
 
Measure of interaction on multiplicative scale: ratio of ORs (95% CI) = 1.52 (0.66-3.53); P = 0.328 
RERI: Relative excess risk due to interaction; No MMD: score <3; MMD: score ≥3 
Note: ORs adjusted for maternal age, race/ethnicity, education, parity, smoking status, and gestational age/birthweight unless otherwise 




Supplemental Figure 6-2. Joint association of maternal obesity/diabetes (ob/DM), BCAA score, 
and child’s sex on the risk of child autism spectrum disorders (ASD) 
 
 
(n, % ASD); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 
-MMD: Maternal multiple metabolic disorders with a score of <3 
+MMD: Maternal multiple metabolic disorders with a score of ≥3 
-BCAA: Below median maternal plasma branched-chain amino acid concentrations 




Supplemental Figure 6-3. Joint association of maternal obesity/diabetes (ob/DM), BCAA score, 
and child’s sex on the risk of child other developmental disorders (other DD) 
 
 
(n, % other DD); *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001 
-MMD: Maternal multiple metabolic disorders with a score of <3 
+MMD: Maternal multiple metabolic disorders with a score of ≥3 
-BCAA: Below median maternal plasma branched-chain amino acid concentrations 







CHAPTER 7 DISCUSSION AND RESEARCH IMPLICATIONS 
 
Maternal obesity and diabetes are known risk factors for autism spectrum disorders (ASD). This 
research was motivated by the potential for understanding mechanistic pathways underlying the 
associations between maternal metabolic disorders and child risk of ASD employing targeted 
metabolomics. In this dissertation, the associations between maternal branched-chain amino 
acids (BCAA; leucine, isoleucine, and valine) metabolites and child’s risk of ASD as well their 
joint effect with maternal metabolic conditions, including obesity/diabetes (ob/DM), 
dyslipidemia, and multiple metabolic disorders (MMD) were examined within a prospective 
birth cohort study design. This chapter summarizes the key findings of this research, its strengths 
and limitations, its implications, and directions for future research. 
SUMMARY OF KEY FINDINGS 
Aim 1 sought to explore the role of maternal plasma BCAAs in the pathway from maternal 
obesity/diabetes to child ASD. Maternal BCAAs were not found to be associated with child risk 
of ASD and thus did not mediate the path between maternal ob/DM and child ASD. However, 
when elevated, all the BCAAs had synergistic associations with maternal ob/DM after being 
adjusted for pertinent covariates (BCAA score OR: 2.35; 95% CI: 1.21, 4.55). Leucine and 
isoleucine had significant interactions on the additive scale and isoleucine on the multiplicative 
scale. The combination of maternal ob/DM and low BCAA concentrations was not associated 
with child risk of ASD, highlighting the strong influence of BCAA concentrations in mothers 
with ob/DM. The BCAAs also had joint effects with the child’s sex on the risk of ASD (crude 
BCAA score OR: 4.9; 95% CI: 1 2.48, 9.69). With all three risk factors – maternal obesity, 
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maternal elevated BCAAs, and male sex – the effect was the greatest (crude BCAA score OR: 
8.72; 95% CI: 3.62, 20.99). This effect was also observed for other DD, though to a lesser extent. 
Aim 2 assessed the association between maternal cholesterol and child ASD and explore the role 
of maternal plasma BCAAs in the pathway from maternal dyslipidemia to child ASD. Maternal 
plasma cholesterols (total cholesterol, high-density lipoprotein cholesterol (HDL-C), low-density 
lipoprotein cholesterol (LDL-C), and non-HDL-C) were not associated with child risk of ASD. 
Low maternal HDL-C concentrations compounded the male child’s risk of ASD (OR: 4.20; 95% 
CI: 2.02, 8.73), though the interaction was not statistically significant. Among mothers with low 
HDL-C, elevated BCAAs further increased the risk of child ASD (BCAA score OR: 4.67; 95% 
CI: 1.33, 16.36; p for interaction: 0.006). Compared to all other combinations, males with 
elevated maternal BCAAs and low HDL-C had the highest risk of ASD (crude OR: 4.78, 95% 
CI: 2.12, 10.78). Results for non-HDL-C and LDL-C cholesterols were not as robust as those for 
HDL. 
Aim 3 assessed the association between maternal multiple metabolic disorders (MMD) and child 
ASD and explore the role of maternal plasma BCAAs in the pathway from maternal MMD to 
child ASD. We found that maternal MMD (composite score ≥3, based on: 1 point for overweight 
or 2 points obesity; 1 point for gestational diabetes or 2 points for diabetes; 1 point for low HDL; 
1 point for hypertensive disorders) was associated with child risk of ASD and had joint additive 
interaction with maternal plasma BCAA concentrations. When stratified by child’s, this 
association remained only in males. The greatest effect was observed for males whose mothers 
had MMD and above median BCAA concentrations compared to females whose mothers did not 
have MMD and had below median BCAA concentrations (crude OR: 12.20, 95% CI: 4.89-
30.46). This pattern was seen among children with other DD as well, though the effect was not as 
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strong. Compared to obesity and/or diabetes alone or HDL-C alone, all the components of MMD 
together contribute to an increased risk. 
STRENGTHS AND LIMITATIONS 
Strengths 
Ours is the first prospective birth cohort study to examine the association of maternal metabolites 
with child risk of ASD. Metabolomics is a comprehensive approach that allows for specific 
analysis of targeted metabolites. The metabolites in this study were targeted based on known 
associations with metabolic conditions like obesity and diabetes. The diagnoses of all ASD cases 
were obtained from electronic medical records after having been evaluated by highly trained 
staff at the Boston Medical Center, who are in direct contact with primary care physicians.  
We leveraged the large Boston Birth Cohort (BBC), a longitudinal and intergenerational study. 
Because of the intergenerational design of the study, we were able to examine temporal 
relationships between maternal and child risk factors during pregnancy and the outcome of child 
ASD. Additionally, as this time period is within the critical window of neurodevelopment, it can 
provide insight on the causal pathways between maternal metabolic conditions, maternal 
BCAAs, child’s, and risk of child ASD. The BBC study population consisted of an urban, low-
income, minority population within the Boston area, where the risk of metabolic conditions like 
obesity and diabetes is higher than the national average.1 Thus, we had greater power to examine 
the potential effects of these conditions on the risk of ASD. Furthermore, we studied an under-
represented population in the literature, adding to the current knowledge in ASD research. 
The population also included female cases of ASD, providing us with the ability to investigate 
sex interactions with risk factors of interest. This is the first study, to our knowledge, to show 
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maternal metabolic conditions, including obesity, diabetes, and low HDL-C, are more harmful to 
male children than female children in terms of ASD risk. Furthermore, it is also the first to assess 
the associations between maternal BCAA concentrations and ASD, as well as joint effects of 
maternal BCAAs and metabolic conditions on ASD. We are also adding to the limited literature 
on the intergenerational effects of maternal cholesterol levels and maternal multiple metabolic 
disorders on child risk of ASD. 
Limitations 
Our study also had limitations. The measurement of maternal plasma lipids and metabolites were 
only measured at one time-point postpartum. During the peri-partum period, hormonal and 
physiological changes have an effect on circulating metabolite concentrations, though it is 
unclear how BCAA concentrations may have been affected or to what extent it affected our 
observed associations with child risk of ASD. Additional measurements throughout pregnancy 
and from the child cord blood and early life would have provided a clearer picture of the 
relationships between maternal BCAAs and child risk of ASD as well as a temporal association 
between maternal cholesterols and child risk of ASD. Blood was collected in a non-fasted state, 
which affected our cholesterol measurements, except for HDL-C. Measurements for total 
cholesterol and triglycerides tend to be inflated during the non-fasted state and may bias the 
results towards the null. Therefore, our study focused mainly on the associations with HDL-C. 
The BBC enrolment spanned across the transition from the American Psychiatric Association’s 
Diagnostic and Statistical Manual fourth edition (DSM-IV) to the fifth edition (DSM-5) and 
from ICD-9 to ICD-10. The definition of ASD changed during this time, so there may be 
inconsistencies in diagnoses between these two periods.  
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Though our study is the largest prospective study of its kind, a larger sample size would have 
allowed for adjusted sex-specific and subtype analyses. Additionally, because our participants 
represented an urban, low-income, minority population, our study findings may not be 
generalizable to the larger ASD community. Thus, our research may be taken as hypothesis-
generating, and future studies with larger numbers of individuals with ASD are needed to 
confirm our findings.  
PUBLIC HEALTH IMPLICATIONS AND FUTURE RESEARCH 
At present, there is no accurate way to predict a newborn’s future risk of ASD and there is no 
cure for ASD. The mechanisms behind the sex difference in ASD are still unknown. Current 
treatments take on behavioral and pharmaceutical approaches;2 however, there are no treatments 
that have shown to improve the core symptoms of social communication or restricted interests 
and stereotyped behaviors, though a few recent studies have shown promise.3,4  Primary 
prevention would significantly improve the quality of life for many individuals and families 
members who would otherwise have been affected, and it would further greatly reduce the 
economic burden associated with ASD.  
This research brought forth insights on the early life origins of ASD, specifically surrounding the 
mechanisms from maternal metabolic disorders to child ASD risk. It also shed light on how 
BCAAs and child’s sex play key roles given these maternal conditions. This was a novel study 
designed to explore the intergenerational relationship between maternal BCAAs and child ASD 
risk. It was also the first to find that elevated BCAA score further increased the risk of mothers 
with ob/DM, HDL-C, or MMD and that these risks were highest among male children. 
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BCAAs are essential amino acids that make up the highest percentage of amino acids in most 
animal-sourced proteins.5 Several studies have pointed to the benefits of lowering BCAA in the 
diet in both animals and humans as reducing dietary proteins have been associated with 
circulating BCAA levels.6 Animal proteins, specifically red meat and poultry have been 
associated with inflammation, obesity, and diabetes.6-8 However, BCAAs are necessary building 
blocks of our muscles and have important roles to support cell growth and maintenance.5 It is 
perhaps in excess amounts they may be harmful as they are highly associated with obesity and 
diabetes according to several sources.5,9,10 Though our investigation was exploratory and our 
findings hypothesis generating, if confirmed, they could lead to clinical or public health 
guidelines for lower BCAA diets in pregnant women at higher risk for a child with ASD, i.e., 
having a metabolic condition and a male fetus. 
Obesity and diabetes are recognized risk factors for child ASD risk.11-13 However, my research 
shows the possibility of low HDL levels, together with elevated BCAA concentrations, may 
increase the risk of child ASD as well, especially among males. MMD revealed an even greater 
risk. Thus, the guidelines for HDL cholesterol levels during pregnancy should be reviewed and 
possibly set to a higher cut-point than the overall recommended level set by the American Heart 
Association (>50 mg/dL) if our finding is confirmed.14 Metabolic conditions arise due to many 
factors, including genetics. However, diet and exercise are key drivers in their pathophysiology 
and should be top priority to women who are pregnant or planning to become pregnant.15  
There is a disproportionate prevalence of ASD in males compared to females, however the cause 
remains elusive.16 Our findings suggest that sexual dimorphism in ASD is influenced by 
maternal metabolic conditions together with maternal plasma BCAA concentrations and thus 
may begin in utero. Authors of a recent study reported sex-specific differences in BCAA 
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concentrations in second trimester amniotic fluid.17 A prevailing theory behind the sex difference 
in ASD is that higher concentrations of estradiol in the womb protect the female fetal brain, 
while male fetuses are left vulnerable to inflammatory insults.18,19 Our findings give credence to 
this theory as estradiol has an anti-inflammatory effect during neurodevelopment. Under 
inflammatory conditions brought about by maternal metabolic disorders and elevated BCAAs, 
estradiol may be protecting female fetuses from inflammatory markers.  
Additional studies with a larger, nationally representative sample are required to confirm our 
findings. These studies would benefit from measurements at multiple time points in both mothers 
and children, particularly from cord blood. Investigating other metabolites in this manner would 
provide additional information that may better help fit the pieces together. 
Metabolic disorders, especially obesity and diabetes, are inflammatory conditions. Thus, it can 
be theorized that pregnant women or women planning to become pregnant with these conditions 
may have a chance of lowering their risk of having a child with ASD by reducing the 
inflammation and oxidative stress in their bodies. Anti-inflammatory diets have shown some 
potential in treating children with ASD. These have included gluten-free and casein-free diets, 
along with dietary supplements.20 However, in a recent review of the literature, dietary therapies 
were not found to have significant impacts on the symptoms of ASD.20 With small sample sizes 
and inadequate study designs, the evidence remains inconclusive.  
In a double-blind randomized controlled trial (RCT), researchers from Harvard and Johns 
Hopkins Medical Schools treated the symptoms of ASD using sulforaphane, an isothiocyanate 
having high antioxidant properties, extracted from broccoli sprouts and also found clinically 
significant improvements in core features.4 One intervention study has since replicated the basic 
findings of this study and there are four others currently underway.21 Though these studies have 
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only been carried out in individuals with ASD, there is potential for antioxidant treatment in 
expectant mothers. Sulforaphane and moringin, its counterpart from the subtropical moringa 
plant, have also been shown to alleviate symptoms of diabetes and prevent cancer via its anti-
inflammatory properties.22,23 Thus, there is pharmacological potential in these plant components 
for prevention of ASD risk in children by supplementing mothers with metabolic conditions 
before or during pregnancy. 
CONCLUSIONS 
The prevalence of ASD has been rapidly increasing over the past few decades and now affects 1 
in 59 children in the United States.24 ASD can be highly disabling and imposes a huge burden to 
the individuals, their families, and societies, as well as an enormous economic cost. The exact 
cause of the disorder is still unclear, as its etiology is complex and treatment methods are limited 
at best. Maternal metabolic conditions, including obesity and diabetes, are known risk factors for 
ASD. This dissertation sought to investigate the underlying mechanisms between maternal 
metabolic disorders and child ASD. We found that when paired with elevated maternal BCAA 
concentrations, ob/DM, low HDL-C, and MMD each further increased the risk of child ASD, 
and these risks were consistently higher among male children. Additional studies are required to 
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